0001377149
false
Q3
2023
--12-31
NONE
0001377149
2023-01-01
2023-09-30
0001377149
2023-11-13
0001377149
2023-09-30
0001377149
2022-12-31
0001377149
2023-07-01
2023-09-30
0001377149
2022-07-01
2022-09-30
0001377149
2022-01-01
2022-09-30
0001377149
crvw:SubscriptionBasedLeaseRevenueMember
2023-07-01
2023-09-30
0001377149
crvw:SubscriptionBasedLeaseRevenueMember
2022-07-01
2022-09-30
0001377149
crvw:SubscriptionBasedLeaseRevenueMember
2023-01-01
2023-09-30
0001377149
crvw:SubscriptionBasedLeaseRevenueMember
2022-01-01
2022-09-30
0001377149
crvw:SalesBasedEquipmentPackageRevenueMember
2023-07-01
2023-09-30
0001377149
crvw:SalesBasedEquipmentPackageRevenueMember
2022-07-01
2022-09-30
0001377149
crvw:SalesBasedEquipmentPackageRevenueMember
2023-01-01
2023-09-30
0001377149
crvw:SalesBasedEquipmentPackageRevenueMember
2022-01-01
2022-09-30
0001377149
crvw:SalesBasedSoftwareBundleRevenueMember
2023-07-01
2023-09-30
0001377149
crvw:SalesBasedSoftwareBundleRevenueMember
2022-07-01
2022-09-30
0001377149
crvw:SalesBasedSoftwareBundleRevenueMember
2023-01-01
2023-09-30
0001377149
crvw:SalesBasedSoftwareBundleRevenueMember
2022-01-01
2022-09-30
0001377149
us-gaap:CommonStockMember
2021-12-31
0001377149
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001377149
us-gaap:RetainedEarningsMember
2021-12-31
0001377149
2021-12-31
0001377149
us-gaap:CommonStockMember
2022-03-31
0001377149
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001377149
us-gaap:RetainedEarningsMember
2022-03-31
0001377149
2022-03-31
0001377149
us-gaap:CommonStockMember
2022-06-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001377149
us-gaap:RetainedEarningsMember
2022-06-30
0001377149
2022-06-30
0001377149
us-gaap:CommonStockMember
2022-12-31
0001377149
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001377149
us-gaap:RetainedEarningsMember
2022-12-31
0001377149
us-gaap:CommonStockMember
2023-03-31
0001377149
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001377149
us-gaap:RetainedEarningsMember
2023-03-31
0001377149
2023-03-31
0001377149
us-gaap:CommonStockMember
2023-06-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001377149
us-gaap:RetainedEarningsMember
2023-06-30
0001377149
2023-06-30
0001377149
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001377149
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001377149
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001377149
2022-01-01
2022-03-31
0001377149
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001377149
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001377149
2022-04-01
2022-06-30
0001377149
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001377149
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001377149
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001377149
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001377149
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001377149
2023-01-01
2023-03-31
0001377149
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001377149
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001377149
2023-04-01
2023-06-30
0001377149
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001377149
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001377149
us-gaap:CommonStockMember
2022-09-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001377149
us-gaap:RetainedEarningsMember
2022-09-30
0001377149
2022-09-30
0001377149
us-gaap:CommonStockMember
2023-09-30
0001377149
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001377149
us-gaap:RetainedEarningsMember
2023-09-30
0001377149
crvw:SalesBasedContractRevenueMember
2023-01-01
2023-09-30
0001377149
crvw:SalesBasedContractRevenueMember
2022-01-01
2022-09-30
0001377149
crvw:SubscriptionBasisContractMember
2023-01-01
2023-09-30
0001377149
crvw:SubscriptionBasisContractMember
2022-01-01
2022-09-30
0001377149
crvw:SalesBasisContractMember
2023-01-01
2023-09-30
0001377149
crvw:SalesBasisContractMember
2022-01-01
2022-09-30
0001377149
crvw:OfficeSpaceMember
2023-09-30
0001377149
us-gaap:EmployeeStockOptionMember
2023-01-01
2023-09-30
0001377149
us-gaap:WarrantMember
2023-01-01
2023-09-30
0001377149
crvw:SubscriptionBasisContractMember
2022-12-31
0001377149
crvw:SubscriptionBasisContractMember
2021-12-31
0001377149
crvw:SubscriptionBasisContractMember
2023-09-30
0001377149
crvw:SubscriptionBasisContractMember
2022-09-30
0001377149
crvw:SalesBasisContractMember
2022-12-31
0001377149
crvw:SalesBasisContractMember
2021-12-31
0001377149
crvw:SalesBasisContractMember
2023-09-30
0001377149
crvw:SalesBasisContractMember
2022-09-30
0001377149
crvw:YearOneMember
2023-09-30
0001377149
crvw:YearTwoMember
2023-09-30
0001377149
crvw:YearThreeMember
2023-09-30
0001377149
crvw:ReplacementNotesMember
2023-03-28
2023-03-30
0001377149
crvw:ReplacementNotesMember
2023-03-30
0001377149
2023-05-22
0001377149
crvw:ReplacementNotesMember
2023-05-23
2023-05-24
0001377149
crvw:ReplacementNotesMember
2023-05-24
0001377149
us-gaap:WarrantMember
2022-12-31
0001377149
us-gaap:WarrantMember
srt:MinimumMember
2022-12-31
0001377149
us-gaap:WarrantMember
srt:MaximumMember
2022-12-31
0001377149
us-gaap:WarrantMember
2023-01-01
2023-09-30
0001377149
us-gaap:WarrantMember
2023-09-30
0001377149
us-gaap:WarrantMember
srt:MinimumMember
2023-09-30
0001377149
us-gaap:WarrantMember
srt:MaximumMember
2023-09-30
0001377149
us-gaap:EmployeeStockOptionMember
2023-01-01
2023-09-30
0001377149
crvw:NetworkEquipmentMember
2023-09-30
0001377149
crvw:NetworkEquipmentMember
2022-12-31
0001377149
us-gaap:OfficeEquipmentMember
2023-09-30
0001377149
us-gaap:OfficeEquipmentMember
2022-12-31
0001377149
us-gaap:VehiclesMember
2023-09-30
0001377149
us-gaap:VehiclesMember
2022-12-31
0001377149
crvw:TestEquipmentMember
2023-09-30
0001377149
crvw:TestEquipmentMember
2022-12-31
0001377149
us-gaap:FurnitureAndFixturesMember
2023-09-30
0001377149
us-gaap:FurnitureAndFixturesMember
2022-12-31
0001377149
us-gaap:EquipmentMember
2023-09-30
0001377149
us-gaap:EquipmentMember
2022-12-31
0001377149
us-gaap:LeaseholdImprovementsMember
2023-09-30
0001377149
us-gaap:LeaseholdImprovementsMember
2022-12-31
0001377149
crvw:PatentsTrademarksMember
2023-09-30
0001377149
us-gaap:OtherIntangibleAssetsMember
2023-09-30
0001377149
crvw:PatentsTrademarksMember
2022-12-31
0001377149
us-gaap:OtherIntangibleAssetsMember
2022-12-31
0001377149
crvw:DeferredInstallationCostsMember
2023-09-30
0001377149
crvw:DeferredSalesCommissionsMember
2023-09-30
0001377149
crvw:PrepaidLicenseFeeMember
2023-09-30
0001377149
crvw:SecurityDepositMember
2023-09-30
0001377149
crvw:DeferredInstallationCostsMember
2022-12-31
0001377149
crvw:DeferredSalesCommissionsMember
2022-12-31
0001377149
crvw:PrepaidLicenseFeeMember
2022-12-31
0001377149
crvw:SecurityDepositMember
2022-12-31
0001377149
us-gaap:InternalRevenueServiceIRSMember
2017-01-01
2017-12-31
0001377149
us-gaap:InternalRevenueServiceIRSMember
2018-01-01
2018-12-31
0001377149
us-gaap:InternalRevenueServiceIRSMember
2018-01-02
0001377149
crvw:PDLBioPharmaIncMember
2015-06-26
0001377149
crvw:PDLBioPharmaIncMember
crvw:Tranche1Member
2015-06-26
0001377149
crvw:PDLModificationAgreementMember
2023-01-01
2023-03-31
0001377149
crvw:PDLModificationAgreementMember
2022-01-01
2022-03-31
0001377149
crvw:SeventhAmendmentToCreditAgreementMember
2023-05-30
2023-05-31
0001377149
crvw:SeventhAmendmentToCreditAgreementMember
2023-05-31
0001377149
crvw:HealthCor3Member
us-gaap:ConvertibleDebtMember
2011-04-21
0001377149
crvw:HealthCor3Member
crvw:ConvertibleDebt1Member
2011-04-21
0001377149
crvw:HealthCor3Member
us-gaap:ConvertibleDebtMember
2011-04-20
2011-04-21
0001377149
crvw:HealthCor3Member
crvw:ConvertibleDebt1Member
2011-04-20
2011-04-21
0001377149
crvw:HealthCor3Member
crvw:ConvertibleDebt2Member
crvw:FirstFiveYearNotePeriodMember
2011-04-20
2011-04-21
0001377149
crvw:HealthCor3Member
crvw:ConvertibleDebt2Member
crvw:SecondFiveYearNotePeriodMember
2011-04-20
2011-04-21
0001377149
crvw:HealthCor3Member
crvw:ConvertibleDebt2Member
2011-04-20
2011-04-21
0001377149
crvw:HealthCorNoteExtensionsMember
crvw:Notes2011Member
2022-03-05
2022-03-06
0001377149
crvw:HealthCorNoteExtensionsMember
crvw:Notes2011Member
2022-03-07
2022-03-08
0001377149
crvw:HealthCorNoteExtensionsMember
crvw:Notes2012Member
2022-03-05
2022-03-06
0001377149
crvw:HealthCorNoteExtensionsMember
crvw:Notes2012Member
2022-03-07
2022-03-08
0001377149
crvw:HealthCorNoteExtensionsMember
2022-03-07
2022-03-08
0001377149
crvw:HealthCorNoteExtensionsMember
2022-03-08
0001377149
crvw:HealthCorNotes2014Member
2022-07-02
0001377149
crvw:SupplementalNotes2015Member
2022-07-02
0001377149
crvw:EighthAmendmentSupplementalClosingNotesMember
2022-07-02
0001377149
crvw:TenthAmendmentSupplementalClosingNotesMember
2022-07-02
0001377149
crvw:TwelfthAmendmentSupplementalClosingNotesMember
2022-07-02
0001377149
crvw:ThirteenthAmendmentSupplementalClosingNotesMember
2022-07-02
0001377149
crvw:ReplacementNotesMember
2022-12-30
0001377149
crvw:ReplacementNotesMember
2022-12-28
2022-12-30
0001377149
crvw:ReplacementNotesMember
crvw:TrancheOneMember
2023-03-28
2023-03-30
0001377149
crvw:ReplacementNotesMember
crvw:TrancheOneMember
2023-03-30
0001377149
crvw:ReplacementNotesMember
crvw:TrancheTwoMember
2023-03-28
2023-03-30
0001377149
crvw:ReplacementNotesMember
crvw:TrancheTwoMember
2023-03-30
0001377149
crvw:Notes2011Member
2023-01-01
2023-09-30
0001377149
crvw:Notes2011Member
2022-01-01
2022-09-30
0001377149
crvw:HealthCor3Member
2023-01-01
2023-09-30
0001377149
crvw:HealthCor3Member
2022-01-01
2022-09-30
0001377149
crvw:HealthCorNinthAmendmentWarrantsMember
2023-09-30
0001377149
crvw:HealthCorAllongeNo3WarrantsMember
2023-09-30
0001377149
crvw:HealthCorAllongeNo4WarrantsMember
2023-09-30
0001377149
crvw:RockwellMember
crvw:SecondRockwellNoteAmendmentMember
crvw:RockwellNoteMember
2019-12-29
2019-12-31
0001377149
2009-09-08
0001377149
2009-09-06
2009-09-08
0001377149
2020-03-02
2020-03-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
utr:sqft
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
|
☑ |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended September 30, 2023
or
|
☐ |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the transition period from________ to ___________
Commission
File No. 000-54090
CAREVIEW
COMMUNICATIONS, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
95-4659068 |
(State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
405
State Highway 121, Suite B-240, Lewisville, TX 75067
(Address
of principal executive offices)
(972)
943-6050
(Registrant’s
telephone number)
N/A
(Former
name, former address and former fiscal year, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act: None
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, $0.001 par value per share |
|
CRVW |
|
OTC
Markets |
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company”
in Rule 12b-2 of the Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated
filer |
☑ |
Smaller
reporting company |
☑ |
|
|
Emerging
growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The
number of shares outstanding of each of the issuer’s classes of Common Stock as of November 13, 2023 was 583,880,748.
CAREVIEW COMMUNICATIONS,
INC. AND SUBSIDIARIES
INDEX
CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
| |
September 30, | |
|
| |
2023 | |
December 31, |
| |
(Unaudited) | |
2022 |
ASSETS |
Current Assets: | |
| | | |
| | |
Cash and restricted cash | |
$ | 674,020 | | |
$ | 520,166 | |
Accounts receivable | |
| 1,825,870 | | |
| 948,328 | |
Inventory | |
| 232,606 | | |
| 301,446 | |
Other current assets | |
| 329,837 | | |
| 71,020 | |
Total current assets | |
| 3,062,333 | | |
| 1,840,960 | |
| |
| | | |
| | |
Property and equipment, net | |
| 375,526 | | |
| 642,559 | |
| |
| | | |
| | |
Intangible assets, net | |
| 738,863 | | |
| 820,106 | |
Operating lease asset | |
| 330,477 | | |
| 434,330 | |
Other assets, net | |
| 270,847 | | |
| 209,649 | |
Total assets | |
$ | 4,778,046 | | |
$ | 3,947,604 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
Current Liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 605,844 | | |
$ | 650,796 | |
Notes payable | |
| 20,000,000 | | |
| 20,000,000 | |
Notes payable - related parties | |
| 700,000 | | |
| 700,000 | |
Convertible notes payable, related parties | |
| — | | |
| 42,394,168 | |
Convertible notes payable, non-related parties | |
| — | | |
| 1,805,832 | |
Operating lease liability, current | |
| 185,304 | | |
| 175,520 | |
Other current liabilities | |
| 17,532,785 | | |
| 14,553,277 | |
Total current liabilities | |
| 39,023,933 | | |
| 80,279,593 | |
| |
| | | |
| | |
Long-term Liabilities: | |
| | | |
| | |
Operating lease liability | |
| 183,297 | | |
| 305,259 | |
Other long-term liabilities | |
| 151,165 | | |
| 23,481 | |
Total long-term liabilities | |
| 334,462 | | |
| 328,740 | |
Total liabilities | |
| 39,358,395 | | |
| 80,608,333 | |
| |
| | | |
| | |
Stockholders' Deficit: | |
| | | |
| | |
Common stock - par value $0.001; 800,000,000 and 500,000,000 shares authorized, respectively; 583,880,748 and 141,880,748 issued and outstanding, respectively | |
| 583,880 | | |
| 141,881 | |
Additional paid in capital | |
| 171,029,956 | | |
| 127,130,055 | |
Accumulated deficit | |
| (206,194,185 | ) | |
| (203,932,665 | ) |
Total stockholders' deficit | |
| (34,580,349 | ) | |
| (76,660,729 | ) |
Total liabilities and stockholders' deficit | |
$ | 4,778,046 | | |
$ | 3,947,604 | |
The accompanying footnotes are an integral part of these condensed consolidated financial statements.
CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations
For the Three and Nine Months Ended September 30, 2023, and 2022
(Unaudited)
| |
| |
| |
| |
|
| |
Three Months Ended | |
Nine Months Ended |
| |
September 30, 2023 | |
September 30, 2022 | |
September 30, 2023 | |
September 30, 2022 |
Revenues | |
| | | |
| | | |
| | | |
| | |
Subscription-based lease | |
$ | 1,031,828 | | |
$ | 1,323,718 | | |
$ | 3,409,523 | | |
$ | 4,064,757 | |
Sales-based equipment package | |
| 876,126 | | |
| 314,495 | | |
| 2,872,911 | | |
| 1,121,817 | |
Sales-based software bundle | |
| 517,436 | | |
| 329,411 | | |
| 1,635,324 | | |
| 796,815 | |
Total revenue | |
| 2,425,390 | | |
| 1,967,624 | | |
| 7,917,758 | | |
| 5,983,389 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of equipment | |
| 105,311 | | |
| 39,630 | | |
| 362,241 | | |
| 157,227 | |
Network operations | |
| 537,779 | | |
| 602,170 | | |
| 2,006,308 | | |
| 1,949,153 | |
General and administration | |
| 684,848 | | |
| 571,658 | | |
| 2,434,568 | | |
| 2,387,898 | |
Sales and marketing | |
| 423,184 | | |
| 234,414 | | |
| 822,417 | | |
| 565,382 | |
Research and development | |
| 621,929 | | |
| 721,339 | | |
| 1,655,934 | | |
| 1,668,883 | |
Depreciation and amortization | |
| 95,874 | | |
| 130,743 | | |
| 376,502 | | |
| 443,695 | |
Total operating expenses | |
| 2,468,925 | | |
| 2,299,954 | | |
| 7,657,970 | | |
| 7,172,238 | |
| |
| | | |
| | | |
| | | |
| | |
Operating income (loss) | |
| (43,535 | ) | |
| (332,330 | ) | |
| 259,788 | | |
| (1,188,849 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income and (expense) | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (830,994 | ) | |
| (1,146,820 | ) | |
| (2,527,955 | ) | |
| (5,137,272 | ) |
Interest income | |
| 4,628 | | |
| 76 | | |
| 6,647 | | |
| 130 | |
Total other expense | |
| (826,366 | ) | |
| (1,146,744 | ) | |
| (2,521,308 | ) | |
| (5,137,142 | ) |
| |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Provision for income taxes | |
| — | | |
| — | | |
| — | | |
| — | |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (869,901 | ) | |
$ | (1,479,074 | ) | |
$ | (2,261,520 | ) | |
$ | (6,325,991 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share | |
$ | (0.00 | ) | |
$ | (0.01 | ) | |
$ | (0.01 | ) | |
$ | (0.05 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of common | |
| | | |
| | | |
| | | |
| | |
Shares outstanding, basic, and diluted | |
| 583,880,748 | | |
| 139,380,748 | | |
| 417,517,785 | | |
| 139,380,748 | |
The accompanying footnotes are an integral part of these condensed consolidated financial statements.
CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(Unaudited)
| |
| |
| |
Additional | |
| |
|
| |
Common Stock | |
Paid in | |
Accumulated | |
|
| |
Shares | |
Amount | |
Capital | |
Deficit | |
Total |
| |
| |
| |
| |
| |
|
Balance, January 1, 2022 | |
| 139,380,748 | | |
$ | 139,381 | | |
$ | 85,052,367 | | |
$ | (197,890,046 | ) | |
$ | (112,698,298 | ) |
Issuance of warrants to purchase common stock | |
| — | | |
| — | | |
| 240,000 | | |
| — | | |
| 240,000 | |
Options granted as compensation | |
| — | | |
| — | | |
| 55,847 | | |
| — | | |
| 55,847 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (2,345,008 | ) | |
| (2,345,008 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, March 31, 2022 | |
| 139,380,748 | | |
$ | 139,381 | | |
$ | 85,348,214 | | |
$ | (200,235,054 | ) | |
$ | (114,747,459 | ) |
Stock based compensation | |
| — | | |
| — | | |
| 58,363 | | |
| — | | |
| 58,363 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (2,501,909 | ) | |
| (2,501,909 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, June 30, 2022 | |
| 139,380,748 | | |
$ | 139,381 | | |
$ | 85,406,577 | | |
$ | (202,736,963 | ) | |
$ | (117,191,005 | ) |
Stock based compensation | |
| — | | |
| — | | |
| 58,858 | | |
| — | | |
| 58,858 | |
Related party forgiveness of interest | |
| — | | |
| — | | |
| 1,667,260 | | |
| — | | |
| 1,667,260 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (1,479,074 | ) | |
| (1,479,074 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, September 30, 2022 | |
| 139,380,748 | | |
$ | 139,381 | | |
$ | 87,132,695 | | |
$ | (204,216,037 | ) | |
$ | (116,943,961 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, January 1, 2023 | |
| 141,880,748 | | |
$ | 141,881 | | |
$ | 127,130,055 | | |
$ | (203,932,665 | ) | |
$ | (76,660,729 | ) |
Stock based compensation | |
| — | | |
| — | | |
| 62,260 | | |
| — | | |
| 62,260 | |
Debt to equity conversion at $0.10 | |
| 262,000,000 | | |
| 262,000 | | |
| 25,938,000 | | |
| — | | |
| 26,200,000 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (1,346,812 | ) | |
| (1,346,812 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, March 31, 2023 | |
| 403,880,748 | | |
$ | 403,881 | | |
$ | 153,130,315 | | |
$ | (205,279,477 | ) | |
$ | (51,745,281 | ) |
Stock based compensation | |
| — | | |
| — | | |
| 54,796 | | |
| — | | |
| 54,796 | |
Debt to equity conversion at $0.10 | |
| 180,000,000 | | |
| 180,000 | | |
| 17,820,000 | | |
| — | | |
| 18,000,000 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (44,807 | ) | |
| (44,807 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, June 30, 2023 | |
| 583,880,748 | | |
$ | 583,881 | | |
$ | 171,005,111 | | |
$ | (205,324,284 | ) | |
$ | (33,735,292 | ) |
Stock based compensation | |
| — | | |
| — | | |
| 24,844 | | |
| — | | |
| 24,844 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (869,901 | ) | |
| (869,901 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, September 30, 2023 | |
| 583,880,748 | | |
$ | 583,881 | | |
$ | 171,029,955 | | |
$ | (206,194,185 | ) | |
$ | (34,580,349 | ) |
The accompanying footnotes are an integral part of these condensed consolidated financial statements.
CAREVIEW COMMUNICATIONS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(Unaudited)
| |
| |
|
| |
Nine Months Ended |
| |
September 30, 2023 | |
September 30, 2022 |
| |
| |
|
CASH FLOWS FROM OPERATING ACTIVITIES | |
| | | |
| | |
Net loss | |
$ | (2,261,520 | ) | |
$ | (6,325,991 | ) |
Adjustments to reconcile net loss to net cash provided by (used in)
operating activities: | |
| | | |
| | |
Depreciation | |
| 273,478 | | |
| 375,867 | |
Amortization of intangible assets | |
| 81,242 | | |
| 40,098 | |
Amortization of deferred installation costs | |
| 21,783 | | |
| 27,730 | |
Amortization of debt discount | |
| — | | |
| 860,239 | |
Amortization of deferred debt issuance and debt financing costs | |
| — | | |
| — | |
Non-cash lease expense | |
| 103,853 | | |
| 88,838 | |
Interest incurred and paid in kind | |
| — | | |
| — | |
Stock based compensation related to options granted and warrants issued | |
| 141,900 | | |
| 2,080,328 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (877,542 | ) | |
| 69,064 | |
Inventory | |
| 68,840 | | |
| (39,960 | ) |
Other current assets | |
| (258,817 | ) | |
| 165,732 | |
Patent license | |
| 12,295 | | |
| 12,295 | |
Accounts payable | |
| (44,952 | ) | |
| 461,222 | |
Accrued interest | |
| 2,406,375 | | |
| 2,219,923 | |
Other current liabilities | |
| 616,225 | | |
| (225,486 | ) |
Operating Lease Liability | |
| (112,178 | ) | |
| (92,497 | ) |
Net cash provided by (used in) operating Activities | |
| 170,982 | | |
| (282,598 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES | |
| | | |
| | |
Purchase of equipment | |
| (6,444 | ) | |
| (5,189 | ) |
Patent, trademark, and other intangible assets costs | |
| — | | |
| (58,260 | ) |
Net cash used in investing activities | |
| (6,444 | ) | |
| (63,449 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES | |
| | | |
| | |
Repayment of notes payable | |
| — | | |
| (13,786 | ) |
Repayment of vehicle loan | |
| (10,684 | ) | |
| (10,567 | ) |
Net cash used in financing Activities | |
| (10,684 | ) | |
| (24,353 | ) |
| |
| | | |
| | |
Increase (decrease) in cash | |
| 153,854 | | |
| (370,400 | ) |
Cash and restricted cash, beginning of period | |
| 520,166 | | |
| 659,228 | |
Cash and restricted cash, end of period | |
$ | 674,020 | | |
$ | 288,828 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | |
| | | |
| | |
Cash paid for interest | |
$ | — | | |
$ | 114,291 | |
| |
| | | |
| | |
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITES: | |
| | | |
| | |
Capital expenditures funded by term loan | |
$ | — | | |
$ | 1,667,260 | |
Replacement Notes conversion to equity at $0.10 per share | |
$ | 44,200,000 | | |
$ | — | |
The accompanying footnotes are an integral part of these condensed consolidated financial statements.
CAREVIEW COMMUNICATIONS,
INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Interim
Financial Statements
The
accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”,
the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted
accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions
to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary
for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities
and Exchange Commission (the “SEC”). The balance sheet at December 31, 2022 has been derived from the audited consolidated
financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations
for interim periods are not necessarily indicative of results for the full year. The accompanying unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual
Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on May 26, 2023.
Revenue
Recognition
We
recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”). For our
subscription service contracts, we have employed the practical expedient discussed in ASC 606-10-55-18 related to invoicing as we have
the right to consideration from our customers in the amount that corresponds directly with the value to the customer of our performance
completed to date and therefore, we recognize revenue upon invoicing as further discussed below.
In
accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized
reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC
606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in
amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply
the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine
the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when,
or as, we satisfy the performance obligation. For those customers for which we are required to collect sales taxes, we record such sales
taxes on a net basis which has no effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the
taxing authority.
We
enter into contracts with customers that may provide multiple combinations of our products, software solutions, and other related services,
which are generally capable of being distinct and accounted for as separate performance obligations. Performance obligations that are
not distinct at contract inception are combined.
Customer
contract fulfillment typically involves multiple procurement promises, which may include various equipment, software subscription, project-related
installation and training services, and support. We allocate the transaction price to each performance obligation based on estimated
relative standalone selling price. Revenue is then recognized for each performance obligation upon transferring control of the hardware,
software, and services to the customer and in an amount that reflects the consideration we expect to receive and the estimated benefit
the customer receives over the term of the contract.
Generally,
we recognize revenue under each of our performance obligations as follows:
|
● |
Subscription
services – We recognize subscription revenues monthly over the contracted license period. |
|
● |
Equipment
packages – We recognize equipment revenues when control of the devices has been transferred to the client (“point in
time”). |
|
● |
Software
bundle and related services related to sales-based contracts – We recognize our software subscription, installation, training,
and other services on a straight-line basis over the estimated contracted license period (“over time”). |
Disaggregation
of Revenue
The
following presents net revenues disaggregated by our business models:
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Sales-based
contract revenue |
|
|
|
|
|
|
|
|
Equipment
package, net (point in time) |
|
$ |
2,872,911 |
|
|
$ |
1,121,817 |
|
Software
bundle (over time) |
|
|
1,635,324 |
|
|
|
796,815 |
|
Total
sales-based contract revenue |
|
|
4,508,235 |
|
|
|
1,918,632 |
|
|
|
|
|
|
|
|
|
|
Subscription-based
lease revenue |
|
|
3,409,523 |
|
|
|
4,064,757 |
|
Net
revenue |
|
$ |
7,917,758 |
|
|
$ |
5,983,389 |
|
Contract
Liabilities
Our
subscription-based contracts payment arrangements are required to be paid monthly which are recognized into revenue when received. Some
customers choose to pay their subscription fee in advance. Customer payments received in advance of satisfaction of the related performance
obligations are deferred as contract liabilities. These amounts are recorded as “deferred revenue” in our condensed consolidated
balance sheets and recognized into revenues over time.
Our
sales-based contract payment arrangements with our customers typically include an initial equipment payment due upon signing of the contract
and subsequent payments when certain performance obligations are completed. Customer payments received in advance of satisfaction of
related performance obligations are deferred as contract liabilities. These amounts are recorded as “deferred revenue” in
our condensed consolidated balance sheets and recognized into revenues as either a point in time or over time.
During
the nine months ended September 30, 2023 and 2022, a total of $21,145 and $210,681, respectively, of subscription-based deferred contract
liability was recognized as revenue. The table below details the subscription-based contract liability activity during the nine months
ended September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
21,145 |
|
|
$ |
231,140 |
|
Additions |
|
|
— |
|
|
|
30,306 |
|
Transfer
to revenue |
|
|
(21,145) |
|
|
|
(210,681 |
) |
Balance,
end of period |
|
$ |
- |
|
|
$ |
50,765 |
|
During
the nine months ended September 30, 2023 and 2022, a total of $1,331,409 and $1,829,720, respectively, of sales-based deferred contract
liability was recognized as revenue. The table below details the sales-based contract liability activity during the nine months ended
September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
869,485 |
|
|
$ |
752,526 |
|
Additions |
|
|
1,807,630 |
|
|
|
2,000,051 |
|
Transfer
to revenue |
|
|
(1,331,409) |
|
|
|
(1,829,720 |
) |
Balance,
end of period |
|
$ |
1,345,706 |
|
|
$ |
922,857 |
|
As
of September 30, 2023, the aggregate amount of deferred revenue from subscription-based contracts and sales-based contracts allocated
to performance obligations that are unsatisfied or partially satisfied is approximately $1,345,706 and will be recognized into revenue
over time as follows:
Years
Ending December 31, |
|
|
Amount |
|
2023 |
|
|
$ |
522,100 |
|
2024 |
|
|
|
685,238 |
|
Thereafter |
|
|
|
138,368 |
|
|
|
|
$ |
1,345,706 |
|
We
defer and capitalize all costs associated with the installation of the CareView System into a healthcare facility until the CareView
System is fully operational and accepted by the healthcare facility. Installation costs are specifically identifiable based on the amounts
we are charged from third party installers or directly identifiable labor hours incurred for each installation. Upon acceptance, the
associated costs are expensed on a straight-line basis over the life of the contract with the healthcare facility. These costs are included
in network operations on the accompanying consolidated statements of operations.
The
table below details the activity in these deferred installation costs during the periods ended September 30, 2023 and 2022, included
in other assets in the accompanying unaudited consolidated balance sheet.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
33,461 |
|
|
$ |
68,901 |
|
Additions |
|
|
— |
|
|
|
— |
|
Transfer
to expense |
|
|
(21,783) |
|
|
|
(27,731 |
) |
Balance,
end of period |
|
$ |
11,678 |
|
|
$ |
41,170 |
|
Significant
Judgements When Applying Topic 606
Contracts
with our customers are typically structured similarly and include various combinations of our products, software solutions, and related
services. Determining whether the various contract promises are considered distinct performance obligations that should be accounted
for separately versus together may require significant judgment.
Contract
transaction price is allocated to distinct performance obligations using estimated standalone selling price. We determine standalone
selling price maximizing observable inputs such as standalone sales, competitor standalone sales, or substantive renewal prices charged
to customers when they exist. In instances where standalone selling price is not observable, we utilize an estimate of standalone selling
price. Such estimates are derived from various methods that include cost plus margin, and historical pricing practices. Judgment may
be required to determine standalone selling prices for each performance obligation and whether it depicts the amount we expect to receive
in exchange for the related good or service.
Contract
modifications occur when we and our customers agree to modify existing customer contracts to change the scope or price (or both) of the
contract or when a customer terminates some, or all, of the existing services provided by us. When a contract modification occurs, it
requires us to exercise judgment to determine if the modification should be accounted for as a separate contract, the termination of
the original contract and creation of a new contract, a cumulative catch-up adjustment to the original contract, or a combination.
Contracts
with our customers include a limited warranty on our products covering materials, workmanship, or design for the duration of the contract.
We do not offer paid additional extended or lifetime warranty packages. We determined the limited warranty in our contract is not a distinct
performance obligation. We do not believe our estimates of warranty costs to be significant to our determination of revenue recognition,
and therefore, did not reserve for warranty costs.
Leases
The
Company has an operating lease primarily consisting of office space with a remaining lease term of 26 months. At the lease commencement
date, an operating lease liability and related operating lease asset are recognized. The operating lease liabilities are calculated using
the present value of lease payments. The discount rate used is either the rate implicit in the lease, when known, or our estimated incremental
borrowing rate. Operating lease assets are valued based on the initial operating lease liabilities plus any prepaid rent and direct costs
from executing the leases.
Earnings
(Loss) Per Share
We
calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts,
basic and diluted. Basic EPS is computed based on the weighted average number of common shares outstanding during the period. Diluted
EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding
during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants to purchase
our Common Stock (the “Warrants”) and convertible debt. Potential common shares totaling 46,801,922 and 222,000,000 on September
30, 2023 and 2022, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to
our reported net loss. The 46,801,922 potential common shares consist of 41,107,477 stock options and 5,694,445 warrants.
Recently Issued and Newly Adopted Accounting Pronouncements
ASU
2016-13
ASU
2016-13 requires organizations to measure all expected credit losses for financial instruments held at the reporting date based on historical
experience, current conditions, and reasonable and supportable forecasts. This guidance:
|
1. |
Eliminates
the probable initial recognition threshold in current GAAP and, instead, reflects an organization’s current estimate of all
expected credit losses over the contractual term of its financial assets. |
|
2. |
Broadens
the information that an entity can consider when measuring credit losses to include forward-looking information. |
|
3. |
Increases
usefulness of the financial statements by requiring timely inclusion of forecasted information in forming expectations of credit
losses. |
|
4. |
Increases
comparability of purchased financial assets with credit deterioration (PCD assets) with other purchased assets that do not have credit
deterioration as well as originated assets because credit losses that are expected will be recorded through an allowance for credit
losses for all assets. |
|
5. |
Increases
users’ understanding of underwriting standards and credit quality trends by requiring additional information about credit quality
indicators by year of origination (vintage). |
|
6. |
For
available-for-sale debt securities, aligns the income statement recognition of credit losses with the reporting period in which changes
occur by recording credit losses (and subsequent changes in credit losses) through an allowance rather than a write down. |
The
guidance affects loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance
receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. We, as a smaller
reporting company as defined by the SEC, have adopted ASU 2016-13 effective for January 1, 2023. As of September 30, 2023, ASU 2016-13
does not have any material effect on the Company.
ASU
2020-06
ASU
2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance
in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and
cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies
to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted
for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding
financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’
equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding
financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded
features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260,
Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted
method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled
in cash or shares. We, as a smaller reporting company as defined by the SEC, will adopt ASU 2020-06 effective for fiscal year 2024.
ASU
2022-03
ASU
2022-03 clarifies that a “contractual sale restriction prohibiting the sale of an equity security is a characteristic of the reporting
entity holding the equity security” and is not included in the equity security’s unit of account. Accordingly, an entity
should not consider the contractual sale restriction when measuring the equity security’s fair value (i.e., the entity should not
apply a discount related to the contractual sale restriction, as stated in ASC 820-10-35-36B as amended by the ASU). In addition, the
ASU prohibits an entity from recognizing a contractual sale restriction as a separate unit of account. Under the existing guidance in
ASC 820-10-35-6B, “although a reporting entity must be able to access the market, the reporting entity does not need to be able
to sell the particular asset or transfer the particular liability on the measurement date to be able to measure fair value on the basis
of the price in that market.” ASU 2022-03 clarifies that an entity should apply this existing guidance when measuring the fair
value of equity securities that are subject to contractual sale restrictions (i.e., a contractual sale restriction on the reporting entity
that prevents the sale of an equity security in the market does not prevent the entity from measuring the fair value of the equity security
on the basis of the price in that principal market). ASU 2022-03 for the Company will be effective for fiscal year 2024.
NOTE
2 – GOING CONCERN, LIQUIDITY AND MANAGEMENT’S PLAN
Accounting
standards require management to evaluate our ability to continue as a going concern for a period of one year after the date of the filing
of this Form 10-Q (“evaluation period”). In evaluating the Company’s ability to continue as a going concern, management
considers the conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern for
a period of twelve months after the Company issues its financial statements. For the nine months ended September 30, 2023, management
considers the Company’s current financial condition and liquidity sources, including current funds available, forecasted future
cash flows, and the Company’s conditional and unconditional obligations due within 12 months of the date these financial statements
are issued.
The
Company is subject to risks like those of healthcare technology companies whereby revenues are generated based on both sales-based and
subscription-based models, which assume dependence on key individuals, uncertainty of product development, generation of revenues, positive
cash flow, dependence on outside sources of capital, risks associated with research, development, and successful testing of its products,
successful protection of intellectual property, ability to maintain and grow its customer base, and susceptibility to infringement on
the proprietary rights of others. The attainment of profitable operations is dependent on future events, including obtaining adequate
financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s
cost structure.
As
of September 30, 2023, the Company had a working capital deficit of $36,099,968. Management has evaluated the significance of the conditions
described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the
Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were
issued. While management will look to continue funding operations by increased sales volumes and raising additional capital from sources
such as sales of its debt or equity securities or loans to meet operating cash requirements, there is no assurance that management’s
plans will be successful.
On
March 30, 2023, noteholders owning Replacement Notes in an aggregate of $26,200,000, entered into a Replacement Note Conversion Agreement,
wherein the Replacement Notes were converted into shares of the Company’s common stock at a conversion price of $0.10 per share,
resulting in the issuance of an aggregate of 262,000,000 shares (the “Conversion Shares”). The Conversion Shares bear a lockup
legend that expires December 31, 2023.
Upon
this conversion, and as of March 31, 2023, the Company’s officers and board of directors held the majority of the Company’s
outstanding voting stock. With controlling interest of the majority of outstanding shares, the Company’s majority shareholders
voted to amend its articles of incorporation to increase the authorized shares available for issuance from 500,000,000 to 800,000,000,
with an effective date of May 22, 2023.
On
May 24, 2023, noteholder owning Replacement Notes in the aggregate of $18,000,000, presented Conversion Notices, per the terms of the
Replacement Notes, to the Company to convert the Replacement Notes into 180,000,000 shares of the Company’s common stock at a conversion
price of $0.10 per share. The shares bear a lock-up legend that expires December 31, 2023.
Management
continues to monitor the immediate and future cash flows needs of the company in a variety of ways which include forecasted net cash
flows from operations, capital expenditure control, new inventory orders, debt modifications, increases in sales outreach, streamlining
and controlling general and administrative costs, competitive industry pricing, sale of equities, debt conversions, new product or services
offerings, and new business partnerships.
The
Company’s net losses, cash outflows, and working capital deficit raise substantial doubt about the Company’s ability to continue
as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as
a going concern. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities
in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive
cash flows adequate to support the Company’s cost structure.
NOTE
3 – STOCKHOLDERS’ EQUITY
Warrants
to Purchase Common Stock of the Company
We
use the Black-Scholes-Merton option pricing model (“Black-Scholes Model”) to determine the fair value of Warrants. The Black-Scholes
Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate,
and the weighted average term of the Warrant.
The
risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is
appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding
the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the
expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer
entities whose stock prices were publicly available) over a period equal to the expected life of the awards.
A
summary of our Warrants activity and related information follows:
|
|
Number
of
Shares Under
Warrant |
|
|
Range
of
Warrant Price
Per Share |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life |
|
Balance
at December 31, 2022 |
|
|
5,694,445 |
|
|
|
$0.01-$0.03 |
|
|
$ |
0.024 |
|
|
|
3.5 |
|
Granted |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Expired |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Canceled |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Balance
at September 30, 2023 |
|
|
5,694,445 |
|
|
|
$0.01-$0.03 |
|
|
$ |
0.024 |
|
|
|
2.8 |
|
Options
to Purchase Common Stock of the Company
During
the nine months ended September 30, 2023, 600,000
options to purchase our Common Stock were granted having a fair value of $33,300
and exercise price of $0.06
per share. The valuation methodology used to determine the fair value of the stock options issued was the Black-Scholes Model. The
Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average
risk-free interest rate, and the weighted average expected term of the options. During the nine months ended September 30, 2023,
310,000 options expired or were terminated.
A
summary of our stock option activity and related information follows:
|
|
Number
of
Shares Under
Options |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life |
|
|
Aggregate
Intrinsic
Value |
|
Balance
at December 31, 2022 |
|
|
40,817,477 |
|
|
$ |
0.12 |
|
|
|
5.8 |
|
|
$ |
526,425 |
|
Granted |
|
|
600,000 |
|
|
|
0.03 |
|
|
|
9.6 |
|
|
|
3,000 |
|
Forfeited/Expired |
|
|
(310,000 |
) |
|
|
(0.06 |
) |
|
|
— |
|
|
|
— |
|
Exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Balance
at September 30, 2023 |
|
|
41,107,477 |
|
|
$ |
0.12 |
|
|
|
5.0 |
|
|
$ |
529,425 |
|
Vested
and Exercisable at September 30, 2023 |
|
|
40,200,144 |
|
|
$ |
0.13 |
|
|
|
4.8 |
|
|
$ |
523,425 |
|
At
September 30, 2023, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately
$49,028, which is expected to be recognized over a weighted-average period of 2.1 years. No tax benefit was realized due to a continued
pattern of operating losses.
NOTE
4 – OTHER CURRENT ASSETS
Other
current assets consist of the following:
|
|
September
30,
2023 |
|
|
December
31, 2022 |
|
Prepaid
insurance |
|
$ |
309,386
|
|
|
$ |
36,639 |
|
Other
prepaid expenses |
|
|
20,451 |
|
|
|
34,381 |
|
|
|
|
|
|
|
|
|
|
TOTAL
OTHER CURRENT ASSETS |
|
$ |
329,837 |
|
|
$ |
71,020 |
|
NOTE
5 – INVENTORY
Inventory
is valued at the lower of cost, determined on a first-in, first-out (FIFO), or net realizable value. Inventory items are analyzed to
determine cost and net realizable value and appropriate valuation adjustments are then established.
Inventory
consists of the following:
|
|
September
30,
2023 |
|
|
December
31,
2022 |
|
Inventory
assets |
|
$ |
232,606 |
|
|
$ |
301,446 |
|
TOTAL
INVENTORY |
|
$ |
232,606 |
|
|
$ |
301,446 |
|
NOTE
6 – PROPERTY AND EQUIPMENT
Property
and equipment consist of the following:
|
|
September
30,
2023 |
|
|
December
31,
2022 |
|
Network
equipment |
|
$ |
12,620,258 |
|
|
$ |
12,620,258 |
|
Office
equipment |
|
|
240,874 |
|
|
|
234,430 |
|
Vehicles |
|
|
232,411 |
|
|
|
232,411 |
|
Test
equipment |
|
|
230,365 |
|
|
|
230,365 |
|
Furniture |
|
|
92,846 |
|
|
|
92,846 |
|
Warehouse
equipment |
|
|
9,523 |
|
|
|
9,523 |
|
Leasehold
improvements |
|
|
5,121 |
|
|
|
5,121 |
|
|
|
|
13,431,398 |
|
|
|
13,424,954 |
|
Less:
accumulated depreciation |
|
|
(13,055,872) |
|
|
|
(12,782,395 |
) |
TOTAL
PROPERTY AND EQUIPMENT, NET |
|
$ |
375,526 |
|
|
$ |
642,559 |
|
Depreciation
expense for the nine months ended September 30, 2023 and 2022 was $273,477 and $375,867, respectively.
NOTE
7 – INTANGIBLE AND OTHER ASSETS, NET
Intangible
assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30, 2023 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Patents
and trademarks |
|
$ |
1,213,850 |
|
|
$ |
481,058 |
|
|
$ |
732,792 |
|
Other
intangible assets |
|
|
20,237 |
|
|
|
14,166 |
|
|
|
6,071 |
|
TOTAL
INTANGIBLE ASSETS |
|
$ |
1,234,087 |
|
|
$ |
495,224 |
|
|
$ |
738,863 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2022 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Patents
and trademarks |
|
$ |
1,213,850 |
|
|
$ |
395,715 |
|
|
$ |
818,135 |
|
Other
intangible assets |
|
|
85,896 |
|
|
|
83,925 |
|
|
|
1,971 |
|
TOTAL
INTANGIBLE ASSETS |
|
$ |
1,299,746 |
|
|
$ |
479,640 |
|
|
$ |
820,106 |
|
Other
assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30, 2023 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Deferred
installation costs |
|
$ |
1,352,041 |
|
|
$ |
1,340,363 |
|
|
$ |
11,678 |
|
Deferred
sales commission |
|
|
368,804 |
|
|
|
207,672 |
|
|
|
161,132 |
|
Prepaid
license fee |
|
|
249,999 |
|
|
|
198,086 |
|
|
|
51,913 |
|
Security
deposit |
|
|
46,124 |
|
|
|
- |
|
|
|
46,124 |
|
TOTAL
OTHER ASSETS |
|
$ |
2,016,968 |
|
|
$ |
1,746,121 |
|
|
$ |
270,847 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2022 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Deferred
installation costs |
|
$ |
1,352,041 |
|
|
$ |
1,318,580 |
|
|
$ |
33,461 |
|
Deferred
sales commissions |
|
|
163,973 |
|
|
|
98,116 |
|
|
|
65,857 |
|
Prepaid
license fee |
|
|
249,999 |
|
|
|
185,792 |
|
|
|
64,207 |
|
Security
deposit |
|
|
46,124 |
|
|
|
— |
|
|
|
46,124 |
|
TOTAL
OTHER ASSETS |
|
$ |
1,812,137 |
|
|
$ |
1,602,488 |
|
|
$ |
209,649 |
|
NOTE
8 – OTHER CURRENT LIABILITIES
Other
current liabilities consist of the following:
|
|
September
30,
2023 |
|
|
December 31,
2022 |
|
Accrued
interest |
$ |
15,258,611 |
|
|
$ |
12,933,611 |
|
Accrued
interest, related parties |
|
418,403 |
|
|
|
337,027 |
|
Allowance
for system removal |
|
54,802 |
|
|
|
54,802 |
|
Accrued
paid time off |
|
152,291 |
|
|
|
154,776 |
|
Deferred
officer compensation(1) |
|
139,041 |
|
|
|
139,041 |
|
Deferred
revenue |
|
1,207,338 |
|
|
|
890,631 |
|
Other
accrued liabilities |
|
302,299 |
|
|
|
43,389 |
|
TOTAL
OTHER CURRENT LIABILITIES |
$ |
17,532,785 |
|
|
$ |
14,553,277 |
|
|
|
|
|
|
|
|
|
|
NOTE
9 – INCOME TAXES
Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities
and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not
expect to pay any significant federal or state income tax for 2023 because of the losses recorded during the nine months ended September
30, 2023 and net operating loss carry forwards from prior years. In assessing the realizability of deferred tax asset, including the
net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient
future taxable income will be generated to utilize its existing deferred assets. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the period when those temporary differences become deductible. Accounting standards
require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component
or all the benefits of deferred tax assets will not be realized. As of September 30, 2023, we maintained a full valuation allowance for
all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded
unrecognized tax benefits at the end of the reporting period.
The
Tax Cuts and Jobs Act (the “Act”) was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue
Code, the Act reduces U.S. corporate rates from 35% to 21%. Additionally, the Act limits the use of net operating loss carry backs, however
any future net operating losses will instead be carried forward indefinitely. Net operating losses generated from January 1, 2018 are
limited to offset 80% of current income, with the remainder of the net operating loss continuing to carry forward indefinitely. Net operating
losses incurred before January 1, 2018 are not subject to the 80% limitations and will begin to expire in 2029. Based on an initial assessment
of the Act, the Company believes that the most significant impact on the Company’s unaudited condensed consolidated financial statements
will be limitations in tax deductions on interest expense. Under the Act, interest deductions disallowed from current income will carryforward
indefinitely. The Act did not impact management’s valuation allowance position.
The
effective tax rate for the nine months ended September 30, 2023 was different from the federal statutory rate due primarily to change
in the valuation allowance and nondeductible interest and amortization expense.
NOTE
10 – AGREEMENT WITH PDL BIOPHARMA, INC.
On June 26, 2015, we entered into a Credit Agreement (as subsequently amended) with PDL BioPharma, Inc. (“PDL”), as administrative
agent and lender (“the Lender”) (the “PDL Credit Agreement”). Under the PDL Credit Agreement the Lender made available
to us up to $40 million in two tranches of $20 million each. Tranche One was funded on October 8, 2015 (the “Tranche One Loan”).
Pursuant to the terms of the PDL Credit Agreement and having not met the Tranche Two Milestones by July 26, 2017, the Tranche Two funding
was terminated in full.
On
June 23, 2022, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Sixth
Amendment to Modification Agreement (the “Twenty-Sixth Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and June 30, 2022 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020, October 7, 2020 and June 30, 2022 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche
One Loan and the Tranche Three Loans that would otherwise be due under the Credit Agreement on June 30, 2022, would each be deferred
until December 31, 2022 (the end of the extended Modification) and that such deferrals would be a covered event. The Company has evaluated
the Twenty-Sixth Modification Agreement Amendment and as the effective borrowing rate under the restructured agreement is less than the
effective borrowing rate on the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has
been granted, the agreement is to be accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.
On
December 30, 2022, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Seventh
Amendment to Modification Agreement (the “Twenty-Seventh Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and February 28, 2023 (with each such date permitted to be extended by the
Lender in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement
on December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September
30, 2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan
and the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until February
28, 2023 (the end of the extended Modification Period) and that such deferrals would be a covered event. The Company has evaluated the
Twenty-seventh Modification Agreement Amendment and as the effective borrowing rate under the restructured agreement is less than the
effective borrowing rate on the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has
been granted, the agreement is to be accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.
On
February 28, 2023, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Eighth
Amendment to Modification Agreement (the “Twenty-Eighth Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and March 31, 2023 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan and
the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until March
30, 2023 (the end of the extended Modification Period).
On
March 31, 2023, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Ninth
Amendment to Modification Agreement (the “Twenty-Ninth Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and April 30, 2023 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan and
the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until April
30, 2023 (the end of the extended Modification Period). Under debt modification/troubled debt guidance, we determined that the first
of the eight amendments had no cash flow impact, and therefore, had no impact on accounting. Amendments nine through ten qualified for
modification accounting, while the final nineteen amendments qualified for troubled debt restructuring accounting. As appropriate, we
expensed the legal costs paid to third parties. For the three months ended March 31, 2023 and 2022, pursuant to the terms of the PDL
Modification Agreement, as amended, $802,125 and $775,000, respectively, was recorded as interest expense on the accompanying unaudited
condensed consolidated financial statements.
On
April 29, 2023, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Thirtieth
Amendment to Modification Agreement (the “Thirtieth Modification Agreement Amendment”), pursuant to which the parties agreed
to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion, to
terminate the Modification Period would be July 31, 2018 and May 31, 2023 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan and
the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until May 31,
2023 (the end of the extended Modification Period).
On
May 31, 2023 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive
Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Seventh Amendment to Credit Agreement (the
“Seventh Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to, among other
things, (i) provide that, after the Effective Date, all accrued but unpaid interest (including interest accrued but unpaid prior to the
Effective Date and excluding interest payable on the Maturity Date, in connection with any prepayment, or in the event of an Event of
Default, which interest will be payable in cash) accruing on Tranche One Loans and Tranche Three Loans will be paid-in-kind on each Interest
Payment Date by being added to the aggregate principal balance of the respective loans in arrears on each Interest Payment Date; (ii)
require certain mandatory prepayments of the loans by the Company, including (A) quarterly prepayments in the amount, if any, that the
Company’s Excess Cash Flow exceeds $600,000, (B) monthly transfers to the Inventory Reserve Account in the amount, if any, the
Company’s cash exceeds $1,200,000, (C) prepayment in the amount, if any, the Company’s Inventory Reserve Account exceeds
$600,000, and (D) prepayment in the amount, if any, of 100% of the gross proceeds of any indebtedness incurred by the Company (other
than permitted indebtedness); and (iii) extend the Maturity Date to December 31, 2024.
On
September 30, 2023 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief
Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into an Eighth Amendment to Credit Agreement
(the “Eighth Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to modify certain
texts originating within the Seventh Credit Agreement. Stricken texts include “all accrued but unpaid interest (including interest
accrued but unpaid prior to the Effective Date and excluding interest payable on the Maturity Date, in connection with any prepayment,
or in the event of an Event of Default, which interest will be payable in cash) accruing on Tranche One Loans and Tranche Three Loans
will be paid-in-kind on each Interest Payment Date by being added to the aggregate principal balance of the respective loans in arrears
on each Interest Payment Date.” Additional texts include Release of Claims, which “in consideration of the Lender’s
and Agent’s agreements contained in this Amendment, each of Holdings, the Borrower and the Subsidiary Guarantor hereby releases
and discharges the Lender and the Agent and their affiliates, subsidiaries, successors, assigns, directors, officers, employees, agents,
consultants and attorneys (each, a “Released Person”) of and from any and all other claims, suits, actions, investigations,
proceedings or demands, whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or
common law of any kind or character, known or unknown, which Holdings, the Borrower or the Subsidiary Guarantor ever had or now has against
the Agent, any Lender or any other Released Person which relates, directly or indirectly, to any acts or omissions of the Agent, any
Lender or any other Released Person relating to the Credit Agreement or any other Loan Document on or prior to the date hereof.”
Accounting
Treatment
In
connection with the PDL Credit Agreement, as amended, we issued the PDL Warrant to the Lender. As of September 30, 2023, the Amended
PDL Warrant has not been exercised.
Due
to the PDL Eighth Credit Agreement Amendment, the calculations for the “interest paid-in-kind” and quarterly “prepayment(s)”
were removed effective with the quarter ending on September 30, 2023. The Company concluded that the Company is encountering financial
hardship and that a concession was not granted. As the Lender has not granted a concession, the guidance contained in ASC 470-50 Modification
and Extinguishment was applied. Given the present value of the cash flows under the Eighth Credit Agreement Amendment differed by less
than 10% from the present value of the remaining cash flows under the terms of the prior debt agreement, the debt was determined to be
not substantially different which resulted in modification accounting. The Company did not have any debt issuance costs, only legal expenses.
NOTE
11 – AGREEMENT WITH HEALTHCOR
On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) with HealthCor Partners Fund, LP (“HealthCor
Partners”) and HealthCor Hybrid Offshore Master Fund, LP (“HealthCor Hybrid” and, together with HealthCor Partners,
“HealthCor”) (the “HealthCor Purchase Agreement”). Pursuant to the terms of the HealthCor Purchase Agreement,
we sold and issued Senior Secured Convertible Notes to HealthCor in the principal amount of $9,316,000 and $10,684,000, respectively (collectively
the “2011 HealthCor Notes”). The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor
for the purchase of an aggregate of up to 5,488,456 and 6,294,403 shares, respectively, of our Common Stock at an exercise price of $1.40
per share (collectively the “2011 HealthCor Warrants”). So long as no event of default has occurred, the outstanding principal
balances of the 2011 HealthCor Notes accrue interest from April 21, 2011 through April 20, 2016 (the “First Five-Year Note Period”)
at the rate of 12.5% per annum, compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes
on the last day of each calendar quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the “Second Five Year Note
Period”) at a rate of 10% per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest
may be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. For the period
from April 21, 2016 through September 30, 2018 interest has been added to the outstanding principal balance. Pursuant to the terms of
the Ninth Amendment, the accrual of interest has been suspended after September 30, 2018. From the date any event of default occurs, the
interest rate, then applicable, shall be increased by five percent (5%) per annum. HealthCor has the right, upon an event of default,
to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid
interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the immediately
preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable. Subject to
the terms of the Ninth Amendment as discussed below, HealthCor’s ability to convert any portion of the outstanding and unpaid accrued
interest on and principal balances of the 2011 HealthCor Notes into fully paid and nonassessable shares of our Common Stock has been eliminated.
The warrants issued with this Note were cancelled with the Ninth-Amendment dated July 10, 2018.
On
March 08, 2022, we agreed with the HealthCor Parties to (i) amend the 2011 HealthCor Notes to extend the maturity date of the 2011 HealthCor
Notes from April 20, 2022 to April 20, 2023 by entering into Allonge No. 4 to the 2011 HealthCor Notes (the “Third 2011 Note Allonges”)
and (ii) amend the 2012 HealthCor Notes to extend the maturity date of the 2012 HealthCor Notes from April 20, 2022 to April 20, 2023
by entering into Allonge No. 4 to the 2012 HealthCor Notes (the “Fourth 2012 Note Allonges”) (such amendments to the 2011
HealthCor Notes and 2012 HealthCor Notes together, the “HealthCor Note Extensions”). In connection with the HealthCor Note
Extensions, we issued warrants to purchase an aggregate of 3,000,000 shares of our Common Stock at an exercise price per share equal
to $0.09 per share (subject to adjustment as described therein) and with an expiration date of March 08, 2032, to the HealthCor Parties
(collectively the “2021 HealthCor Warrants”). The warrants were valued at $240,000 and are amortized over the life of the
debt. The conclusion was that this was a debt modification and this was accounted for as such.
Also
on March 08, 2022, in connection with the HealthCor Note Extensions and the issuance of the 2021 HealthCor Warrants, we entered into
a Consent and Agreement Pursuant to Note and Warrant Purchase Agreement (the “2022 NWPA Consent”) with the HealthCor Parties
and certain additional Existing Investors (in their capacity as Majority Holders acting together with the HealthCor Parties), pursuant
to which, among other things, (i) the Majority Holders consented to the HealthCor Note Extensions, (ii) the Majority Holders consented
to the issuance of the 2021 HealthCor Warrants and (iii) the parties agreed that the holders of the 2021 HealthCor Warrants would have
registration rights for the shares of Common Stock issuable upon exercise of the 2021 HealthCor Warrants under the Registration Rights
Agreement dated as of April 20, 2011, as amended June 30, 2015, by and among the Company, the HealthCor Parties and the additional investors
party thereto (the “Registration Rights Agreement”).
On
July 1, 2022, we entered into amendments to the 2014 HealthCor Notes, 2015 Supplemental Notes, Eighth Amendment Supplemental Closing
Notes, Tenth Amendment Supplemental Closing Notes, Twelfth Amendment Supplemental Closing Note and Thirteenth Amendment Supplemental
Closing Note (collectively, the “2022 Allonges”) to suspend the accrual of interest on the 2014 HealthCor Notes as to 100%
of the outstanding principal amount under such notes, 2015 Supplemental Notes as to 100% of the outstanding principal amount under such
notes, Eighth Amendment Supplemental Closing Notes as to 100% of the outstanding principal amount under such notes, Tenth Amendment Supplemental
Closing Notes as to 100% of the outstanding principal amount under such notes, Twelfth Amendment Supplemental Closing Note as to 100%
of the outstanding principal amount under such note, and Thirteenth Amendment Supplemental Closing Note as to 100% of the outstanding
principal amount under such note, for all periods beginning on and after January 1, 2022. This was determined to be a Troubled Debt Restructure
and is accounted for accordingly.
Also
on December 30, 2022, the Existing Investors agreed to the cancellation by the Company and the forfeiting of their respective rights
in and to the 2011 Warrants, 2014 Supplemental Warrants, Fifth Amendment Supplemental Warrants, Sixth Amendment Supplemental Warrants,
Eighth Amendment Supplemental Warrants, 2021 Warrants and 2022 Warrants (collectively, the “Warrants”); and the Existing
Investors have agreed to waive any and all interest that has accrued, but remains unpaid on the Existing Notes held by the Existing Investors;
in exchange for releasing its second senior secured position they hold in connection with the 2011 Notes and 2012 Notes. The Existing
Investors have agreed to waive any and all interest that has accrued, but remains unpaid on the Existing Notes held by the Existing Investors
with the 2014 Notes along with the 2015 Notes, 2018 Notes, 2019 Note and 2020 Note. In exchange for releasing its second senior secured
position they hold in connection with the 2011 Notes and 2012 Notes, the HealthCor Parties will receive an additional $5,000,000 in value
in the Replacement Notes. In this troubled debt restructuring, all the conversion rates were changed to $0.10. The gain from this troubled
debt restructuring was $1,489,357.
On
March 30, 2023, HealthCor noteholders owning an aggregate of $36,000,000 Replacement Notes, entered into a Replacement Note Conversion
Agreement, wherein half, fifty percent, of the HealthCor Replacement Notes were converted into shares of the Company’s common stock
at a conversion price of $0.10 per share, resulting in the issuance of an aggregate of 180,000,000 shares. The other related and non-related
parties Replacement Notes of $8,200,000 were likewise converted into shares of the Company’s common stock at a conversion price
of $0.10 per share, resulting in the issuance of a combined total aggregate of 262,000,000 shares (the “Conversion Shares”).
The shares bear a lockup legend that expires December 31, 2023.
On
May 24, 2023, HealthCor noteholders owning an aggregate of $18,000,000 Replacement Notes, presented Conversion Notices, pursuant to the
terms of the Replacement Note, for the conversion of the Replacement Notes into 180,000,000 shares of the Company’s common stock
at a conversion price of $0.10 per share. The shares bear a lockup legend that expires December 31, 2023.
Accounting
Treatment
When
issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt
or equity financing is committed, a company is required to record a beneficial conversion feature (“BCF”) charge. We had
three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011
HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor
Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued due to the down round provision and the removal
of the provision requiring liability treatment, and subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor
Notes were amended, only the accrued interest capitalized as payment in kind (‘‘PIK’’) since reclassification
qualifies under this accounting treatment. We recorded an aggregate of $0 and $0 in interest for the nine months ended September 30,
2023, and 2022, respectively, related to these transactions. For the nine months ended September 30, 2023, and 2022, we recorded $0 and
$0, respectively, of PIK related to the notes included in the HealthCor Purchase Agreement. Under the accounting standards, we determined
that the restructuring of the HealthCor notes, pursuant to the terms of the Ninth Amendment, resulted in a troubled debt restructuring.
Warrants
were issued with the Fourth, Fifth, Eighth, Ninth, and Allonge 3 Amendment Notes and the proceeds were allocated to the instruments based
on relative fair value as the warrants did not contain any features requiring liability treatment and therefore were classified as equity.
At each amendment date, the warrants were recorded as debt discount, as a reduction of the net carrying amount of the debt. The debt
discounts are amortized into interest expense each period under the effective interest method. The value allocated to the Ninth Amendment
Warrants was $378,000. The value allocated to the Allonge 3 Amendment Warrants was $420,000.
Warrants
were issued with Allonge 4 Amendment Notes and the proceeds were allocated to the instruments based on relative fair value as the warrants
did not contain any features requiring liability treatment and therefore were classified as equity. At each amendment date, the warrants
were recorded as debt discount, as a reduction of the net carrying amount of the debt. The debt discounts are amortized into interest
expense each period under the effective interest method. The value allocated to the Allonge 4 Amendment Warrants was $240,000.
NOTE
12 – JOINT VENTURE AGREEMENT
On
December 31, 2019, the Company and Rockwell entered into a Second Amendment to the Rockwell Note (the “Second Rockwell Note Amendment”)
pursuant to which Rockwell agreed to extend the term of the Rockwell Note by one year, to December 31, 2020, and agreed to extend the
time to make the quarterly payment that would otherwise be due on December 31, 2019 to January 31, 2020. We have evaluated the Second
Amendment to the Rockwell Note under ASC 470 and determined that the amendment should be treated as a debt modification.
As
of March 31, 2022, the Rockwell Note was paid off.
NOTE
13 – LEASE
Under
ASC Topic 842, Leases (“ASC 842”), operating lease expense is generally recognized evenly over the term of the lease. The
Company has an operating lease primarily consisting of office space with a remaining lease term of 23 months (Lease through August
31, 2025).
On
September 8, 2009, we entered into a Commercial Lease Agreement (the “Lease”) for 10,578 square feet of office
and warehouse space expiring on June 30, 2015. On March 4, 2020, we entered into the Fourth Amendment to Commercial Lease Agreement
(the “Lease Extension”), wherein we extended the Lease through August 31, 2025.
The
Company has further concluded that the Lease Extension has no effects on the classification of the Lease. Rent expense for the nine months
ended September 30, 2023, and 2022 was $221,535 and $226,108, respectively.
Undiscounted
Cash Flows
Future
lease payments included in the measurement of operating lease liability on the condensed consolidated balance sheet as of September 30,
2023, for the following five fiscal years and thereafter as follows:
Quarter
ending
September 30, 2023 |
|
Operating
Leases |
|
Remaining
2023 |
|
$ |
54,451 |
|
2024 |
|
|
221,069 |
|
2025 |
|
|
150,679 |
|
Total
minimum lease payments |
|
|
426,199 |
|
Less
effects of discounting |
|
|
(57,598) |
|
Present
value of future minimum lease payments |
|
$ |
368,601 |
|
NOTE
14 – SUBSEQUENT EVENTS
The
Company has evaluated subsequent events through November 13, 2023.
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
General
The
following discussion and analysis provide information which our management believes to be relevant to an assessment and understanding
of our results of operations and financial condition. This discussion should be read together with our financial statements and the notes
to the financial statements, which are included in this Quarterly Report on Form 10-Q (the “Report”). This information should
also be read in conjunction with the information contained in our Form 10-K/A filed with the Securities and Exchange Commission (the
“SEC”) filed on May 30, 2023. The reported results will not necessarily reflect future results of operations or financial
condition.
Throughout
this Quarterly Report on Form 10-Q (the “Report”), the terms “we,” “us,” “our,” “CareView,”
or “Company” refers to CareView Communications, Inc., a Nevada corporation, and unless otherwise specified, includes our
wholly owned subsidiaries, CareView Communications, Inc., a Texas corporation (“CareView-TX”) and CareView Operations, LLC,
a Nevada limited liability company (“CareView Operations”) (collectively known as the “Company’s Subsidiaries”).
We
maintain a website at www.care-view.com and our Common Stock trades on the OTCQB under the symbol “CRVW.’’
Company
Overview and Recent Developments
For
over a decade, CareView has been dedicated to supporting hospital care teams with its innovative virtual care solutions. The Company
has established successful partnerships with over 200 hospitals nationwide, implementing effective inpatient virtual care strategies
that greatly enhance patient safety and overcome critical staffing challenges. The CareView platform, fueled by industry-leading predictive
technology and supported by its purpose-built hardware, specifically addresses the unique requirements of virtual nursing and virtual
sitting use cases. The CareView team works closely with their hospital partners to understand their evolving needs and deliver tailored
virtual care strategies that align with their objectives. By providing healthcare professionals with the tools they need to deliver exceptional
care, CareView contributes to improved patient outcomes and a more sustainable healthcare ecosystem.
Software:
The CareView Platform
The
CareView platform comprises two essential components: the Patient Safety System® and the Patient Care System. These systems work
in harmony to deliver unparalleled patient safety and exceptional virtual nursing care. The Patient Safety System is purposefully designed
to optimize virtual sitting outcomes. Leveraging our patented predictive technology, including Virtual Bed Rails® and Virtual Chair
Rails®, it ensures continuous monitoring of 25-35 patients from a centralized location. By utilizing these innovative tools, we enhance
patient safety while reducing sitter costs across the nation. The Patient Care System revolutionizes virtual nursing by harnessing our
clinically-designed technology. By reallocating professional nursing and administrative tasks to virtual Registered Nurses (vRNs), it
alleviates the bedside workload and enables virtual engagement with patients and their families. This transformational approach allows
for personalized care and improved patient experiences.
The
CareView platform seamlessly integrates with CareView's in-room cameras, third party technology integrations, and clinical workflows,
empowering hospitals to implement their virtual care strategies effortlessly. The CareView platform includes a real-time analytics dashboard
and a range of reporting tools, providing valuable insights and data to optimize patient care delivery. CareView also understands the
importance of system management and maintenance. The CareView team is dedicated to providing exceptional support, monitoring, and maintenance
services for the platform and hardware, ensuring optimal performance and peace of mind for our valued partners.
CareView
prioritizes the privacy and security of our customers' confidential data and information systems. The Company has implemented comprehensive
measures to provide robust protection, as evidenced by their privacy and information security assessment certifications. Since 2017,
CareView has been HITRUST certified, an internationally recognized standard that ensures the implementation of adequate and proportionate
security controls. This certification validates their commitment to safeguarding customers' information and intellectual property assets.
With HITRUST certification, customers can trust that CareView adheres to stringent information security policies. To handle sensitive
information securely, CareView leverages a FIPS 140-2 validated cryptographic module certificate #3998. This certificate demonstrates
compliance with the Federal Information Processing Standard (FIPS) 140-2 Level 1, providing a high level of confidence in their encryption
practices. Importantly, this validation is achieved without the need for additional hardware, ensuring a streamlined and efficient security
infrastructure. CareView is fully compliant with the Health Insurance Portability and Accountability Act (HIPAA). Their commitment to
HIPAA standards ensures that sensitive information is safeguarded at all times. With CareView's additional HIPAA-compliant features,
customers have the power to control their privacy settings. A patient, nurse, or physician, can enable privacy options whenever needed.
In
October 2022, CareView received Innovative Technology Designation after the Innovative Technology Exchange in Dallas, Texas. Every year,
healthcare experts serving on the member-led councils of Vizient, Inc., (“Vizient”), the nation’s largest healthcare
performance improvement company, review select products and technologies for their potential to enhance clinical care, patient safety,
healthcare worker safety or to improve business operations of healthcare organizations. Vizient’s diverse membership and customer
base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute
health care providers, and represents more than $130 billion in annual purchase volume. Technology designations are awarded to previously
contracted products to signal to healthcare providers the impact of these innovations on patient care and business models of healthcare
organizations.
Hardware:
In-room Cameras
CareView
takes pride in their meticulously designed and engineered hardware that seamlessly integrates with the CareView platform, elevating the
virtual care experience for their esteemed hospital partners and their patients. To cater to various patient care scenarios, CareView
offers a range of in-room cameras, each carefully crafted to handle different care situations while ensuring optimal monitoring capabilities.
All of the CareView cameras are equipped with low-light/night vision cameras, pan tilt zoom and high-fidelity 2-way audio for effective
communication. For virtual sitting use cases, the CareView cameras use machine learning to differentiate between normal patient movements
and behaviors of a patient at risk. This technology results in less false alarms, faster staff intervention, and a significant reduction
in patient falls.
The
CareView cameras are available in multiple configurations for permanent or temporary situations; the Mobile, Portable, and Fixed Controller.
For virtual care situations that demand that the camera come to the patient, the Mobile Controller on wheels comes with an uninterrupted
external power supply for situations where power may not be readily available and can operate on the facility’s wireless network.
For monitoring patients within a general care unit, the Portable Controller can be easily removed from mounts and moved where the workflow
dictates, making this application perfect for general use. For high-risk patient rooms where behavior and self-harm may be a factor,
or where a patient must be continuously monitored, the Fixed Controller can be installed seamlessly in the ceiling tiles leaving no exposed
wiring making it ligature resistant.
CareView
System Products and Services Agreement with Healthcare Facilities
CareView’s
subscription-based model is offered to healthcare facilities through a Products and Services Agreement (the “P&S Agreement(s)”).
During the term of the P&S Agreement, we provide continuous monitoring of the CareView System products and services deployed to a
healthcare facility and maintain and service all equipment installed by us. Under the subscription-based model, terms of each P&S
Agreement require the healthcare facility to pay us a monthly fee based on the number of selected, installed, and activated services.
None of the services provided through the Primary Package are paid or reimbursed by any third-party provider including insurance companies,
Medicare, or Medicaid. We also enter into corporate-wide agreements with healthcare companies (the “Master Agreement(s)”),
wherein the healthcare companies enter into individual facility level agreements that are substantially like our P&S Agreements.
Master
Agreements and P&S Agreements are currently negotiated for a period of three years with a provision for automatic renewal. P&S
Agreements specific to pilot programs (“P&S Pilot Agreements”) contain pricing terms substantially like P&S Agreements,
are generally three or six-months in length and can be extended on a month-to-month basis as required. Regarding the subscription-based
model, we own all rights, title, and interest in and to the equipment we install at each location and agree to maintain and repair it;
although, we may charge for repairs or replacements due to damage or misuse. We are not responsible for maintaining data arising from
use of the CareView System or for transmission errors, corruption or compromise of data carried over local or interchange telecommunication
carriers. We grant each healthcare facility a limited, revocable, non-transferable, and nonexclusive license to use the software, network
facilities, content, and documentation on and in the CareView System to the extent, and only to the extent, necessary to access, explore
and otherwise use the CareView System in real time. Such non-exclusive license expires upon termination of the P&S Agreement.
We
use specific terminology to better define and track the staging and billing of the individual components of the CareView System. The
CareView System includes three components which are separately billed; the CareView Controller (previously known as RCP), the CareView
SitterView Monitor, and the CareView Application Server (each component referred to as a “unit”). The term “bed”
refers to each healthcare facility bed as part of the overall potential volume that a healthcare facility represents. For example, if
a healthcare facility has 200 beds, the aggregate of those beds is the overall potential volume of that healthcare facility. The term
“bed” is often used interchangeably with “CareView Controller” as this component of the CareView System consistently
resides within each room where the “bed” is located. On average, there are six SitterView Monitors for each 100 beds. The
term “deployed” means that the units have been delivered to the healthcare facility but have not yet been installed at their
respective locations within the facility. The term “installed” means that the units have been mounted and are operational.
The term “billable” refers to the aggregate of all units on which we charge fees. Units become billable once they are installed
and the required personnel have been trained in their use. Units are only deployed upon the execution of a P&S Agreement or P&S
Pilot Agreement.
CareView
System Sales-Based Model
CareView’s
sales-based model commenced with the introduction of our updated technology. CareView has also aligned its contracting model to meet
the preferred acquisition model in the hospital industry. CareView now sells its proprietary equipment to facilities in lieu of lending
the equipment as defined under the subscription-based model. In doing so, the facility is billed for the hardware on acceptance of the
contract. After CareView’s equipment is delivered to the facility, CareView begins the process of installing and securely integrating
the equipment and software. Upon completion of installation, training, and “go-live”; referring to all systems in full operation,
CareView bills the facility for the installation, training, and an annual software license fee. CareView will continue to bill the facility
an annual software license fee until the end of the contract. The shift to the sales-based model has an immediate impact on our operations
resulting in greater cash flow within 30 days of contract signing.
CareView
continues its dedication to provide service and support on a 24x7x365 basis for every customer under every contract.
CareView
Connect
Our
mission is to be the leading provider of resident monitoring products and services for the long-term care industry. We took what we learned
in our medical facility business and applied it to developing a product to serve the long-term care market. With CareView Connect Quality
of Life® System (“CareView Connect”), CareView has again positioned itself as a technology leader with its innovative
suite of products specifically designed for all aspects of the long-term care market, including Nursing Care, Home Care, Assisted Living
and Independent Living.
With
this mission in mind, in the second quarter of 2018, the Company introduced a new sensor product with application in both the assisted
living center market and the home health market. CareView Connect leverages both passive and active sensors to track the activities of
daily life. CareView Connect provides peace of mind by using data from the resident’s activity, existing conditions, and environment
to notify a caregiver of potential emergencies and identify the need for dignified support. CareView Connect consists of a small emergency
assist button, two motion sensors, one sleep sensor, and one event sensor. Resident activity levels, medication administration, sleep
patterns, and requests for assistance can all be monitored depending on which options are selected.
The
skilled nursing home market consists of approximately 2,000,000 beds, which is double the size of the current hospital/healthcare facility
bed market. The assisted living center market is even larger at approximately 3,000,000 beds. Our products flow naturally into the nursing
home space as it is substantially the same setting as hospital rooms.
CareView
Connect is a platform consisting of several products and applications targeted at improving the level of care and efficiency. CareView
built a cohesive and tightly integrated solution that solves several problems that long-term care facilities face. We offer an array
of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance, which can be anything
from toileting help to assistance putting on their shoes. We offer a mobile app capable of delivering an alert to the caregiver and allows
them to document information around that alert, how long before the alert was handled and, what was the cause of the alert, and if it
was not acknowledged in a timely manner then the alert is escalated to another individual or group. This ensures that every alert is
responded to in a timely manner and is verifiable.
Alert
Management and Monitoring System
CareView
Connect provides a suite of hardware and software that facilitate a data-driven solution for alert management and monitoring. CareView
Connect’s solution provides additional context, including location of the resident, which improves response time by the staff.
The alert system includes a documentation platform that allows the facility’s staff to classify the reason for alerts and provides
metrics around response time. CareView Connect’s solution involves several passive sensors that monitor the resident.
Caregiver
Platform
The
caregiver platform includes a “Leave of Absence” component, which allows the facility to document when the resident is outside
of their room for a duration of time. This information is incorporated with known data from the workflows and sensors to improve awareness.
The Caregiver Connect mobile application provides a convenient and intuitive interface to the CareView Connect platform. The caregiver
can use the mobile app to capture important information and interface with critical workflows, such as acknowledging and documenting
alert presses by the resident. CareView Connect also provides a product focused on capturing and measuring the mental state and pain
experienced by the resident. “How are you feeling today?” provides a convenient way to capture information about the mental
state of the resident using emojis. Similarly, “What is your pain today?” allows the staff to categorize and document pain.
Connect Resident is a tablet application intended for the resident’s direct use. This product currently supports video conferencing
with a remote caregiver, becoming a communications conduit for telehealth. Connect Resident also supports “How are you feeling
today?”, which allows the resident to submit this information directly.
Quality
of Life Metrics
CareView
developed its own algorithm for measuring quality of life based on “best of breed” research and leveraging the data collected
by the platform. CareView Connect’s Quality of Life Metrics focuses on several categories, including Physical Activity, Bodily
Pain, General Health, Vitality, Social Interaction, Mental Health, and Sleep Quality. Leveraging this data, the facility and their staff
have improved visibility into the health and well-being of their residents. By applying machine learning and predictive analytics, subtle
patterns and trends that may not otherwise be visible become actionable. The facility can use this information to present a more compassionate
and capable level of care, differentiating the facility from their competition. The Quality-of-Life Metrics information can be made available
to the family and loved ones, opening a new channel of remote awareness and care. Because the information is collected automatically,
the family gains awareness on issues of which their loved ones may normally be unaware. The Connect Family mobile application allows
family members to monitor their loved one and receive alerts and notifications based on their preferences.
Pricing
Structure and Revenue Streams
The
CareView Connect suite of products and services offers multiple pricing models. We work with each facility on pricing to offer an affordable
package based on the demographics of the residents of the facility. The pricing structure with each facility is negotiated separately.
Typically, we offer the CareView Connect basic package at a price per monitored room with varying price structures based on number of
sensors and number of residents in each facility.
Purchasing
Agreement with Decisive Point Consulting Group, LLC
On
February 2, 2021, we partnered with Decisive Point Consulting Group, a Department of Veterans Affairs Contractor Verification Enterprise
(CVE) and a Verified Service-Disabled Veteran Owned Small Business (SDVOSB), to expand our reach within the VA hospitals and Community
Living Centers space. Our partnership reflects our desire to collaborate with companies that share our vision of patient safety. We continue
to use this partnership to contract with VA hospitals and their Community Living Centers (“CLC”).
Indefinite
Delivery Indefinite Quality (IDIQ) Contract
On
September 10, 2021, the Company entered an Indefinite Delivery Indefinite Quality (IDIQ) contract for Telecare Services with Shore Systems
and Solutions, LLC (S3). The award provides S3 with a path to providing the CareView System to veterans and their families receiving
care at the 1,293 Veterans Health Administration (“VHA”) facilities across the United States and Territories.
General
Service Administration Multiple Award Schedule
Pursuant
to the terms of the Company’s General Service Administration (“GSA”) Multiple Award Schedule contract (“MAS”),
the MAS allows us to sell the CareView System at a negotiated rate to the approximate 169 United States Department of Veterans Affairs
(“VA”) facilities with over 39,000 licensed beds and the approximate 42 DOD hospitals with over 2,600 licensed beds. The
sales-based model was added to the MAS, which allows us to sell the proprietary hardware and license the software on an annualized basis.
The MAS is one of the most widely accepted government contract vehicles available to agency procurement officers. GSA’s application
process requires potential vendors to be recognized as highly credible and well established. CareView is the sole source provider. Our
products and services represent an enormous opportunity to improve the health and safety of our Nation’s veterans.
Group
Purchasing Agreement with HealthTrust Purchasing Group, LP
On
December 14, 2016, the Company entered a Group Purchasing Agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”)
(the “HealthTrust GPO Agreement”), the Nation’s only committed-model Group Purchasing Organization (“GPO”)
headquartered in Nashville, Tennessee. HealthTrust serves approximately 1,600 acute care facilities and members in more than 26,000 other
locations, including ambulatory surgery centers, physician practices, long-term care, and alternate care sites. The agreement was effective
on January 1, 2017 and all CareView System components and modules are available for purchase by HealthTrust’s exclusive membership.
HealthTrust members may order CareView’s products and services included in the agreement directly from CareView.
On
October 1, 2018, the Company added CareView Connect to the HealthTrust GPO Agreement.
On
November 1, 2020, the sales-based contract model was added to the HealthTrust GPO Agreement which allows us to sell the proprietary hardware
and license the software on an annualized basis. On December 1, 2021, the HealthTrust GPO Agreement was renewed for another 3-year term.
We continue to work with HealthTrust and their members to expand contracts.
Group
Purchasing Agreement with Premier, Inc.
On
June 8, 2022, the Company entered a Group Purchasing Agreement with Premier, Inc. (“Premier”), headquartered in Charlotte,
N.C. Premier is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and
approximately 225,000 other providers and organizations to transform healthcare. The agreement was effective on June 15, 2022 and all
Gen 5 CareView System components and modules are available for purchase by Premier’s exclusive membership. Premier members may
order CareView’s products and services included in the agreement directly from CareView. We are continuing to work with Premier
on new contracts.
Group
Purchasing Agreement with Vizient
On
February 15, 2023, the Company entered a Group Purchasing Agreement with Vizient, headquartered in Irving, TX. Vizient, the nation’s
largest health care performance improvement company, has a diverse membership and customer base, including academic medical centers,
pediatric facilities, community hospitals, integrated health delivery networks, and non-acute health care providers, and represents more
than $130 billion in annual purchasing volume. The multi-year agreement allows Vizient members the opportunity to benefit from pre-negotiated
pricing for CareView products. The agreement was effective on February 15, 2023 and all Gen 5 CareView System components and modules
are available for purchase by Vizient’s exclusive membership. Vizient members may order CareView’s products and services
included in the agreement directly from CareView. We are continuing to work with Vizient on new contracts.
Summary
of Product and Service Usage
Our
contracts typically include multiple combinations of our products, software solutions, and related services with multiple payment options.
Customers can continue to lease our equipment under our subscription model or can purchase our equipment upfront under our sales-based
contract model with an auto-renewal at the end of each contract period. The new sales-based contract offers our customers the flexibility
of capitalizing on their investment, which in turn, replenishes our cash reserves. For the years ended December 31, 2022, and 2021, the
Company executed sales-based contracts in approximate aggregated amounts of $4,309,000 and $5,600,000.
Results
of Operations
Three
months ended September 30, 2023, compared to three months ended September 30, 2022
|
|
Three
months ended
September
30, |
|
|
|
|
|
|
2023 |
|
|
2022 |
|
|
Change |
|
|
|
(000
’s) |
|
Revenue |
|
$ |
2,425 |
|
|
$ |
1,968 |
|
|
$ |
457 |
|
Operating
expenses |
|
|
2,469 |
|
|
|
2,300 |
|
|
|
169 |
|
Operating
income |
|
|
(44) |
|
|
|
(332) |
|
|
|
288 |
|
Other,
net |
|
|
(826) |
|
|
|
(1,147 |
) |
|
|
(321) |
|
Net
loss |
|
$ |
(869) |
|
|
$ |
(1,479 |
) |
|
$ |
(609) |
|
Revenue
Revenue
increased approximately $457,000 for the three months ended September 30, 2023, as compared to the same period in 2022. The increase
was attributable to recognizing hardware order fulfillment of two new customers.
Operating
Expenses
Our
principal operating costs include the following items as a percentage of total operating expense.
| |
Three Months Ended September 30, |
| |
2023 | |
2022 |
Human resource costs, including benefits and non-cash compensation | |
| 54 | % | |
| 60 | % |
Professional and consulting costs | |
| 8 | % | |
| 8 | % |
Depreciation and amortization | |
| 4 | % | |
| 6 | % |
Other product deployment costs, excluding human resources and travel and entertainment costs | |
| 9 | % | |
| 2 | % |
Travel and entertainment expense | |
| 2 | % | |
| 8 | % |
Other expenses | |
| 23 | % | |
| 16 | % |
Operating
expenses increased by a net 7.3% because of the following items:
| |
| (000’s) | |
Human resource costs, including benefits and non-cash compensation | |
$ | (31 | ) |
Depreciation and amortization | |
| (35 | ) |
Other product deployment costs, excluding human resources and travel and entertainment expense | |
| 171 | |
Professional and consulting costs | |
| 23 | |
Travel and entertainment expense | |
| (145 | ) |
Other expenses | |
| 186 | |
| |
$ | 169 | |
Human
resource related costs (including salaries and benefits and non-cash compensation) decreased approximately $31,000 due to less stock
compensation and paid time off during the three months ended September 30, 2023 as compared to the three months ended September 30, 2022.
Product deployment costs increased approximately $171,000 due to installations and equipment costs of new sales. Travel and entertainment
costs decreased approximately $145,000 due to installation employee reimbursements in 2022 third quarter mistakenly recorded to corporate
transportation. For the comparable periods, other expenses increased approximately $186,000, primarily because of advertising & marketing,
property taxes, dues & subscriptions and research & development.
Other,
net
Other
non-operating income and expense decreased by approximately $321,000, or 28%, for the three months ended September 30, 2023 in comparison
to the same period in 2022, primarily because of the cancellation of all Non-PDL related and non-related parties’ interest expense
in consideration for the debt to equity conversion.
Net
Loss
As
a result of the factors above, our third quarter 2023 net loss of approximately $869,000 decreased approximately $609,000, or 41%, as
compared to approximately $1,479,000 net loss for the third quarter of 2022.
Nine
months ended September 30, 2023, compared to nine months ended September 30, 2022
| |
Nine months ended September 30, | |
|
| |
2023 | |
2022 | |
Change |
| |
| (000 ’s) |
Revenue | |
$ | 7,917 | | |
$ | 5,983 | | |
$ | 1,934 | |
Operating expenses | |
| 7,657 | | |
| 7,172 | | |
| 485 | |
Operating income | |
| 260 | | |
| (1,189 | ) | |
| 1,449 | |
Other, net | |
| (2,521 | ) | |
| (5,137 | ) | |
| 2,616 | |
Net loss | |
$ | (2,261 | ) | |
$ | (6,326 | ) | |
$ | 4,065 | |
Revenue
Revenue
increased approximately $1,934,000 for the nine months ended September 30, 2023, as compared to the same period in 2022. The increase
was attributable to recognizing hardware order fulfillment of new customers as well as software sales.
Other,
net decreased approximately $2,616,000 for the nine months ended September 30, 2023, as compared to the same period in 2022. The decrease
was attributable to the cancellation of all non-PDL, related and non-related parties’ interest expense and warrants in consideration
for the debt to equity conversion.
Operating
Expenses
Our
principal operating costs include the following items as a percentage of total operating expense.
| |
Nine Months Ended September 30, |
| |
2023 | |
2022 |
Human resource costs, including benefits and non-cash compensation | |
| 54 | % | |
| 56 | % |
Professional and consulting costs | |
| 10 | % | |
| 10 | % |
Depreciation and amortization | |
| 5 | % | |
| 6 | % |
Other product deployment costs, excluding human resources and travel and entertainment costs | |
| 8 | % | |
| 3 | % |
Travel and entertainment expense | |
| 3 | % | |
| 4 | % |
Other expenses | |
| 21 | % | |
| 21 | % |
Operating
expenses increased by a net 6.8% or approximately $485,000. The increase was attributable to other product deployment costs of hardware
sales and associated installation, training and go-live as well as sales commissions and advertising & marketing being higher than
the comparable period. Other expenses comprising mainly of business insurances, rent, software licenses, public entity costs and patent
maintenance expense remained relatively the same.
Net
Loss
Year-to-date
2023 net loss of approximately $2,261,000 decreased approximately $4,065,000 or 64%, as compared to approximately $6,326,000 net loss
for the comparable nine months of 2022.
Liquidity
and Capital Resources
Accounting
standards require management to evaluate whether the Company can continue as a going concern for a period of one year after the date
of the filing of this Form 10-Q (“evaluation period”). In evaluating the Company’s ability to continue as a going concern,
management considers the conditions and events that raise substantial doubt about the Company’s ability to continue as a going
concern for a period of twelve months after the Company issues its financial statements. For the period ended September 30, 2023, management
considers the Company’s current financial condition and liquidity sources, including current funds available, forecasted future
cash flows, and the Company’s conditional and unconditional obligations due before November 12, 2024.
The
Company is subject to risks like those of healthcare technology companies whereby revenues are generated based on both on a sales-based
and subscription-based business model such as dependence on key individuals, uncertainty of product development, generation of revenues,
positive cash flow, dependence on outside sources of capital, risks associated with research, development, and successful testing of
its products, successful protection of intellectual property, ability to maintain and grow its customer base, and susceptibility to infringement
on the proprietary rights of others. The attainment of profitable operations is dependent on future events, including obtaining adequate
financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s
cost structure.
The
Company has experienced net losses and significant cash outflows from cash used in operating activities over the past years. As of and
for the nine months ended September 30, 2023, the Company had an accumulated deficit of $206,194,185, income from operations of $259,788,
net cash provided by operating activities of $170,982, and an ending cash balance of $674,020.
As
of September 30, 2023, the Company had a working capital deficit of $36,099,968 consisting primarily of PDL notes payables including
accrued interest. Management has evaluated the significance of the conditions described above in relation to the Company’s ability
to meet its obligations and concluded that, without additional funding, the Company will not have sufficient funds to meet its obligations
within one year from the date the condensed consolidated financial statements were issued. While management will look to continue funding
operations by increased sales volumes and raising additional capital from sources such as sales of its debt or equity securities or loans
to meet operating cash requirements, there is no assurance that management’s plans will be successful.
On
March 8, 2022, we agreed with the HealthCor Parties to (i) amend the 2011 HealthCor Notes to extend the maturity date of the 2011 HealthCor
Notes from April 20, 2022 to April 20, 2023 by entering into Allonge No. 4 to the 2011 HealthCor Notes (the “Third 2011 Note Allonges”)
and (ii) amend the 2012 HealthCor Notes to extend the maturity date of the 2012 HealthCor Notes from April 20, 2022 to April 20, 2023
by entering into Allonge No. 4 to the 2012 HealthCor Notes (the “Fourth 2012 Note Allonges”) (such amendments to the 2011
HealthCor Notes and 2012 HealthCor Notes together, the “HealthCor Note Extensions”). In connection with the HealthCor Note
Extensions, we issued the HealthCor parties warrants to purchase an aggregate of 3,000,000 shares of our Common Stock at an exercise
price per share equal to $0.09 per share (subject to adjustment as described therein) and with an expiration date of March 08, 2032 (collectively
the “2021 HealthCor Warrants”).
On
December 30, 2022, the Company entered into a consent and agreement to cancel and exchange existing notes and issue replacement notes
and cancel warrants (the “Cancellation Agreement”) with certain holders (the “Investors”) of senior secured convertible
promissory notes (“Notes”) and warrants (“Warrants”) to purchase the Company’s common stock, that were
issued pursuant to the Note and Warrant Purchase Agreement, dated as of April 21, 2011 (as amended, modified, or supplemented from time
to time) (the “Purchase Agreement”). The Cancellation Agreement provided for the cancellation of all outstanding Notes and
Warrants issued pursuant to the Purchase Agreement in exchange for the issuance of replacement senior secured convertible promissory
notes (the “Replacement Notes”) with an aggregate principal amount of $44,200,000. The maturity date of the Replacement Notes
was December 31, 2023. No interest accrues on the Replacement Notes. As of June 30, 2023, all replacement note were converted into shares
of the Company’s common stock at $0.10 per share.
On
March 30, 2023, investors holding an aggregate of $26,200,000 of Replacement Notes exercised their right to convert the debt into shares
of the Company’s common stock at $0.10 per share (the “First Tranche”). Upon conversion, the Company issued the investors
in the First Tranche an aggregate of 262,000,000 shares. The First Tranche only converted 50% of the HealthCor Replacement Notes. Due
to the insufficient number of the Company’s available authorized shares of common stock, a shareholder vote to authorize an increase
in the Company’s authorized shares of common stock to 800,000,000 was approved on May 26, 2023.
Effective
May 22, 2023, the Company’s increased its authorized shares of common stock from 500,000,000 shares to 800,000,000 shares.
On
May 24, 2023, noteholders owning an aggregate of $18,000,000 Replacement Notes, provided the Company with a Conversion Notice, pursuant
to the terms of the Replacement Notes, to convert the Replacement Notes into shares of the Company’s common stock at a conversion
price of $0.10 per share, resulting in the issuance of an aggregate of 180,000,000 shares.
Management
continues to monitor the immediate and future cash flow needs of the Company in a variety of ways which include forecasted net cash flows
from operations, capital expenditure control, new inventory orders, debt modifications, increases sales outreach, streamlining and controlling
general and administrative costs, competitive industry pricing, sale of equities, debt conversions, new product or services offerings,
and new business partnerships.
The
Company’s net losses, cash outflows, and working capital deficit raise substantial doubt about the Company’s ability to continue
as a going concern through November 12, 2024. The accompanying condensed consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company’s assets and
the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent
upon achieving a level of positive cash flows adequate to support the Company’s cost structure.
Critical
Accounting Estimates
Please
refer to our Annual Report on Form 10-K/A for the year ended December 31, 2022 filed with the Commission on May 26, 2023 and incorporated
herein by reference, for detailed explanation of our critical accounting estimates, which have not changed significantly during the three
and nine months ended September 30, 2023.
Recently
Issued and Newly Adopted Accounting Pronouncements
We
do not expect that the adoption of any recent accounting pronouncements will have a material impact on our accompanying condensed consolidated
financial statements.
Recent
Events
None.
Item
3. Quantitative and Qualitative Disclosures about Market Risk
None.
Item
4. Controls and Procedures
Disclosure
Controls and Procedures
Disclosure
controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our
reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed,
summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted
under the Exchange Act is accumulated and communicated to management, including our chief executive officer and principal financial officer,
as appropriate to allow timely decisions regarding required disclosure.
Evaluation
of Disclosure Controls and Procedures
Pursuant
to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), we carried out an evaluation, with the participation
of our management, including Steve G. Johnson, our Chief Executive Officer (“CEO”) and principal executive officer, and Jason
T. Thompson, our principal financial officer and chief accounting officer, of the effectiveness of our disclosure controls and procedures
(as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Report.
Under
the supervision and with the participation of our CEO and principal financial and chief accounting officer, our management evaluated
the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2023. Based on that evaluation,
our CEO and principal financial and chief accounting officer concluded that our disclosure controls and procedures were not effective
as of September 30, 2023 due to the continuing existence of a material weakness in internal control over financial reporting described
below (which we view as an integral part of our disclosure controls and procedures). Based on the performance of additional procedures
designed to ensure the reliability of our financial reporting, we believe that the condensed consolidated financial statements included
in this Report fairly present, in all material respects, our financial position, results of operations and cash flows as of the dates,
and for the periods, presented, in conformity with accounting principles generally accepted in the United States (“GAAP”).
Material
Weakness and Remediation Plan
A
material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is
a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented
or detected on a timely basis. Management has determined that the Company did not maintain effective internal control over financial
reporting as of the quarter ended Sepember 30, 2023 due to the existence of the material weaknesses described below.
Management
determined that the Company did not maintain effective internal control over financial reporting as of September 30, 2023, due to the
existence of the following material weaknesses:
|
● |
It
was determined that the Company does not have effective controls over the identification and evaluation of the GAAP accounting for
certain complex transactions in the areas of revenues, debt, and income taxes, due to a lack of technical expertise. |
|
● |
Due
to a lack of accounting resources, it was determined that the Company had inadequate segregation of duties in place related to its
financial reporting and other management oversight. Specifically, the accounting personnel had responsibility for initiating transactions
in the financial statement areas of revenues, equity, payroll, debt, and financial reporting, recording transactions, and preparing
financial reports. |
Based
on additional procedures and post-closing review, Management concluded that the consolidated financial statements including this report
present fairly, in all material respects, results of operations, and cash flows for the periods presented, in conformity with accounting
principles accepted in the United States.
We
began to take steps to address our material weaknesses, through our remediation plan. We implemented the following measures:
|
● |
Identify
and employ additional full-time highly qualified accounting personnel to join the corporate accounting function to enhance overall
monitoring, maintain standard internal controls, and accounting oversight within the Company. |
|
● |
The
Company hired a certified public accountant (“CPA”) as its Controller and a Senior Accountant while contracting with
the former Senior Accountant. |
|
● |
Implement
enhanced documentation associated with management review controls and validation of the completeness and accuracy of financial reporting
and key management financial reports. |
|
● |
Provide
training of standard operating procedures and internal controls to key stakeholders within the supply chain, logistics, and inventory
processes. |
|
● |
Enhance
and automate existing internal control to ensure proper authorization, review, and recording of financial transactions. |
|
● |
On
an as-needed basis, identify and engage certain third-party subject matter experts to assist with the preparation and reporting of
complex business and accounting transactions. |
Changes
in Internal Control Over Financial Reporting
Other
than as described above, there were no changes in our internal control over financial reporting identified in management’s evaluations
pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended September 30, 2023 that materially affected, or
are reasonably likely to materially affect, our internal control over financial reporting.
Limitations
on Controls
Our
management can provide no assurance that our disclosure controls and procedures or our internal control over financial reporting can
prevent all errors and all fraud under all circumstances. A control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect
the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the
inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances
of fraud, if any, within the Company have been or will be detected. The design of any system of controls also is based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated
goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree
of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements
due to error or fraud may occur and not be detected.
PART
II - OTHER INFORMATION
Item
1. Legal Proceedings.
None.
Item
1A. Risk Factors.
Our
Company is a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, and as such, is not required to provide
the information required under this Item.
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.
On
May 24, 2023, noteholders owning an aggregate of $18,000,000 Replacement Notes, provided the Company with a Conversion Notice, pursuant
to the terms of the Replacement Notes, to convert the Replacement Notes into shares of the Company’s common stock at a conversion
price of $0.10 per share, resulting in the issuance of an aggregate of 180,000,000 shares.
The
shares were offered and sold to accredited investors in a transaction not involving a public offering, pursuant to Section 4(a)(2) of
the Securities Act and Rule 506 of Regulation D promulgated thereunder. The investors represented their intentions to acquire the securities
for investment only and not with a view to sale in connection with any distribution thereof, and appropriate legends were placed upon
the shares issued in the transaction. The offer and sale of the securities were made without any general solicitation or advertising.
Item
3. Defaults Upon Senior Securities.
None.
Item
4. Mine Safety Disclosures.
Not
applicable.
Item
5. Other Information.
None.
Item
6. Exhibits.
Exhibit
No. |
Date
of Document |
Name
of Document |
31.1 |
November
13, 2023 |
Certification
of Chief Executive Officer of Periodic Report pursuant to Rule 13a-14a and Rule 14d-14(a)* |
31.2 |
November
13, 2023 |
Certification
of Chief Financial Officer of Periodic Report pursuant to Rule 13a-14a and Rule 15d-14(a)* |
32 |
November
13, 2023 |
Certifications
under Section 906* |
101.SCH |
n/a |
XBRL
Taxonomy Extension Schema Document* |
101.CAL |
n/a |
XBRL
Taxonomy Extension Calculation Linkbase Document* |
101.DEF |
n/a |
XBRL
Taxonomy Extension Definition Linkbase Document* |
101.LAB |
n/a |
XBRL
Taxonomy Extension Label Linkbase Document* |
101.PRE |
n/a |
XBRL
Taxonomy Extension Presentation Linkbase Document* |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DATE:
November 13, 2023
|
CAREVIEW
COMMUNICATIONS, INC. |
|
|
|
|
By: |
/s/
Steven G. Johnson |
|
|
Steven
G. Johnson |
|
|
Chief
Executive Officer |
|
|
Principal
Executive Officer |
|
|
|
|
By: |
/s/
Jason T. Thompson |
|
|
Jason
T. Thompson |
|
|
Principal
Financial Officer |
|
|
Chief
Accounting Officer |
CAREVIEW COMMUNICATIONS, INC. 10-Q
EXHIBIT
31.1
CERTIFICATION
OF PRI NCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I,
Steven G. Johnson, certify that:
|
(1) |
I
have reviewed this quarterly report on Form 10-Q of CareView Communications, Inc. |
|
(2) |
Based
on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report’ |
|
(3) |
Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
this report; |
|
(4) |
The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations;
and |
|
d. |
Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
(5) |
The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions): |
|
a. |
All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and |
|
b. |
Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting. |
November
13, 2023 |
/s/
Steven G. Johnson |
|
Steven
G. Johnson |
|
Chief
Executive Officer |
|
Principal
Executive Officer |
CAREVIEW COMMUNICATIONS, INC. 10-Q
EXHIBIT
31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Jason T. Thompson, certify that:
|
(1) |
I have reviewed this quarterly report on Form 10-Q of CareView Communications, Inc. |
|
(2) |
Based on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report’ |
|
(3) |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
(4) |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and |
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
(5) |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
November 13, 2023 |
/s/ Jason T. Thompson |
|
Jason T. Thompson |
|
Principal Financial Officer |
|
Chief Accounting Officer |
CAREVIEW COMMUNICATIONS, INC. 10-Q
EXHIBIT 32
CERTIFICATIONS UNDER SECTION 906
Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned
officers of CareView Communications, Inc., a Nevada corporation (the “Company”), does hereby certify, to such officer’s
knowledge, that:
The Quarterly Report for
the quarter ended June 30, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects,
the financial condition and results of operations of the Company.
November 13, 2023 |
/s/ Steven G. Johnson |
|
Steven G. Johnson |
|
Chief Executive Officer |
|
Principal Executive Officer |
November 13, 2023 |
/s/ Jason T. Thompson |
|
Jason T. Thompson |
|
Chief Accounting Officer |
|
Principal Financial Officer |
v3.23.3
Cover - shares
|
9 Months Ended |
|
Sep. 30, 2023 |
Nov. 13, 2023 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Sep. 30, 2023
|
|
Document Fiscal Period Focus |
Q3
|
|
Document Fiscal Year Focus |
2023
|
|
Current Fiscal Year End Date |
--12-31
|
|
Entity File Number |
000-54090
|
|
Entity Registrant Name |
CAREVIEW
COMMUNICATIONS, INC.
|
|
Entity Central Index Key |
0001377149
|
|
Entity Tax Identification Number |
95-4659068
|
|
Entity Incorporation, State or Country Code |
NV
|
|
Entity Address, Address Line One |
405
State Highway 121
|
|
Entity Address, Address Line Two |
Suite B-240
|
|
Entity Address, City or Town |
Lewisville
|
|
Entity Address, State or Province |
TX
|
|
Entity Address, Postal Zip Code |
75067
|
|
City Area Code |
(972)
|
|
Local Phone Number |
943-6050
|
|
Title of 12(b) Security |
Common
Stock, $0.001 par value per share
|
|
Trading Symbol |
CRVW
|
|
Security Exchange Name |
NONE
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
583,880,748
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Current Assets: |
|
|
Cash and restricted cash |
$ 674,020
|
$ 520,166
|
Accounts receivable |
1,825,870
|
948,328
|
Inventory |
232,606
|
301,446
|
Other current assets |
329,837
|
71,020
|
Total current assets |
3,062,333
|
1,840,960
|
Property and equipment, net |
375,526
|
642,559
|
Intangible assets, net |
738,863
|
820,106
|
Operating lease asset |
330,477
|
434,330
|
Other assets, net |
270,847
|
209,649
|
Total assets |
4,778,046
|
3,947,604
|
Current Liabilities: |
|
|
Accounts payable |
605,844
|
650,796
|
Notes payable |
20,000,000
|
20,000,000
|
Notes payable - related parties |
700,000
|
700,000
|
Convertible notes payable, related parties |
|
42,394,168
|
Convertible notes payable, non-related parties |
|
1,805,832
|
Operating lease liability, current |
185,304
|
175,520
|
Other current liabilities |
17,532,785
|
14,553,277
|
Total current liabilities |
39,023,933
|
80,279,593
|
Long-term Liabilities: |
|
|
Operating lease liability |
183,297
|
305,259
|
Other long-term liabilities |
151,165
|
23,481
|
Total long-term liabilities |
334,462
|
328,740
|
Total liabilities |
39,358,395
|
80,608,333
|
Stockholders' Deficit: |
|
|
Common stock - par value $0.001; 800,000,000 and 500,000,000 shares authorized, respectively; 583,880,748 and 141,880,748 issued and outstanding, respectively |
583,880
|
141,881
|
Additional paid in capital |
171,029,956
|
127,130,055
|
Accumulated deficit |
(206,194,185)
|
(203,932,665)
|
Total stockholders' deficit |
(34,580,349)
|
(76,660,729)
|
Total liabilities and stockholders' deficit |
$ 4,778,046
|
$ 3,947,604
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleNotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_OtherAssetsMiscellaneousNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherNotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherShortTermBorrowings |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Statement of Financial Position [Abstract] |
|
|
Common stock, par value (in dollars per share) |
$ 0.001
|
$ 0.001
|
Common stock, authorized |
800,000,000
|
500,000,000
|
Common stock, issued |
583,880,748
|
141,880,748
|
Common stock, outstanding |
583,880,748
|
141,880,748
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Revenues |
|
|
|
|
Total revenue |
$ 2,425,390
|
$ 1,967,624
|
$ 7,917,758
|
$ 5,983,389
|
Operating expenses: |
|
|
|
|
Cost of equipment |
105,311
|
39,630
|
362,241
|
157,227
|
Network operations |
537,779
|
602,170
|
2,006,308
|
1,949,153
|
General and administration |
684,848
|
571,658
|
2,434,568
|
2,387,898
|
Sales and marketing |
423,184
|
234,414
|
822,417
|
565,382
|
Research and development |
621,929
|
721,339
|
1,655,934
|
1,668,883
|
Depreciation and amortization |
95,874
|
130,743
|
376,502
|
443,695
|
Total operating expenses |
2,468,925
|
2,299,954
|
7,657,970
|
7,172,238
|
Operating income (loss) |
(43,535)
|
(332,330)
|
259,788
|
(1,188,849)
|
Other income and (expense) |
|
|
|
|
Interest expense |
(830,994)
|
(1,146,820)
|
(2,527,955)
|
(5,137,272)
|
Interest income |
4,628
|
76
|
6,647
|
130
|
Total other expense |
(826,366)
|
(1,146,744)
|
(2,521,308)
|
(5,137,142)
|
Loss before taxes |
(869,901)
|
(1,479,074)
|
(2,261,520)
|
(6,325,991)
|
Provision for income taxes |
|
|
|
|
Net loss |
$ (869,901)
|
$ (1,479,074)
|
$ (2,261,520)
|
$ (6,325,991)
|
Net loss per share, basic |
$ (0.00)
|
$ (0.01)
|
$ (0.01)
|
$ (0.05)
|
Net loss per share, diluted |
$ (0.00)
|
$ (0.01)
|
$ (0.01)
|
$ (0.05)
|
Weighted average number of common shares outstanding, basic |
583,880,748
|
139,380,748
|
417,517,785
|
139,380,748
|
Weighted average number of common shares outstanding, diuted |
583,880,748
|
139,380,748
|
417,517,785
|
139,380,748
|
Subscription-based lease revenue [Member] |
|
|
|
|
Revenues |
|
|
|
|
Total revenue |
$ 1,031,828
|
$ 1,323,718
|
$ 3,409,523
|
$ 4,064,757
|
Sales-based equipment package revenue [Member] |
|
|
|
|
Revenues |
|
|
|
|
Total revenue |
876,126
|
314,495
|
2,872,911
|
1,121,817
|
Sales-based software bundle revenue [Member] |
|
|
|
|
Revenues |
|
|
|
|
Total revenue |
$ 517,436
|
$ 329,411
|
$ 1,635,324
|
$ 796,815
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.
+ References
+ Details
Name: |
us-gaap_EquipmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_InvestmentIncomeInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_RevenuesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
+ Details
Name: |
us-gaap_SellingAndMarketingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=crvw_SubscriptionBasedLeaseRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=crvw_SalesBasedEquipmentPackageRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=crvw_SalesBasedSoftwareBundleRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($)
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Total |
Beginning balance, value at Dec. 31, 2021 |
$ 139,381
|
$ 85,052,367
|
$ (197,890,046)
|
$ (112,698,298)
|
Beginning balance (in shares) at Dec. 31, 2021 |
139,380,748
|
|
|
|
Issuance of warrants to purchase common stock |
|
240,000
|
|
240,000
|
Stock based compensation |
|
55,847
|
|
55,847
|
Net loss |
|
|
(2,345,008)
|
(2,345,008)
|
Ending balance, value at Mar. 31, 2022 |
$ 139,381
|
85,348,214
|
(200,235,054)
|
(114,747,459)
|
Ending balance (in shares) at Mar. 31, 2022 |
139,380,748
|
|
|
|
Beginning balance, value at Dec. 31, 2021 |
$ 139,381
|
85,052,367
|
(197,890,046)
|
(112,698,298)
|
Beginning balance (in shares) at Dec. 31, 2021 |
139,380,748
|
|
|
|
Net loss |
|
|
|
(6,325,991)
|
Ending balance, value at Sep. 30, 2022 |
$ 139,381
|
87,132,695
|
(204,216,037)
|
(116,943,961)
|
Ending balance (in shares) at Sep. 30, 2022 |
139,380,748
|
|
|
|
Beginning balance, value at Mar. 31, 2022 |
$ 139,381
|
85,348,214
|
(200,235,054)
|
(114,747,459)
|
Beginning balance (in shares) at Mar. 31, 2022 |
139,380,748
|
|
|
|
Stock based compensation |
|
58,363
|
|
58,363
|
Net loss |
|
|
(2,501,909)
|
(2,501,909)
|
Ending balance, value at Jun. 30, 2022 |
$ 139,381
|
85,406,577
|
(202,736,963)
|
(117,191,005)
|
Ending balance (in shares) at Jun. 30, 2022 |
139,380,748
|
|
|
|
Stock based compensation |
|
58,858
|
|
58,858
|
Related party forgiveness of interest |
|
1,667,260
|
|
1,667,260
|
Net loss |
|
|
(1,479,074)
|
(1,479,074)
|
Ending balance, value at Sep. 30, 2022 |
$ 139,381
|
87,132,695
|
(204,216,037)
|
(116,943,961)
|
Ending balance (in shares) at Sep. 30, 2022 |
139,380,748
|
|
|
|
Beginning balance, value at Dec. 31, 2022 |
$ 141,881
|
127,130,055
|
(203,932,665)
|
(76,660,729)
|
Beginning balance (in shares) at Dec. 31, 2022 |
141,880,748
|
|
|
|
Stock based compensation |
|
62,260
|
|
62,260
|
Debt to equity conversion at $0.10 |
$ 262,000
|
25,938,000
|
|
26,200,000
|
Debt to equity conversion at $0.10 (in shares) |
262,000,000
|
|
|
|
Net loss |
|
|
(1,346,812)
|
(1,346,812)
|
Ending balance, value at Mar. 31, 2023 |
$ 403,881
|
153,130,315
|
(205,279,477)
|
(51,745,281)
|
Ending balance (in shares) at Mar. 31, 2023 |
403,880,748
|
|
|
|
Beginning balance, value at Dec. 31, 2022 |
$ 141,881
|
127,130,055
|
(203,932,665)
|
(76,660,729)
|
Beginning balance (in shares) at Dec. 31, 2022 |
141,880,748
|
|
|
|
Net loss |
|
|
|
(2,261,520)
|
Ending balance, value at Sep. 30, 2023 |
$ 583,881
|
171,029,955
|
(206,194,185)
|
(34,580,349)
|
Ending balance (in shares) at Sep. 30, 2023 |
583,880,748
|
|
|
|
Beginning balance, value at Mar. 31, 2023 |
$ 403,881
|
153,130,315
|
(205,279,477)
|
(51,745,281)
|
Beginning balance (in shares) at Mar. 31, 2023 |
403,880,748
|
|
|
|
Stock based compensation |
|
54,796
|
|
54,796
|
Debt to equity conversion at $0.10 |
$ 180,000
|
17,820,000
|
|
18,000,000
|
Debt to equity conversion at $0.10 (in shares) |
180,000,000
|
|
|
|
Net loss |
|
|
(44,807)
|
(44,807)
|
Ending balance, value at Jun. 30, 2023 |
$ 583,881
|
171,005,111
|
(205,324,284)
|
(33,735,292)
|
Ending balance (in shares) at Jun. 30, 2023 |
583,880,748
|
|
|
|
Stock based compensation |
|
24,844
|
|
24,844
|
Net loss |
|
|
(869,901)
|
(869,901)
|
Ending balance, value at Sep. 30, 2023 |
$ 583,881
|
$ 171,029,955
|
$ (206,194,185)
|
$ (34,580,349)
|
Ending balance (in shares) at Sep. 30, 2023 |
583,880,748
|
|
|
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfStockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
Net loss |
$ (2,261,520)
|
$ (6,325,991)
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
Depreciation |
273,478
|
375,867
|
Amortization of intangible assets |
81,242
|
40,098
|
Amortization of deferred installation costs |
21,783
|
27,730
|
Amortization of debt discount |
|
860,239
|
Amortization of deferred debt issuance and debt financing costs |
|
|
Non-cash lease expense |
103,853
|
88,838
|
Interest incurred and paid in kind |
|
|
Stock based compensation related to options granted and warrants issued |
141,900
|
2,080,328
|
Changes in operating assets and liabilities: |
|
|
Accounts receivable |
(877,542)
|
69,064
|
Inventory |
68,840
|
(39,960)
|
Other current assets |
(258,817)
|
165,732
|
Patent license |
12,295
|
12,295
|
Accounts payable |
(44,952)
|
461,222
|
Accrued interest |
2,406,375
|
2,219,923
|
Other current liabilities |
616,225
|
(225,486)
|
Operating Lease Liability |
(112,178)
|
(92,497)
|
Net cash provided by (used in) operating Activities |
170,982
|
(282,598)
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
Purchase of equipment |
(6,444)
|
(5,189)
|
Patent, trademark, and other intangible assets costs |
|
(58,260)
|
Net cash used in investing activities |
(6,444)
|
(63,449)
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
Repayment of notes payable |
|
(13,786)
|
Repayment of vehicle loan |
(10,684)
|
(10,567)
|
Net cash used in financing Activities |
(10,684)
|
(24,353)
|
Increase (decrease) in cash |
153,854
|
(370,400)
|
Cash and restricted cash, beginning of period |
520,166
|
659,228
|
Cash and restricted cash, end of period |
674,020
|
288,828
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
Cash paid for interest |
|
114,291
|
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITES: |
|
|
Capital expenditures funded by term loan |
|
1,667,260
|
Replacement Notes conversion to equity at $0.10 per share |
$ 44,200,000
|
|
X |
- DefinitionPeriodic amortization of installation costs.
+ References
+ Details
Name: |
crvw_AmortizationOfInstallationCosts |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of amortization expense attributable to debt issuance costs.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfFinancingCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_CapitalExpendituresIncurredButNotYetPaid |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in intangible assets (for example patents and licenses).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInterestPayableNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current liabilities classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NoncashInvestingAndFinancingItemsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_PaidInKindInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfOtherLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.3
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfCashFlowsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS |
NOTE
1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Interim
Financial Statements
The
accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”,
the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted
accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions
to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary
for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities
and Exchange Commission (the “SEC”). The balance sheet at December 31, 2022 has been derived from the audited consolidated
financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations
for interim periods are not necessarily indicative of results for the full year. The accompanying unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual
Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on May 26, 2023.
Revenue
Recognition
We
recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”). For our
subscription service contracts, we have employed the practical expedient discussed in ASC 606-10-55-18 related to invoicing as we have
the right to consideration from our customers in the amount that corresponds directly with the value to the customer of our performance
completed to date and therefore, we recognize revenue upon invoicing as further discussed below.
In
accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized
reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC
606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in
amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply
the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine
the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when,
or as, we satisfy the performance obligation. For those customers for which we are required to collect sales taxes, we record such sales
taxes on a net basis which has no effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the
taxing authority.
We
enter into contracts with customers that may provide multiple combinations of our products, software solutions, and other related services,
which are generally capable of being distinct and accounted for as separate performance obligations. Performance obligations that are
not distinct at contract inception are combined.
Customer
contract fulfillment typically involves multiple procurement promises, which may include various equipment, software subscription, project-related
installation and training services, and support. We allocate the transaction price to each performance obligation based on estimated
relative standalone selling price. Revenue is then recognized for each performance obligation upon transferring control of the hardware,
software, and services to the customer and in an amount that reflects the consideration we expect to receive and the estimated benefit
the customer receives over the term of the contract.
Generally,
we recognize revenue under each of our performance obligations as follows:
|
● |
Subscription
services – We recognize subscription revenues monthly over the contracted license period. |
|
● |
Equipment
packages – We recognize equipment revenues when control of the devices has been transferred to the client (“point in
time”). |
|
● |
Software
bundle and related services related to sales-based contracts – We recognize our software subscription, installation, training,
and other services on a straight-line basis over the estimated contracted license period (“over time”). |
Disaggregation
of Revenue
The
following presents net revenues disaggregated by our business models:
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Sales-based
contract revenue |
|
|
|
|
|
|
|
|
Equipment
package, net (point in time) |
|
$ |
2,872,911 |
|
|
$ |
1,121,817 |
|
Software
bundle (over time) |
|
|
1,635,324 |
|
|
|
796,815 |
|
Total
sales-based contract revenue |
|
|
4,508,235 |
|
|
|
1,918,632 |
|
|
|
|
|
|
|
|
|
|
Subscription-based
lease revenue |
|
|
3,409,523 |
|
|
|
4,064,757 |
|
Net
revenue |
|
$ |
7,917,758 |
|
|
$ |
5,983,389 |
|
Contract
Liabilities
Our
subscription-based contracts payment arrangements are required to be paid monthly which are recognized into revenue when received. Some
customers choose to pay their subscription fee in advance. Customer payments received in advance of satisfaction of the related performance
obligations are deferred as contract liabilities. These amounts are recorded as “deferred revenue” in our condensed consolidated
balance sheets and recognized into revenues over time.
Our
sales-based contract payment arrangements with our customers typically include an initial equipment payment due upon signing of the contract
and subsequent payments when certain performance obligations are completed. Customer payments received in advance of satisfaction of
related performance obligations are deferred as contract liabilities. These amounts are recorded as “deferred revenue” in
our condensed consolidated balance sheets and recognized into revenues as either a point in time or over time.
During
the nine months ended September 30, 2023 and 2022, a total of $21,145 and $210,681, respectively, of subscription-based deferred contract
liability was recognized as revenue. The table below details the subscription-based contract liability activity during the nine months
ended September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
21,145 |
|
|
$ |
231,140 |
|
Additions |
|
|
— |
|
|
|
30,306 |
|
Transfer
to revenue |
|
|
(21,145) |
|
|
|
(210,681 |
) |
Balance,
end of period |
|
$ |
- |
|
|
$ |
50,765 |
|
During
the nine months ended September 30, 2023 and 2022, a total of $1,331,409 and $1,829,720, respectively, of sales-based deferred contract
liability was recognized as revenue. The table below details the sales-based contract liability activity during the nine months ended
September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
869,485 |
|
|
$ |
752,526 |
|
Additions |
|
|
1,807,630 |
|
|
|
2,000,051 |
|
Transfer
to revenue |
|
|
(1,331,409) |
|
|
|
(1,829,720 |
) |
Balance,
end of period |
|
$ |
1,345,706 |
|
|
$ |
922,857 |
|
As
of September 30, 2023, the aggregate amount of deferred revenue from subscription-based contracts and sales-based contracts allocated
to performance obligations that are unsatisfied or partially satisfied is approximately $1,345,706 and will be recognized into revenue
over time as follows:
Years
Ending December 31, |
|
|
Amount |
|
2023 |
|
|
$ |
522,100 |
|
2024 |
|
|
|
685,238 |
|
Thereafter |
|
|
|
138,368 |
|
|
|
|
$ |
1,345,706 |
|
We
defer and capitalize all costs associated with the installation of the CareView System into a healthcare facility until the CareView
System is fully operational and accepted by the healthcare facility. Installation costs are specifically identifiable based on the amounts
we are charged from third party installers or directly identifiable labor hours incurred for each installation. Upon acceptance, the
associated costs are expensed on a straight-line basis over the life of the contract with the healthcare facility. These costs are included
in network operations on the accompanying consolidated statements of operations.
The
table below details the activity in these deferred installation costs during the periods ended September 30, 2023 and 2022, included
in other assets in the accompanying unaudited consolidated balance sheet.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
33,461 |
|
|
$ |
68,901 |
|
Additions |
|
|
— |
|
|
|
— |
|
Transfer
to expense |
|
|
(21,783) |
|
|
|
(27,731 |
) |
Balance,
end of period |
|
$ |
11,678 |
|
|
$ |
41,170 |
|
Significant
Judgements When Applying Topic 606
Contracts
with our customers are typically structured similarly and include various combinations of our products, software solutions, and related
services. Determining whether the various contract promises are considered distinct performance obligations that should be accounted
for separately versus together may require significant judgment.
Contract
transaction price is allocated to distinct performance obligations using estimated standalone selling price. We determine standalone
selling price maximizing observable inputs such as standalone sales, competitor standalone sales, or substantive renewal prices charged
to customers when they exist. In instances where standalone selling price is not observable, we utilize an estimate of standalone selling
price. Such estimates are derived from various methods that include cost plus margin, and historical pricing practices. Judgment may
be required to determine standalone selling prices for each performance obligation and whether it depicts the amount we expect to receive
in exchange for the related good or service.
Contract
modifications occur when we and our customers agree to modify existing customer contracts to change the scope or price (or both) of the
contract or when a customer terminates some, or all, of the existing services provided by us. When a contract modification occurs, it
requires us to exercise judgment to determine if the modification should be accounted for as a separate contract, the termination of
the original contract and creation of a new contract, a cumulative catch-up adjustment to the original contract, or a combination.
Contracts
with our customers include a limited warranty on our products covering materials, workmanship, or design for the duration of the contract.
We do not offer paid additional extended or lifetime warranty packages. We determined the limited warranty in our contract is not a distinct
performance obligation. We do not believe our estimates of warranty costs to be significant to our determination of revenue recognition,
and therefore, did not reserve for warranty costs.
Leases
The
Company has an operating lease primarily consisting of office space with a remaining lease term of 26 months. At the lease commencement
date, an operating lease liability and related operating lease asset are recognized. The operating lease liabilities are calculated using
the present value of lease payments. The discount rate used is either the rate implicit in the lease, when known, or our estimated incremental
borrowing rate. Operating lease assets are valued based on the initial operating lease liabilities plus any prepaid rent and direct costs
from executing the leases.
Earnings
(Loss) Per Share
We
calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts,
basic and diluted. Basic EPS is computed based on the weighted average number of common shares outstanding during the period. Diluted
EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding
during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants to purchase
our Common Stock (the “Warrants”) and convertible debt. Potential common shares totaling 46,801,922 and 222,000,000 on September
30, 2023 and 2022, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to
our reported net loss. The 46,801,922 potential common shares consist of 41,107,477 stock options and 5,694,445 warrants.
Recently Issued and Newly Adopted Accounting Pronouncements
ASU
2016-13
ASU
2016-13 requires organizations to measure all expected credit losses for financial instruments held at the reporting date based on historical
experience, current conditions, and reasonable and supportable forecasts. This guidance:
|
1. |
Eliminates
the probable initial recognition threshold in current GAAP and, instead, reflects an organization’s current estimate of all
expected credit losses over the contractual term of its financial assets. |
|
2. |
Broadens
the information that an entity can consider when measuring credit losses to include forward-looking information. |
|
3. |
Increases
usefulness of the financial statements by requiring timely inclusion of forecasted information in forming expectations of credit
losses. |
|
4. |
Increases
comparability of purchased financial assets with credit deterioration (PCD assets) with other purchased assets that do not have credit
deterioration as well as originated assets because credit losses that are expected will be recorded through an allowance for credit
losses for all assets. |
|
5. |
Increases
users’ understanding of underwriting standards and credit quality trends by requiring additional information about credit quality
indicators by year of origination (vintage). |
|
6. |
For
available-for-sale debt securities, aligns the income statement recognition of credit losses with the reporting period in which changes
occur by recording credit losses (and subsequent changes in credit losses) through an allowance rather than a write down. |
The
guidance affects loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance
receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. We, as a smaller
reporting company as defined by the SEC, have adopted ASU 2016-13 effective for January 1, 2023. As of September 30, 2023, ASU 2016-13
does not have any material effect on the Company.
ASU
2020-06
ASU
2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance
in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and
cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies
to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted
for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding
financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’
equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding
financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded
features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260,
Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted
method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled
in cash or shares. We, as a smaller reporting company as defined by the SEC, will adopt ASU 2020-06 effective for fiscal year 2024.
ASU
2022-03
ASU
2022-03 clarifies that a “contractual sale restriction prohibiting the sale of an equity security is a characteristic of the reporting
entity holding the equity security” and is not included in the equity security’s unit of account. Accordingly, an entity
should not consider the contractual sale restriction when measuring the equity security’s fair value (i.e., the entity should not
apply a discount related to the contractual sale restriction, as stated in ASC 820-10-35-36B as amended by the ASU). In addition, the
ASU prohibits an entity from recognizing a contractual sale restriction as a separate unit of account. Under the existing guidance in
ASC 820-10-35-6B, “although a reporting entity must be able to access the market, the reporting entity does not need to be able
to sell the particular asset or transfer the particular liability on the measurement date to be able to measure fair value on the basis
of the price in that market.” ASU 2022-03 clarifies that an entity should apply this existing guidance when measuring the fair
value of equity securities that are subject to contractual sale restrictions (i.e., a contractual sale restriction on the reporting entity
that prevents the sale of an equity security in the market does not prevent the entity from measuring the fair value of the equity security
on the basis of the price in that principal market). ASU 2022-03 for the Company will be effective for fiscal year 2024.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
GOING CONCERN, LIQUIDITY AND MANAGEMENT’S PLAN
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
GOING CONCERN, LIQUIDITY AND MANAGEMENT’S PLAN |
NOTE
2 – GOING CONCERN, LIQUIDITY AND MANAGEMENT’S PLAN
Accounting
standards require management to evaluate our ability to continue as a going concern for a period of one year after the date of the filing
of this Form 10-Q (“evaluation period”). In evaluating the Company’s ability to continue as a going concern, management
considers the conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern for
a period of twelve months after the Company issues its financial statements. For the nine months ended September 30, 2023, management
considers the Company’s current financial condition and liquidity sources, including current funds available, forecasted future
cash flows, and the Company’s conditional and unconditional obligations due within 12 months of the date these financial statements
are issued.
The
Company is subject to risks like those of healthcare technology companies whereby revenues are generated based on both sales-based and
subscription-based models, which assume dependence on key individuals, uncertainty of product development, generation of revenues, positive
cash flow, dependence on outside sources of capital, risks associated with research, development, and successful testing of its products,
successful protection of intellectual property, ability to maintain and grow its customer base, and susceptibility to infringement on
the proprietary rights of others. The attainment of profitable operations is dependent on future events, including obtaining adequate
financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s
cost structure.
As
of September 30, 2023, the Company had a working capital deficit of $36,099,968. Management has evaluated the significance of the conditions
described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the
Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were
issued. While management will look to continue funding operations by increased sales volumes and raising additional capital from sources
such as sales of its debt or equity securities or loans to meet operating cash requirements, there is no assurance that management’s
plans will be successful.
On
March 30, 2023, noteholders owning Replacement Notes in an aggregate of $26,200,000, entered into a Replacement Note Conversion Agreement,
wherein the Replacement Notes were converted into shares of the Company’s common stock at a conversion price of $0.10 per share,
resulting in the issuance of an aggregate of 262,000,000 shares (the “Conversion Shares”). The Conversion Shares bear a lockup
legend that expires December 31, 2023.
Upon
this conversion, and as of March 31, 2023, the Company’s officers and board of directors held the majority of the Company’s
outstanding voting stock. With controlling interest of the majority of outstanding shares, the Company’s majority shareholders
voted to amend its articles of incorporation to increase the authorized shares available for issuance from 500,000,000 to 800,000,000,
with an effective date of May 22, 2023.
On
May 24, 2023, noteholder owning Replacement Notes in the aggregate of $18,000,000, presented Conversion Notices, per the terms of the
Replacement Notes, to the Company to convert the Replacement Notes into 180,000,000 shares of the Company’s common stock at a conversion
price of $0.10 per share. The shares bear a lock-up legend that expires December 31, 2023.
Management
continues to monitor the immediate and future cash flows needs of the company in a variety of ways which include forecasted net cash
flows from operations, capital expenditure control, new inventory orders, debt modifications, increases in sales outreach, streamlining
and controlling general and administrative costs, competitive industry pricing, sale of equities, debt conversions, new product or services
offerings, and new business partnerships.
The
Company’s net losses, cash outflows, and working capital deficit raise substantial doubt about the Company’s ability to continue
as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as
a going concern. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities
in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive
cash flows adequate to support the Company’s cost structure.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-40/tableOfContent
+ Details
Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
STOCKHOLDERS’ EQUITY
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
STOCKHOLDERS’ EQUITY |
NOTE
3 – STOCKHOLDERS’ EQUITY
Warrants
to Purchase Common Stock of the Company
We
use the Black-Scholes-Merton option pricing model (“Black-Scholes Model”) to determine the fair value of Warrants. The Black-Scholes
Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate,
and the weighted average term of the Warrant.
The
risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is
appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding
the grant date. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the
expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer
entities whose stock prices were publicly available) over a period equal to the expected life of the awards.
A
summary of our Warrants activity and related information follows:
|
|
Number
of
Shares Under
Warrant |
|
|
Range
of
Warrant Price
Per Share |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life |
|
Balance
at December 31, 2022 |
|
|
5,694,445 |
|
|
|
$0.01-$0.03 |
|
|
$ |
0.024 |
|
|
|
3.5 |
|
Granted |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Expired |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Canceled |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Balance
at September 30, 2023 |
|
|
5,694,445 |
|
|
|
$0.01-$0.03 |
|
|
$ |
0.024 |
|
|
|
2.8 |
|
Options
to Purchase Common Stock of the Company
During
the nine months ended September 30, 2023, 600,000
options to purchase our Common Stock were granted having a fair value of $33,300
and exercise price of $0.06
per share. The valuation methodology used to determine the fair value of the stock options issued was the Black-Scholes Model. The
Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average
risk-free interest rate, and the weighted average expected term of the options. During the nine months ended September 30, 2023,
310,000 options expired or were terminated.
A
summary of our stock option activity and related information follows:
|
|
Number
of
Shares Under
Options |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life |
|
|
Aggregate
Intrinsic
Value |
|
Balance
at December 31, 2022 |
|
|
40,817,477 |
|
|
$ |
0.12 |
|
|
|
5.8 |
|
|
$ |
526,425 |
|
Granted |
|
|
600,000 |
|
|
|
0.03 |
|
|
|
9.6 |
|
|
|
3,000 |
|
Forfeited/Expired |
|
|
(310,000 |
) |
|
|
(0.06 |
) |
|
|
— |
|
|
|
— |
|
Exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Balance
at September 30, 2023 |
|
|
41,107,477 |
|
|
$ |
0.12 |
|
|
|
5.0 |
|
|
$ |
529,425 |
|
Vested
and Exercisable at September 30, 2023 |
|
|
40,200,144 |
|
|
$ |
0.13 |
|
|
|
4.8 |
|
|
$ |
523,425 |
|
At
September 30, 2023, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately
$49,028, which is expected to be recognized over a weighted-average period of 2.1 years. No tax benefit was realized due to a continued
pattern of operating losses.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
OTHER CURRENT ASSETS
|
9 Months Ended |
Sep. 30, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
OTHER CURRENT ASSETS |
NOTE
4 – OTHER CURRENT ASSETS
Other
current assets consist of the following:
|
|
September
30,
2023 |
|
|
December
31, 2022 |
|
Prepaid
insurance |
|
$ |
309,386
|
|
|
$ |
36,639 |
|
Other
prepaid expenses |
|
|
20,451 |
|
|
|
34,381 |
|
|
|
|
|
|
|
|
|
|
TOTAL
OTHER CURRENT ASSETS |
|
$ |
329,837 |
|
|
$ |
71,020 |
|
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other current assets.
+ References
+ Details
Name: |
us-gaap_OtherCurrentAssetsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
INVENTORY
|
9 Months Ended |
Sep. 30, 2023 |
Inventory Disclosure [Abstract] |
|
INVENTORY |
NOTE
5 – INVENTORY
Inventory
is valued at the lower of cost, determined on a first-in, first-out (FIFO), or net realizable value. Inventory items are analyzed to
determine cost and net realizable value and appropriate valuation adjustments are then established.
Inventory
consists of the following:
|
|
September
30,
2023 |
|
|
December
31,
2022 |
|
Inventory
assets |
|
$ |
232,606 |
|
|
$ |
301,446 |
|
TOTAL
INVENTORY |
|
$ |
232,606 |
|
|
$ |
301,446 |
|
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
+ Details
Name: |
us-gaap_InventoryDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
PROPERTY AND EQUIPMENT
|
9 Months Ended |
Sep. 30, 2023 |
Property, Plant and Equipment [Abstract] |
|
PROPERTY AND EQUIPMENT |
NOTE
6 – PROPERTY AND EQUIPMENT
Property
and equipment consist of the following:
|
|
September
30,
2023 |
|
|
December
31,
2022 |
|
Network
equipment |
|
$ |
12,620,258 |
|
|
$ |
12,620,258 |
|
Office
equipment |
|
|
240,874 |
|
|
|
234,430 |
|
Vehicles |
|
|
232,411 |
|
|
|
232,411 |
|
Test
equipment |
|
|
230,365 |
|
|
|
230,365 |
|
Furniture |
|
|
92,846 |
|
|
|
92,846 |
|
Warehouse
equipment |
|
|
9,523 |
|
|
|
9,523 |
|
Leasehold
improvements |
|
|
5,121 |
|
|
|
5,121 |
|
|
|
|
13,431,398 |
|
|
|
13,424,954 |
|
Less:
accumulated depreciation |
|
|
(13,055,872) |
|
|
|
(12,782,395 |
) |
TOTAL
PROPERTY AND EQUIPMENT, NET |
|
$ |
375,526 |
|
|
$ |
642,559 |
|
Depreciation
expense for the nine months ended September 30, 2023 and 2022 was $273,477 and $375,867, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
INTANGIBLE AND OTHER ASSETS, NET
|
9 Months Ended |
Sep. 30, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
INTANGIBLE AND OTHER ASSETS, NET |
NOTE
7 – INTANGIBLE AND OTHER ASSETS, NET
Intangible
assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30, 2023 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Patents
and trademarks |
|
$ |
1,213,850 |
|
|
$ |
481,058 |
|
|
$ |
732,792 |
|
Other
intangible assets |
|
|
20,237 |
|
|
|
14,166 |
|
|
|
6,071 |
|
TOTAL
INTANGIBLE ASSETS |
|
$ |
1,234,087 |
|
|
$ |
495,224 |
|
|
$ |
738,863 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2022 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Patents
and trademarks |
|
$ |
1,213,850 |
|
|
$ |
395,715 |
|
|
$ |
818,135 |
|
Other
intangible assets |
|
|
85,896 |
|
|
|
83,925 |
|
|
|
1,971 |
|
TOTAL
INTANGIBLE ASSETS |
|
$ |
1,299,746 |
|
|
$ |
479,640 |
|
|
$ |
820,106 |
|
Other
assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30, 2023 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Deferred
installation costs |
|
$ |
1,352,041 |
|
|
$ |
1,340,363 |
|
|
$ |
11,678 |
|
Deferred
sales commission |
|
|
368,804 |
|
|
|
207,672 |
|
|
|
161,132 |
|
Prepaid
license fee |
|
|
249,999 |
|
|
|
198,086 |
|
|
|
51,913 |
|
Security
deposit |
|
|
46,124 |
|
|
|
- |
|
|
|
46,124 |
|
TOTAL
OTHER ASSETS |
|
$ |
2,016,968 |
|
|
$ |
1,746,121 |
|
|
$ |
270,847 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2022 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Deferred
installation costs |
|
$ |
1,352,041 |
|
|
$ |
1,318,580 |
|
|
$ |
33,461 |
|
Deferred
sales commissions |
|
|
163,973 |
|
|
|
98,116 |
|
|
|
65,857 |
|
Prepaid
license fee |
|
|
249,999 |
|
|
|
185,792 |
|
|
|
64,207 |
|
Security
deposit |
|
|
46,124 |
|
|
|
— |
|
|
|
46,124 |
|
TOTAL
OTHER ASSETS |
|
$ |
1,812,137 |
|
|
$ |
1,602,488 |
|
|
$ |
209,649 |
|
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all or part of the information related to intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent
+ Details
Name: |
us-gaap_IntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
OTHER CURRENT LIABILITIES
|
9 Months Ended |
Sep. 30, 2023 |
Payables and Accruals [Abstract] |
|
OTHER CURRENT LIABILITIES |
NOTE
8 – OTHER CURRENT LIABILITIES
Other
current liabilities consist of the following:
|
|
September
30,
2023 |
|
|
December 31,
2022 |
|
Accrued
interest |
$ |
15,258,611 |
|
|
$ |
12,933,611 |
|
Accrued
interest, related parties |
|
418,403 |
|
|
|
337,027 |
|
Allowance
for system removal |
|
54,802 |
|
|
|
54,802 |
|
Accrued
paid time off |
|
152,291 |
|
|
|
154,776 |
|
Deferred
officer compensation(1) |
|
139,041 |
|
|
|
139,041 |
|
Deferred
revenue |
|
1,207,338 |
|
|
|
890,631 |
|
Other
accrued liabilities |
|
302,299 |
|
|
|
43,389 |
|
TOTAL
OTHER CURRENT LIABILITIES |
$ |
17,532,785 |
|
|
$ |
14,553,277 |
|
|
|
|
|
|
|
|
|
|
|
(1) |
Salary
for Steve Johnson, CEO, between February 15, 2018 and September 30, 2020. |
|
X |
- DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
INCOME TAXES
|
9 Months Ended |
Sep. 30, 2023 |
Income Tax Disclosure [Abstract] |
|
INCOME TAXES |
NOTE
9 – INCOME TAXES
Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities
and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not
expect to pay any significant federal or state income tax for 2023 because of the losses recorded during the nine months ended September
30, 2023 and net operating loss carry forwards from prior years. In assessing the realizability of deferred tax asset, including the
net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient
future taxable income will be generated to utilize its existing deferred assets. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the period when those temporary differences become deductible. Accounting standards
require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component
or all the benefits of deferred tax assets will not be realized. As of September 30, 2023, we maintained a full valuation allowance for
all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded
unrecognized tax benefits at the end of the reporting period.
The
Tax Cuts and Jobs Act (the “Act”) was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue
Code, the Act reduces U.S. corporate rates from 35% to 21%. Additionally, the Act limits the use of net operating loss carry backs, however
any future net operating losses will instead be carried forward indefinitely. Net operating losses generated from January 1, 2018 are
limited to offset 80% of current income, with the remainder of the net operating loss continuing to carry forward indefinitely. Net operating
losses incurred before January 1, 2018 are not subject to the 80% limitations and will begin to expire in 2029. Based on an initial assessment
of the Act, the Company believes that the most significant impact on the Company’s unaudited condensed consolidated financial statements
will be limitations in tax deductions on interest expense. Under the Act, interest deductions disallowed from current income will carryforward
indefinitely. The Act did not impact management’s valuation allowance position.
The
effective tax rate for the nine months ended September 30, 2023 was different from the federal statutory rate due primarily to change
in the valuation allowance and nondeductible interest and amortization expense.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
AGREEMENT WITH PDL BIOPHARMA, INC.
|
9 Months Ended |
Sep. 30, 2023 |
Agreement With Pdl Biopharma Inc. |
|
AGREEMENT WITH PDL BIOPHARMA, INC. |
NOTE
10 – AGREEMENT WITH PDL BIOPHARMA, INC.
On June 26, 2015, we entered into a Credit Agreement (as subsequently amended) with PDL BioPharma, Inc. (“PDL”), as administrative
agent and lender (“the Lender”) (the “PDL Credit Agreement”). Under the PDL Credit Agreement the Lender made available
to us up to $40 million in two tranches of $20 million each. Tranche One was funded on October 8, 2015 (the “Tranche One Loan”).
Pursuant to the terms of the PDL Credit Agreement and having not met the Tranche Two Milestones by July 26, 2017, the Tranche Two funding
was terminated in full.
On
June 23, 2022, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Sixth
Amendment to Modification Agreement (the “Twenty-Sixth Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and June 30, 2022 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020, October 7, 2020 and June 30, 2022 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche
One Loan and the Tranche Three Loans that would otherwise be due under the Credit Agreement on June 30, 2022, would each be deferred
until December 31, 2022 (the end of the extended Modification) and that such deferrals would be a covered event. The Company has evaluated
the Twenty-Sixth Modification Agreement Amendment and as the effective borrowing rate under the restructured agreement is less than the
effective borrowing rate on the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has
been granted, the agreement is to be accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.
On
December 30, 2022, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Seventh
Amendment to Modification Agreement (the “Twenty-Seventh Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and February 28, 2023 (with each such date permitted to be extended by the
Lender in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement
on December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September
30, 2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan
and the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until February
28, 2023 (the end of the extended Modification Period) and that such deferrals would be a covered event. The Company has evaluated the
Twenty-seventh Modification Agreement Amendment and as the effective borrowing rate under the restructured agreement is less than the
effective borrowing rate on the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has
been granted, the agreement is to be accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.
On
February 28, 2023, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Eighth
Amendment to Modification Agreement (the “Twenty-Eighth Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and March 31, 2023 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan and
the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until March
30, 2023 (the end of the extended Modification Period).
On
March 31, 2023, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Ninth
Amendment to Modification Agreement (the “Twenty-Ninth Modification Agreement Amendment”), pursuant to which the parties
agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion,
to terminate the Modification Period would be July 31, 2018 and April 30, 2023 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan and
the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until April
30, 2023 (the end of the extended Modification Period). Under debt modification/troubled debt guidance, we determined that the first
of the eight amendments had no cash flow impact, and therefore, had no impact on accounting. Amendments nine through ten qualified for
modification accounting, while the final nineteen amendments qualified for troubled debt restructuring accounting. As appropriate, we
expensed the legal costs paid to third parties. For the three months ended March 31, 2023 and 2022, pursuant to the terms of the PDL
Modification Agreement, as amended, $802,125 and $775,000, respectively, was recorded as interest expense on the accompanying unaudited
condensed consolidated financial statements.
On
April 29, 2023, the Company, the Borrower, the Subsidiary Guarantor, the Lender and the Tranche Three Lenders entered into a Thirtieth
Amendment to Modification Agreement (the “Thirtieth Modification Agreement Amendment”), pursuant to which the parties agreed
to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion, to
terminate the Modification Period would be July 31, 2018 and May 31, 2023 (with each such date permitted to be extended by the Lender
in its sole discretion); and that the Borrower’s (i) interest payments that would otherwise be due under the Credit Agreement on
December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30,
2020 and October 7, 2020 and (ii) payments for principal and for any other Obligations then outstanding under the Tranche One Loan and
the Tranche Three Loans that would otherwise be due under the Credit Agreement on October 7, 2020, would each be deferred until May 31,
2023 (the end of the extended Modification Period).
On
May 31, 2023 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive
Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Seventh Amendment to Credit Agreement (the
“Seventh Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to, among other
things, (i) provide that, after the Effective Date, all accrued but unpaid interest (including interest accrued but unpaid prior to the
Effective Date and excluding interest payable on the Maturity Date, in connection with any prepayment, or in the event of an Event of
Default, which interest will be payable in cash) accruing on Tranche One Loans and Tranche Three Loans will be paid-in-kind on each Interest
Payment Date by being added to the aggregate principal balance of the respective loans in arrears on each Interest Payment Date; (ii)
require certain mandatory prepayments of the loans by the Company, including (A) quarterly prepayments in the amount, if any, that the
Company’s Excess Cash Flow exceeds $600,000, (B) monthly transfers to the Inventory Reserve Account in the amount, if any, the
Company’s cash exceeds $1,200,000, (C) prepayment in the amount, if any, the Company’s Inventory Reserve Account exceeds
$600,000, and (D) prepayment in the amount, if any, of 100% of the gross proceeds of any indebtedness incurred by the Company (other
than permitted indebtedness); and (iii) extend the Maturity Date to December 31, 2024.
On
September 30, 2023 (the “Effective Date”), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief
Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into an Eighth Amendment to Credit Agreement
(the “Eighth Credit Agreement Amendment”), pursuant to which the parties agreed to amend the Credit Agreement to modify certain
texts originating within the Seventh Credit Agreement. Stricken texts include “all accrued but unpaid interest (including interest
accrued but unpaid prior to the Effective Date and excluding interest payable on the Maturity Date, in connection with any prepayment,
or in the event of an Event of Default, which interest will be payable in cash) accruing on Tranche One Loans and Tranche Three Loans
will be paid-in-kind on each Interest Payment Date by being added to the aggregate principal balance of the respective loans in arrears
on each Interest Payment Date.” Additional texts include Release of Claims, which “in consideration of the Lender’s
and Agent’s agreements contained in this Amendment, each of Holdings, the Borrower and the Subsidiary Guarantor hereby releases
and discharges the Lender and the Agent and their affiliates, subsidiaries, successors, assigns, directors, officers, employees, agents,
consultants and attorneys (each, a “Released Person”) of and from any and all other claims, suits, actions, investigations,
proceedings or demands, whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or
common law of any kind or character, known or unknown, which Holdings, the Borrower or the Subsidiary Guarantor ever had or now has against
the Agent, any Lender or any other Released Person which relates, directly or indirectly, to any acts or omissions of the Agent, any
Lender or any other Released Person relating to the Credit Agreement or any other Loan Document on or prior to the date hereof.”
Accounting
Treatment
In
connection with the PDL Credit Agreement, as amended, we issued the PDL Warrant to the Lender. As of September 30, 2023, the Amended
PDL Warrant has not been exercised.
Due
to the PDL Eighth Credit Agreement Amendment, the calculations for the “interest paid-in-kind” and quarterly “prepayment(s)”
were removed effective with the quarter ending on September 30, 2023. The Company concluded that the Company is encountering financial
hardship and that a concession was not granted. As the Lender has not granted a concession, the guidance contained in ASC 470-50 Modification
and Extinguishment was applied. Given the present value of the cash flows under the Eighth Credit Agreement Amendment differed by less
than 10% from the present value of the remaining cash flows under the terms of the prior debt agreement, the debt was determined to be
not substantially different which resulted in modification accounting. The Company did not have any debt issuance costs, only legal expenses.
|
X |
- DefinitionThe entire disclosure regarding the Agreement with PDL BioPharma, Inc.
+ References
+ Details
Name: |
crvw_AgreementWithPdlBiopharmaTextBlock |
Namespace Prefix: |
crvw_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
crvw_DisclosureAgreementWithPdlBiopharmaInc.Abstract |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
AGREEMENT WITH HEALTHCOR
|
9 Months Ended |
Sep. 30, 2023 |
Agreement With Healthcor |
|
AGREEMENT WITH HEALTHCOR |
NOTE
11 – AGREEMENT WITH HEALTHCOR
On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) with HealthCor Partners Fund, LP (“HealthCor
Partners”) and HealthCor Hybrid Offshore Master Fund, LP (“HealthCor Hybrid” and, together with HealthCor Partners,
“HealthCor”) (the “HealthCor Purchase Agreement”). Pursuant to the terms of the HealthCor Purchase Agreement,
we sold and issued Senior Secured Convertible Notes to HealthCor in the principal amount of $9,316,000 and $10,684,000, respectively (collectively
the “2011 HealthCor Notes”). The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor
for the purchase of an aggregate of up to 5,488,456 and 6,294,403 shares, respectively, of our Common Stock at an exercise price of $1.40
per share (collectively the “2011 HealthCor Warrants”). So long as no event of default has occurred, the outstanding principal
balances of the 2011 HealthCor Notes accrue interest from April 21, 2011 through April 20, 2016 (the “First Five-Year Note Period”)
at the rate of 12.5% per annum, compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes
on the last day of each calendar quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the “Second Five Year Note
Period”) at a rate of 10% per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest
may be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar quarter. For the period
from April 21, 2016 through September 30, 2018 interest has been added to the outstanding principal balance. Pursuant to the terms of
the Ninth Amendment, the accrual of interest has been suspended after September 30, 2018. From the date any event of default occurs, the
interest rate, then applicable, shall be increased by five percent (5%) per annum. HealthCor has the right, upon an event of default,
to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued but unpaid
interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the immediately
preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable. Subject to
the terms of the Ninth Amendment as discussed below, HealthCor’s ability to convert any portion of the outstanding and unpaid accrued
interest on and principal balances of the 2011 HealthCor Notes into fully paid and nonassessable shares of our Common Stock has been eliminated.
The warrants issued with this Note were cancelled with the Ninth-Amendment dated July 10, 2018.
On
March 08, 2022, we agreed with the HealthCor Parties to (i) amend the 2011 HealthCor Notes to extend the maturity date of the 2011 HealthCor
Notes from April 20, 2022 to April 20, 2023 by entering into Allonge No. 4 to the 2011 HealthCor Notes (the “Third 2011 Note Allonges”)
and (ii) amend the 2012 HealthCor Notes to extend the maturity date of the 2012 HealthCor Notes from April 20, 2022 to April 20, 2023
by entering into Allonge No. 4 to the 2012 HealthCor Notes (the “Fourth 2012 Note Allonges”) (such amendments to the 2011
HealthCor Notes and 2012 HealthCor Notes together, the “HealthCor Note Extensions”). In connection with the HealthCor Note
Extensions, we issued warrants to purchase an aggregate of 3,000,000 shares of our Common Stock at an exercise price per share equal
to $0.09 per share (subject to adjustment as described therein) and with an expiration date of March 08, 2032, to the HealthCor Parties
(collectively the “2021 HealthCor Warrants”). The warrants were valued at $240,000 and are amortized over the life of the
debt. The conclusion was that this was a debt modification and this was accounted for as such.
Also
on March 08, 2022, in connection with the HealthCor Note Extensions and the issuance of the 2021 HealthCor Warrants, we entered into
a Consent and Agreement Pursuant to Note and Warrant Purchase Agreement (the “2022 NWPA Consent”) with the HealthCor Parties
and certain additional Existing Investors (in their capacity as Majority Holders acting together with the HealthCor Parties), pursuant
to which, among other things, (i) the Majority Holders consented to the HealthCor Note Extensions, (ii) the Majority Holders consented
to the issuance of the 2021 HealthCor Warrants and (iii) the parties agreed that the holders of the 2021 HealthCor Warrants would have
registration rights for the shares of Common Stock issuable upon exercise of the 2021 HealthCor Warrants under the Registration Rights
Agreement dated as of April 20, 2011, as amended June 30, 2015, by and among the Company, the HealthCor Parties and the additional investors
party thereto (the “Registration Rights Agreement”).
On
July 1, 2022, we entered into amendments to the 2014 HealthCor Notes, 2015 Supplemental Notes, Eighth Amendment Supplemental Closing
Notes, Tenth Amendment Supplemental Closing Notes, Twelfth Amendment Supplemental Closing Note and Thirteenth Amendment Supplemental
Closing Note (collectively, the “2022 Allonges”) to suspend the accrual of interest on the 2014 HealthCor Notes as to 100%
of the outstanding principal amount under such notes, 2015 Supplemental Notes as to 100% of the outstanding principal amount under such
notes, Eighth Amendment Supplemental Closing Notes as to 100% of the outstanding principal amount under such notes, Tenth Amendment Supplemental
Closing Notes as to 100% of the outstanding principal amount under such notes, Twelfth Amendment Supplemental Closing Note as to 100%
of the outstanding principal amount under such note, and Thirteenth Amendment Supplemental Closing Note as to 100% of the outstanding
principal amount under such note, for all periods beginning on and after January 1, 2022. This was determined to be a Troubled Debt Restructure
and is accounted for accordingly.
Also
on December 30, 2022, the Existing Investors agreed to the cancellation by the Company and the forfeiting of their respective rights
in and to the 2011 Warrants, 2014 Supplemental Warrants, Fifth Amendment Supplemental Warrants, Sixth Amendment Supplemental Warrants,
Eighth Amendment Supplemental Warrants, 2021 Warrants and 2022 Warrants (collectively, the “Warrants”); and the Existing
Investors have agreed to waive any and all interest that has accrued, but remains unpaid on the Existing Notes held by the Existing Investors;
in exchange for releasing its second senior secured position they hold in connection with the 2011 Notes and 2012 Notes. The Existing
Investors have agreed to waive any and all interest that has accrued, but remains unpaid on the Existing Notes held by the Existing Investors
with the 2014 Notes along with the 2015 Notes, 2018 Notes, 2019 Note and 2020 Note. In exchange for releasing its second senior secured
position they hold in connection with the 2011 Notes and 2012 Notes, the HealthCor Parties will receive an additional $5,000,000 in value
in the Replacement Notes. In this troubled debt restructuring, all the conversion rates were changed to $0.10. The gain from this troubled
debt restructuring was $1,489,357.
On
March 30, 2023, HealthCor noteholders owning an aggregate of $36,000,000 Replacement Notes, entered into a Replacement Note Conversion
Agreement, wherein half, fifty percent, of the HealthCor Replacement Notes were converted into shares of the Company’s common stock
at a conversion price of $0.10 per share, resulting in the issuance of an aggregate of 180,000,000 shares. The other related and non-related
parties Replacement Notes of $8,200,000 were likewise converted into shares of the Company’s common stock at a conversion price
of $0.10 per share, resulting in the issuance of a combined total aggregate of 262,000,000 shares (the “Conversion Shares”).
The shares bear a lockup legend that expires December 31, 2023.
On
May 24, 2023, HealthCor noteholders owning an aggregate of $18,000,000 Replacement Notes, presented Conversion Notices, pursuant to the
terms of the Replacement Note, for the conversion of the Replacement Notes into 180,000,000 shares of the Company’s common stock
at a conversion price of $0.10 per share. The shares bear a lockup legend that expires December 31, 2023.
Accounting
Treatment
When
issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt
or equity financing is committed, a company is required to record a beneficial conversion feature (“BCF”) charge. We had
three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011
HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor
Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued due to the down round provision and the removal
of the provision requiring liability treatment, and subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor
Notes were amended, only the accrued interest capitalized as payment in kind (‘‘PIK’’) since reclassification
qualifies under this accounting treatment. We recorded an aggregate of $0 and $0 in interest for the nine months ended September 30,
2023, and 2022, respectively, related to these transactions. For the nine months ended September 30, 2023, and 2022, we recorded $0 and
$0, respectively, of PIK related to the notes included in the HealthCor Purchase Agreement. Under the accounting standards, we determined
that the restructuring of the HealthCor notes, pursuant to the terms of the Ninth Amendment, resulted in a troubled debt restructuring.
Warrants
were issued with the Fourth, Fifth, Eighth, Ninth, and Allonge 3 Amendment Notes and the proceeds were allocated to the instruments based
on relative fair value as the warrants did not contain any features requiring liability treatment and therefore were classified as equity.
At each amendment date, the warrants were recorded as debt discount, as a reduction of the net carrying amount of the debt. The debt
discounts are amortized into interest expense each period under the effective interest method. The value allocated to the Ninth Amendment
Warrants was $378,000. The value allocated to the Allonge 3 Amendment Warrants was $420,000.
Warrants
were issued with Allonge 4 Amendment Notes and the proceeds were allocated to the instruments based on relative fair value as the warrants
did not contain any features requiring liability treatment and therefore were classified as equity. At each amendment date, the warrants
were recorded as debt discount, as a reduction of the net carrying amount of the debt. The debt discounts are amortized into interest
expense each period under the effective interest method. The value allocated to the Allonge 4 Amendment Warrants was $240,000.
|
X |
- DefinitionThe entire disclosure regarding the Agreement with Healthcor.
+ References
+ Details
Name: |
crvw_AgreementWithHealthcorTextBlock |
Namespace Prefix: |
crvw_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
crvw_DisclosureAgreementWithHealthcorAbstract |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
JOINT VENTURE AGREEMENT
|
9 Months Ended |
Sep. 30, 2023 |
Equity Method Investments and Joint Ventures [Abstract] |
|
JOINT VENTURE AGREEMENT |
NOTE
12 – JOINT VENTURE AGREEMENT
On
December 31, 2019, the Company and Rockwell entered into a Second Amendment to the Rockwell Note (the “Second Rockwell Note Amendment”)
pursuant to which Rockwell agreed to extend the term of the Rockwell Note by one year, to December 31, 2020, and agreed to extend the
time to make the quarterly payment that would otherwise be due on December 31, 2019 to January 31, 2020. We have evaluated the Second
Amendment to the Rockwell Note under ASC 470 and determined that the amendment should be treated as a debt modification.
As
of March 31, 2022, the Rockwell Note was paid off.
|
X |
- References
+ Details
Name: |
us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 323 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 323 -Publisher FASB -URI https://asc.fasb.org//323/tableOfContent
+ Details
Name: |
us-gaap_EquityMethodInvestmentsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
LEASE
|
9 Months Ended |
Sep. 30, 2023 |
Lease |
|
LEASE |
NOTE
13 – LEASE
Under
ASC Topic 842, Leases (“ASC 842”), operating lease expense is generally recognized evenly over the term of the lease. The
Company has an operating lease primarily consisting of office space with a remaining lease term of 23 months (Lease through August
31, 2025).
On
September 8, 2009, we entered into a Commercial Lease Agreement (the “Lease”) for 10,578 square feet of office
and warehouse space expiring on June 30, 2015. On March 4, 2020, we entered into the Fourth Amendment to Commercial Lease Agreement
(the “Lease Extension”), wherein we extended the Lease through August 31, 2025.
The
Company has further concluded that the Lease Extension has no effects on the classification of the Lease. Rent expense for the nine months
ended September 30, 2023, and 2022 was $221,535 and $226,108, respectively.
Undiscounted
Cash Flows
Future
lease payments included in the measurement of operating lease liability on the condensed consolidated balance sheet as of September 30,
2023, for the following five fiscal years and thereafter as follows:
Quarter
ending
September 30, 2023 |
|
Operating
Leases |
|
Remaining
2023 |
|
$ |
54,451 |
|
2024 |
|
|
221,069 |
|
2025 |
|
|
150,679 |
|
Total
minimum lease payments |
|
|
426,199 |
|
Less
effects of discounting |
|
|
(57,598) |
|
Present
value of future minimum lease payments |
|
$ |
368,601 |
|
|
X |
- References
+ Details
Name: |
crvw_DisclosureLeaseAbstract |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent
+ Details
Name: |
us-gaap_LesseeOperatingLeasesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies)
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Interim Financial Statements |
Interim
Financial Statements
The
accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”,
the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted
accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions
to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary
for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities
and Exchange Commission (the “SEC”). The balance sheet at December 31, 2022 has been derived from the audited consolidated
financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations
for interim periods are not necessarily indicative of results for the full year. The accompanying unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual
Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on May 26, 2023.
|
Revenue Recognition |
Revenue
Recognition
We
recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”). For our
subscription service contracts, we have employed the practical expedient discussed in ASC 606-10-55-18 related to invoicing as we have
the right to consideration from our customers in the amount that corresponds directly with the value to the customer of our performance
completed to date and therefore, we recognize revenue upon invoicing as further discussed below.
In
accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized
reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC
606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in
amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply
the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine
the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when,
or as, we satisfy the performance obligation. For those customers for which we are required to collect sales taxes, we record such sales
taxes on a net basis which has no effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the
taxing authority.
We
enter into contracts with customers that may provide multiple combinations of our products, software solutions, and other related services,
which are generally capable of being distinct and accounted for as separate performance obligations. Performance obligations that are
not distinct at contract inception are combined.
Customer
contract fulfillment typically involves multiple procurement promises, which may include various equipment, software subscription, project-related
installation and training services, and support. We allocate the transaction price to each performance obligation based on estimated
relative standalone selling price. Revenue is then recognized for each performance obligation upon transferring control of the hardware,
software, and services to the customer and in an amount that reflects the consideration we expect to receive and the estimated benefit
the customer receives over the term of the contract.
Generally,
we recognize revenue under each of our performance obligations as follows:
|
● |
Subscription
services – We recognize subscription revenues monthly over the contracted license period. |
|
● |
Equipment
packages – We recognize equipment revenues when control of the devices has been transferred to the client (“point in
time”). |
|
● |
Software
bundle and related services related to sales-based contracts – We recognize our software subscription, installation, training,
and other services on a straight-line basis over the estimated contracted license period (“over time”). |
Disaggregation
of Revenue
The
following presents net revenues disaggregated by our business models:
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Sales-based
contract revenue |
|
|
|
|
|
|
|
|
Equipment
package, net (point in time) |
|
$ |
2,872,911 |
|
|
$ |
1,121,817 |
|
Software
bundle (over time) |
|
|
1,635,324 |
|
|
|
796,815 |
|
Total
sales-based contract revenue |
|
|
4,508,235 |
|
|
|
1,918,632 |
|
|
|
|
|
|
|
|
|
|
Subscription-based
lease revenue |
|
|
3,409,523 |
|
|
|
4,064,757 |
|
Net
revenue |
|
$ |
7,917,758 |
|
|
$ |
5,983,389 |
|
Contract
Liabilities
Our
subscription-based contracts payment arrangements are required to be paid monthly which are recognized into revenue when received. Some
customers choose to pay their subscription fee in advance. Customer payments received in advance of satisfaction of the related performance
obligations are deferred as contract liabilities. These amounts are recorded as “deferred revenue” in our condensed consolidated
balance sheets and recognized into revenues over time.
Our
sales-based contract payment arrangements with our customers typically include an initial equipment payment due upon signing of the contract
and subsequent payments when certain performance obligations are completed. Customer payments received in advance of satisfaction of
related performance obligations are deferred as contract liabilities. These amounts are recorded as “deferred revenue” in
our condensed consolidated balance sheets and recognized into revenues as either a point in time or over time.
During
the nine months ended September 30, 2023 and 2022, a total of $21,145 and $210,681, respectively, of subscription-based deferred contract
liability was recognized as revenue. The table below details the subscription-based contract liability activity during the nine months
ended September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
21,145 |
|
|
$ |
231,140 |
|
Additions |
|
|
— |
|
|
|
30,306 |
|
Transfer
to revenue |
|
|
(21,145) |
|
|
|
(210,681 |
) |
Balance,
end of period |
|
$ |
- |
|
|
$ |
50,765 |
|
During
the nine months ended September 30, 2023 and 2022, a total of $1,331,409 and $1,829,720, respectively, of sales-based deferred contract
liability was recognized as revenue. The table below details the sales-based contract liability activity during the nine months ended
September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
869,485 |
|
|
$ |
752,526 |
|
Additions |
|
|
1,807,630 |
|
|
|
2,000,051 |
|
Transfer
to revenue |
|
|
(1,331,409) |
|
|
|
(1,829,720 |
) |
Balance,
end of period |
|
$ |
1,345,706 |
|
|
$ |
922,857 |
|
As
of September 30, 2023, the aggregate amount of deferred revenue from subscription-based contracts and sales-based contracts allocated
to performance obligations that are unsatisfied or partially satisfied is approximately $1,345,706 and will be recognized into revenue
over time as follows:
Years
Ending December 31, |
|
|
Amount |
|
2023 |
|
|
$ |
522,100 |
|
2024 |
|
|
|
685,238 |
|
Thereafter |
|
|
|
138,368 |
|
|
|
|
$ |
1,345,706 |
|
We
defer and capitalize all costs associated with the installation of the CareView System into a healthcare facility until the CareView
System is fully operational and accepted by the healthcare facility. Installation costs are specifically identifiable based on the amounts
we are charged from third party installers or directly identifiable labor hours incurred for each installation. Upon acceptance, the
associated costs are expensed on a straight-line basis over the life of the contract with the healthcare facility. These costs are included
in network operations on the accompanying consolidated statements of operations.
The
table below details the activity in these deferred installation costs during the periods ended September 30, 2023 and 2022, included
in other assets in the accompanying unaudited consolidated balance sheet.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
33,461 |
|
|
$ |
68,901 |
|
Additions |
|
|
— |
|
|
|
— |
|
Transfer
to expense |
|
|
(21,783) |
|
|
|
(27,731 |
) |
Balance,
end of period |
|
$ |
11,678 |
|
|
$ |
41,170 |
|
Significant
Judgements When Applying Topic 606
Contracts
with our customers are typically structured similarly and include various combinations of our products, software solutions, and related
services. Determining whether the various contract promises are considered distinct performance obligations that should be accounted
for separately versus together may require significant judgment.
Contract
transaction price is allocated to distinct performance obligations using estimated standalone selling price. We determine standalone
selling price maximizing observable inputs such as standalone sales, competitor standalone sales, or substantive renewal prices charged
to customers when they exist. In instances where standalone selling price is not observable, we utilize an estimate of standalone selling
price. Such estimates are derived from various methods that include cost plus margin, and historical pricing practices. Judgment may
be required to determine standalone selling prices for each performance obligation and whether it depicts the amount we expect to receive
in exchange for the related good or service.
Contract
modifications occur when we and our customers agree to modify existing customer contracts to change the scope or price (or both) of the
contract or when a customer terminates some, or all, of the existing services provided by us. When a contract modification occurs, it
requires us to exercise judgment to determine if the modification should be accounted for as a separate contract, the termination of
the original contract and creation of a new contract, a cumulative catch-up adjustment to the original contract, or a combination.
Contracts
with our customers include a limited warranty on our products covering materials, workmanship, or design for the duration of the contract.
We do not offer paid additional extended or lifetime warranty packages. We determined the limited warranty in our contract is not a distinct
performance obligation. We do not believe our estimates of warranty costs to be significant to our determination of revenue recognition,
and therefore, did not reserve for warranty costs.
|
Leases |
Leases
The
Company has an operating lease primarily consisting of office space with a remaining lease term of 26 months. At the lease commencement
date, an operating lease liability and related operating lease asset are recognized. The operating lease liabilities are calculated using
the present value of lease payments. The discount rate used is either the rate implicit in the lease, when known, or our estimated incremental
borrowing rate. Operating lease assets are valued based on the initial operating lease liabilities plus any prepaid rent and direct costs
from executing the leases.
|
Earnings (Loss) Per Share |
Earnings
(Loss) Per Share
We
calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts,
basic and diluted. Basic EPS is computed based on the weighted average number of common shares outstanding during the period. Diluted
EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding
during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants to purchase
our Common Stock (the “Warrants”) and convertible debt. Potential common shares totaling 46,801,922 and 222,000,000 on September
30, 2023 and 2022, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to
our reported net loss. The 46,801,922 potential common shares consist of 41,107,477 stock options and 5,694,445 warrants.
|
Recently Issued and Newly Adopted Accounting Pronouncements |
Recently Issued and Newly Adopted Accounting Pronouncements
ASU
2016-13
ASU
2016-13 requires organizations to measure all expected credit losses for financial instruments held at the reporting date based on historical
experience, current conditions, and reasonable and supportable forecasts. This guidance:
|
1. |
Eliminates
the probable initial recognition threshold in current GAAP and, instead, reflects an organization’s current estimate of all
expected credit losses over the contractual term of its financial assets. |
|
2. |
Broadens
the information that an entity can consider when measuring credit losses to include forward-looking information. |
|
3. |
Increases
usefulness of the financial statements by requiring timely inclusion of forecasted information in forming expectations of credit
losses. |
|
4. |
Increases
comparability of purchased financial assets with credit deterioration (PCD assets) with other purchased assets that do not have credit
deterioration as well as originated assets because credit losses that are expected will be recorded through an allowance for credit
losses for all assets. |
|
5. |
Increases
users’ understanding of underwriting standards and credit quality trends by requiring additional information about credit quality
indicators by year of origination (vintage). |
|
6. |
For
available-for-sale debt securities, aligns the income statement recognition of credit losses with the reporting period in which changes
occur by recording credit losses (and subsequent changes in credit losses) through an allowance rather than a write down. |
The
guidance affects loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance
receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. We, as a smaller
reporting company as defined by the SEC, have adopted ASU 2016-13 effective for January 1, 2023. As of September 30, 2023, ASU 2016-13
does not have any material effect on the Company.
ASU
2020-06
ASU
2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance
in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and
cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies
to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted
for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding
financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’
equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding
financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded
features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260,
Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted
method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled
in cash or shares. We, as a smaller reporting company as defined by the SEC, will adopt ASU 2020-06 effective for fiscal year 2024.
ASU
2022-03
ASU
2022-03 clarifies that a “contractual sale restriction prohibiting the sale of an equity security is a characteristic of the reporting
entity holding the equity security” and is not included in the equity security’s unit of account. Accordingly, an entity
should not consider the contractual sale restriction when measuring the equity security’s fair value (i.e., the entity should not
apply a discount related to the contractual sale restriction, as stated in ASC 820-10-35-36B as amended by the ASU). In addition, the
ASU prohibits an entity from recognizing a contractual sale restriction as a separate unit of account. Under the existing guidance in
ASC 820-10-35-6B, “although a reporting entity must be able to access the market, the reporting entity does not need to be able
to sell the particular asset or transfer the particular liability on the measurement date to be able to measure fair value on the basis
of the price in that market.” ASU 2022-03 clarifies that an entity should apply this existing guidance when measuring the fair
value of equity securities that are subject to contractual sale restrictions (i.e., a contractual sale restriction on the reporting entity
that prevents the sale of an equity security in the market does not prevent the entity from measuring the fair value of the equity security
on the basis of the price in that principal market). ASU 2022-03 for the Company will be effective for fiscal year 2024.
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1
+ Details
Name: |
us-gaap_LesseeLeasesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
+ Details
Name: |
us-gaap_RevenueRecognitionPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
The following presents net revenues disaggregated by our business models: |
The
following presents net revenues disaggregated by our business models:
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Sales-based
contract revenue |
|
|
|
|
|
|
|
|
Equipment
package, net (point in time) |
|
$ |
2,872,911 |
|
|
$ |
1,121,817 |
|
Software
bundle (over time) |
|
|
1,635,324 |
|
|
|
796,815 |
|
Total
sales-based contract revenue |
|
|
4,508,235 |
|
|
|
1,918,632 |
|
|
|
|
|
|
|
|
|
|
Subscription-based
lease revenue |
|
|
3,409,523 |
|
|
|
4,064,757 |
|
Net
revenue |
|
$ |
7,917,758 |
|
|
$ |
5,983,389 |
|
|
The table below details the subscription-based contract liability activity during the nine months ended September 30, 2023 and 2022, included in the Other current liabilities. |
During
the nine months ended September 30, 2023 and 2022, a total of $21,145 and $210,681, respectively, of subscription-based deferred contract
liability was recognized as revenue. The table below details the subscription-based contract liability activity during the nine months
ended September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
21,145 |
|
|
$ |
231,140 |
|
Additions |
|
|
— |
|
|
|
30,306 |
|
Transfer
to revenue |
|
|
(21,145) |
|
|
|
(210,681 |
) |
Balance,
end of period |
|
$ |
- |
|
|
$ |
50,765 |
|
During
the nine months ended September 30, 2023 and 2022, a total of $1,331,409 and $1,829,720, respectively, of sales-based deferred contract
liability was recognized as revenue. The table below details the sales-based contract liability activity during the nine months ended
September 30, 2023 and 2022, included in the Other current liabilities.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
869,485 |
|
|
$ |
752,526 |
|
Additions |
|
|
1,807,630 |
|
|
|
2,000,051 |
|
Transfer
to revenue |
|
|
(1,331,409) |
|
|
|
(1,829,720 |
) |
Balance,
end of period |
|
$ |
1,345,706 |
|
|
$ |
922,857 |
|
|
As of September 30, 2023, the aggregate amount of deferred revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied or partially satisfied |
As
of September 30, 2023, the aggregate amount of deferred revenue from subscription-based contracts and sales-based contracts allocated
to performance obligations that are unsatisfied or partially satisfied is approximately $1,345,706 and will be recognized into revenue
over time as follows:
Years
Ending December 31, |
|
|
Amount |
|
2023 |
|
|
$ |
522,100 |
|
2024 |
|
|
|
685,238 |
|
Thereafter |
|
|
|
138,368 |
|
|
|
|
$ |
1,345,706 |
|
|
The table below details the activity in these deferred installation costs during the periods ended September 30, 2023 and 2022, included in other assets in the accompanying unaudited consolidated balance sheet. |
The
table below details the activity in these deferred installation costs during the periods ended September 30, 2023 and 2022, included
in other assets in the accompanying unaudited consolidated balance sheet.
|
|
|
|
|
|
|
|
|
|
|
Nine
Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Balance,
beginning of period |
|
$ |
33,461 |
|
|
$ |
68,901 |
|
Additions |
|
|
— |
|
|
|
— |
|
Transfer
to expense |
|
|
(21,783) |
|
|
|
(27,731 |
) |
Balance,
end of period |
|
$ |
11,678 |
|
|
$ |
41,170 |
|
|
X |
- DefinitionTabular disclosure of cost capitalized in obtaining or fulfilling contract with customer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3
+ Details
Name: |
us-gaap_CapitalizedContractCostTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10
+ Details
Name: |
us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
+ Details
Name: |
us-gaap_DisaggregationOfRevenueTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of expected timing for satisfying remaining performance obligation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13
+ Details
Name: |
us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
STOCKHOLDERS’ EQUITY (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
A summary of our Warrants activity and related information follows: |
A
summary of our Warrants activity and related information follows:
|
|
Number
of
Shares Under
Warrant |
|
|
Range
of
Warrant Price
Per Share |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life |
|
Balance
at December 31, 2022 |
|
|
5,694,445 |
|
|
|
$0.01-$0.03 |
|
|
$ |
0.024 |
|
|
|
3.5 |
|
Granted |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Expired |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Canceled |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Balance
at September 30, 2023 |
|
|
5,694,445 |
|
|
|
$0.01-$0.03 |
|
|
$ |
0.024 |
|
|
|
2.8 |
|
|
A summary of our stock option activity and related information follows: |
A
summary of our stock option activity and related information follows:
|
|
Number
of
Shares Under
Options |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contractual
Life |
|
|
Aggregate
Intrinsic
Value |
|
Balance
at December 31, 2022 |
|
|
40,817,477 |
|
|
$ |
0.12 |
|
|
|
5.8 |
|
|
$ |
526,425 |
|
Granted |
|
|
600,000 |
|
|
|
0.03 |
|
|
|
9.6 |
|
|
|
3,000 |
|
Forfeited/Expired |
|
|
(310,000 |
) |
|
|
(0.06 |
) |
|
|
— |
|
|
|
— |
|
Exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Balance
at September 30, 2023 |
|
|
41,107,477 |
|
|
$ |
0.12 |
|
|
|
5.0 |
|
|
$ |
529,425 |
|
Vested
and Exercisable at September 30, 2023 |
|
|
40,200,144 |
|
|
$ |
0.13 |
|
|
|
4.8 |
|
|
$ |
523,425 |
|
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
OTHER CURRENT ASSETS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
Other current assets consist of the following: |
Other
current assets consist of the following:
|
|
September
30,
2023 |
|
|
December
31, 2022 |
|
Prepaid
insurance |
|
$ |
309,386
|
|
|
$ |
36,639 |
|
Other
prepaid expenses |
|
|
20,451 |
|
|
|
34,381 |
|
|
|
|
|
|
|
|
|
|
TOTAL
OTHER CURRENT ASSETS |
|
$ |
329,837 |
|
|
$ |
71,020 |
|
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amounts of other current assets.
+ References
+ Details
Name: |
us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfInventoryCurrentTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
PROPERTY AND EQUIPMENT (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Property, Plant and Equipment [Abstract] |
|
Property and equipment consist of the following: |
Property
and equipment consist of the following:
|
|
September
30,
2023 |
|
|
December
31,
2022 |
|
Network
equipment |
|
$ |
12,620,258 |
|
|
$ |
12,620,258 |
|
Office
equipment |
|
|
240,874 |
|
|
|
234,430 |
|
Vehicles |
|
|
232,411 |
|
|
|
232,411 |
|
Test
equipment |
|
|
230,365 |
|
|
|
230,365 |
|
Furniture |
|
|
92,846 |
|
|
|
92,846 |
|
Warehouse
equipment |
|
|
9,523 |
|
|
|
9,523 |
|
Leasehold
improvements |
|
|
5,121 |
|
|
|
5,121 |
|
|
|
|
13,431,398 |
|
|
|
13,424,954 |
|
Less:
accumulated depreciation |
|
|
(13,055,872) |
|
|
|
(12,782,395 |
) |
TOTAL
PROPERTY AND EQUIPMENT, NET |
|
$ |
375,526 |
|
|
$ |
642,559 |
|
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
INTANGIBLE AND OTHER ASSETS, NET (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
Intangible assets consist of the following: |
Intangible
assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30, 2023 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Patents
and trademarks |
|
$ |
1,213,850 |
|
|
$ |
481,058 |
|
|
$ |
732,792 |
|
Other
intangible assets |
|
|
20,237 |
|
|
|
14,166 |
|
|
|
6,071 |
|
TOTAL
INTANGIBLE ASSETS |
|
$ |
1,234,087 |
|
|
$ |
495,224 |
|
|
$ |
738,863 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2022 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Patents
and trademarks |
|
$ |
1,213,850 |
|
|
$ |
395,715 |
|
|
$ |
818,135 |
|
Other
intangible assets |
|
|
85,896 |
|
|
|
83,925 |
|
|
|
1,971 |
|
TOTAL
INTANGIBLE ASSETS |
|
$ |
1,299,746 |
|
|
$ |
479,640 |
|
|
$ |
820,106 |
|
|
Other assets consist of the following: |
Other
assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30, 2023 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Deferred
installation costs |
|
$ |
1,352,041 |
|
|
$ |
1,340,363 |
|
|
$ |
11,678 |
|
Deferred
sales commission |
|
|
368,804 |
|
|
|
207,672 |
|
|
|
161,132 |
|
Prepaid
license fee |
|
|
249,999 |
|
|
|
198,086 |
|
|
|
51,913 |
|
Security
deposit |
|
|
46,124 |
|
|
|
- |
|
|
|
46,124 |
|
TOTAL
OTHER ASSETS |
|
$ |
2,016,968 |
|
|
$ |
1,746,121 |
|
|
$ |
270,847 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2022 |
|
|
|
Cost |
|
|
Accumulated
Amortization |
|
|
Net |
|
Deferred
installation costs |
|
$ |
1,352,041 |
|
|
$ |
1,318,580 |
|
|
$ |
33,461 |
|
Deferred
sales commissions |
|
|
163,973 |
|
|
|
98,116 |
|
|
|
65,857 |
|
Prepaid
license fee |
|
|
249,999 |
|
|
|
185,792 |
|
|
|
64,207 |
|
Security
deposit |
|
|
46,124 |
|
|
|
— |
|
|
|
46,124 |
|
TOTAL
OTHER ASSETS |
|
$ |
1,812,137 |
|
|
$ |
1,602,488 |
|
|
$ |
209,649 |
|
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of noncurrent assets.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
OTHER CURRENT LIABILITIES (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Payables and Accruals [Abstract] |
|
Other current liabilities consist of the following: |
Other
current liabilities consist of the following:
|
|
September
30,
2023 |
|
|
December 31,
2022 |
|
Accrued
interest |
$ |
15,258,611 |
|
|
$ |
12,933,611 |
|
Accrued
interest, related parties |
|
418,403 |
|
|
|
337,027 |
|
Allowance
for system removal |
|
54,802 |
|
|
|
54,802 |
|
Accrued
paid time off |
|
152,291 |
|
|
|
154,776 |
|
Deferred
officer compensation(1) |
|
139,041 |
|
|
|
139,041 |
|
Deferred
revenue |
|
1,207,338 |
|
|
|
890,631 |
|
Other
accrued liabilities |
|
302,299 |
|
|
|
43,389 |
|
TOTAL
OTHER CURRENT LIABILITIES |
$ |
17,532,785 |
|
|
$ |
14,553,277 |
|
|
|
|
|
|
|
|
|
|
|
(1) |
Salary
for Steve Johnson, CEO, between February 15, 2018 and September 30, 2020. |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
+ Details
Name: |
us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
LEASE (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Lease |
|
Future lease payments included in the measurement of operating lease liability on the condensed consolidated balance sheet as of September 30, 2023, for the following five fiscal years and thereafter as follows: |
Future
lease payments included in the measurement of operating lease liability on the condensed consolidated balance sheet as of September 30,
2023, for the following five fiscal years and thereafter as follows:
Quarter
ending
September 30, 2023 |
|
Operating
Leases |
|
Remaining
2023 |
|
$ |
54,451 |
|
2024 |
|
|
221,069 |
|
2025 |
|
|
150,679 |
|
Total
minimum lease payments |
|
|
426,199 |
|
Less
effects of discounting |
|
|
(57,598) |
|
Present
value of future minimum lease payments |
|
$ |
368,601 |
|
|
X |
- References
+ Details
Name: |
crvw_DisclosureLeaseAbstract |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
The following presents net revenues disaggregated by our business models: (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Disaggregation of Revenue [Line Items] |
|
|
|
|
Net revenue |
$ 2,425,390
|
$ 1,967,624
|
$ 7,917,758
|
$ 5,983,389
|
Sales-based equipment package revenue [Member] |
|
|
|
|
Disaggregation of Revenue [Line Items] |
|
|
|
|
Net revenue |
876,126
|
314,495
|
2,872,911
|
1,121,817
|
Sales-based software bundle revenue [Member] |
|
|
|
|
Disaggregation of Revenue [Line Items] |
|
|
|
|
Net revenue |
517,436
|
329,411
|
1,635,324
|
796,815
|
Sales-based contract revenue [Member] |
|
|
|
|
Disaggregation of Revenue [Line Items] |
|
|
|
|
Net revenue |
|
|
4,508,235
|
1,918,632
|
Subscription-based lease revenue [Member] |
|
|
|
|
Disaggregation of Revenue [Line Items] |
|
|
|
|
Net revenue |
$ 1,031,828
|
$ 1,323,718
|
$ 3,409,523
|
$ 4,064,757
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
+ Details
Name: |
us-gaap_DisaggregationOfRevenueLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=crvw_SalesBasedEquipmentPackageRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=crvw_SalesBasedSoftwareBundleRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=crvw_SalesBasedContractRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=crvw_SubscriptionBasedLeaseRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($)
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Performance obligations |
$ 1,345,706
|
|
Remaining lease term |
23 months
|
|
Anti-dilutive common share equivalents excluded from EPS calculation |
46,801,922
|
222,000,000
|
Share-Based Payment Arrangement, Option [Member] |
|
|
Anti-dilutive common share equivalents excluded from EPS calculation |
41,107,477
|
|
Warrant [Member] |
|
|
Anti-dilutive common share equivalents excluded from EPS calculation |
5,694,445
|
|
Office Space [Member] |
|
|
Remaining lease term |
26 months
|
|
Subscription-Based Contract Liability [Member] |
|
|
Contract liability recognized as revenue |
$ 21,145
|
$ 210,681
|
Sales-Based Contract Liability [Member] |
|
|
Contract liability recognized as revenue |
$ 1,331,409
|
$ 1,829,720
|
X |
- DefinitionAmount of contract with customer liability transfer to revenue.
+ References
+ Details
Name: |
crvw_ContractWithCustomerLiabilityTransferToRevenue |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeOperatingLeaseRemainingLeaseTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13
+ Details
Name: |
us-gaap_RevenueRemainingPerformanceObligation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvw_OfficeSpaceMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ContractWithCustomerBasisOfPricingAxis=crvw_SubscriptionBasisContractMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ContractWithCustomerBasisOfPricingAxis=crvw_SalesBasisContractMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
The table below details the subscription-based contract liability activity during the nine months ended September 30, 2023 and 2022, included in the Other current liabilities. (Details) - USD ($)
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Subscription-Based Contract Liability [Member] |
|
|
Disaggregation of Revenue [Line Items] |
|
|
Balance, beginning of period |
$ 21,145
|
$ 231,140
|
Additions |
|
30,306
|
Transfer to revenue |
(21,145)
|
(210,681)
|
Balance, end of period |
|
50,765
|
Sales-Based Contract Liability [Member] |
|
|
Disaggregation of Revenue [Line Items] |
|
|
Balance, beginning of period |
869,485
|
752,526
|
Additions |
1,807,630
|
2,000,051
|
Transfer to revenue |
(1,331,409)
|
(1,829,720)
|
Balance, end of period |
$ 1,345,706
|
$ 922,857
|
X |
- DefinitionAmount of contract with customer liability additions.
+ References
+ Details
Name: |
crvw_ContractWithCustomerLiabilityAdditions |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of contract with customer liability transfer to revenue.
+ References
+ Details
Name: |
crvw_ContractWithCustomerLiabilityTransferToRevenue |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2
+ Details
Name: |
us-gaap_ContractWithCustomerLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
+ Details
Name: |
us-gaap_DisaggregationOfRevenueLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ContractWithCustomerBasisOfPricingAxis=crvw_SubscriptionBasisContractMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ContractWithCustomerBasisOfPricingAxis=crvw_SalesBasisContractMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
As of September 30, 2023, the aggregate amount of deferred revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied or partially satisfied (Details)
|
Sep. 30, 2023
USD ($)
|
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |
|
Performance obligations |
$ 1,345,706
|
2023 [Member] |
|
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |
|
Performance obligations |
522,100
|
2024 [Member] |
|
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |
|
Performance obligations |
685,238
|
Thereafter [Member] |
|
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |
|
Performance obligations |
$ 138,368
|
X |
- DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13
+ Details
Name: |
us-gaap_RevenueRemainingPerformanceObligation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
The table below details the activity in these deferred installation costs during the periods ended September 30, 2023 and 2022, included in other assets in the accompanying unaudited consolidated balance sheet. (Details) - USD ($)
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
Balance, beginning of period |
$ 33,461
|
$ 68,901
|
Additions |
|
|
Transfer to expense |
(21,783)
|
(27,731)
|
Balance, end of period |
$ 11,678
|
$ 41,170
|
X |
- DefinitionThe amount of deferred installation costs for reporting period for installations that are not fully operational and accepted by facility.
+ References
+ Details
Name: |
crvw_AdditionsToDeferredCosts |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized for deferred installation costs for reporting period for installations.
+ References
+ Details
Name: |
crvw_TransferToExpense |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3
+ Details
Name: |
us-gaap_CapitalizedContractCostGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
GOING CONCERN, LIQUIDITY AND MANAGEMENT’S PLAN (Details Narrative) - USD ($)
|
|
|
3 Months Ended |
|
|
|
|
May 24, 2023 |
Mar. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2023 |
May 22, 2023 |
Dec. 31, 2022 |
Dec. 30, 2022 |
Working capital |
|
|
|
|
$ 36,099,968
|
|
|
|
Noteholders owning replacement notes |
|
|
$ 18,000,000
|
$ 26,200,000
|
|
|
|
|
Debt to equity conversion (in dollars per share) |
|
|
$ 0.10
|
$ 0.10
|
$ 0.10
|
|
|
|
Common stock, authorized |
|
|
|
|
800,000,000
|
800,000,000
|
500,000,000
|
|
Replacement Notes [Member] |
|
|
|
|
|
|
|
|
Noteholders owning replacement notes |
$ 18,000,000
|
$ 26,200,000
|
|
|
|
|
|
|
Debt to equity conversion (in dollars per share) |
$ 0.10
|
$ 0.10
|
|
|
|
|
|
$ 0.10
|
Noteholders owning replacement notes (in shares) |
180,000,000
|
262,000,000
|
|
|
|
|
|
|
X |
- DefinitionNet working capital, which is accounts receivable plus inventory minus accounts payable.
+ References
+ Details
Name: |
crvw_WorkingCapital |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_ReplacementNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
A summary of our Warrants activity and related information follows: (Details) - Warrant [Member]
|
9 Months Ended |
Sep. 30, 2023
$ / shares
shares
|
Class of Warrant or Right [Line Items] |
|
Warrants outstanding, beginning | shares |
5,694,445
|
Weighted average exercise price, beginning |
$ 0.024
|
Warrant term, beginning |
3 years 6 months
|
Warrants outstanding, ending | shares |
5,694,445
|
Weighted average exercise price, ending |
$ 0.024
|
Warrant term, ending |
2 years 9 months 18 days
|
Minimum [Member] |
|
Class of Warrant or Right [Line Items] |
|
Warrant price, beginning |
$ 0.01
|
Warrant price, ending |
0.01
|
Maximum [Member] |
|
Class of Warrant or Right [Line Items] |
|
Warrant price, beginning |
0.03
|
Warrant price, ending |
$ 0.03
|
X |
- DefinitionContractual life of warrants or rights at beginning of period.
+ References
+ Details
Name: |
crvw_ClassOfWarrantOrRightsContractualLifeBeginning |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionContractual life of warrants or rights at end of period.
+ References
+ Details
Name: |
crvw_ClassOfWarrantOrRightsContractualLifeEnding |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance of warrants.
+ References
+ Details
Name: |
crvw_WeightedAverageExercisePriceWarrant |
Namespace Prefix: |
crvw_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionFair value of options granted during the period.
+ References
+ Details
Name: |
crvw_StockGrantedDuringPeriodValueSharebasedCompensationGrossStockGrantedDuringPeriodValueSharebasedCompensationGross |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cost to be recognized for option under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
A summary of our stock option activity and related information follows: (Details)
|
9 Months Ended |
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Equity [Abstract] |
|
Stock Options Outstanding, Beginning | shares |
40,817,477
|
Stock Options Outstanding, Weighted Average Exercise Price, Beginning | $ / shares |
$ 0.12
|
Stock Options Outstanding, Weighted Average Remaining Contractual Life, Beginning |
5 years 9 months 18 days
|
Stock Options Outstanding, Aggregate Intrinsic Value, Beginning | $ |
$ 526,425
|
Stock Options Outstanding, Granted | shares |
600,000
|
Stock Options Outstanding, Weighted Average Exercise Price, Granted | $ / shares |
$ 0.03
|
Stock Options Outstanding, Weighted Average Remaining Contractual Life, Granted |
9 years 7 months 6 days
|
Stock Options Outstanding, Aggregate Intrinsic Value, Granted | $ |
$ 3,000
|
Stock Options Outstanding, Forfeited/Expired | shares |
(310,000)
|
Stock Options Outstanding, Weighted Average Exercise Price, Forfeited/Expired | $ / shares |
$ (0.06)
|
Stock Options Outstanding, Ending | shares |
41,107,477
|
Stock Options Outstanding, Weighted Average Exercise Price, Ending | $ / shares |
$ 0.12
|
Stock Options Outstanding, Weighted Average Remaining Contractual Life, Ending |
5 years
|
Stock Options Outstanding, Aggregate Intrinsic Value, Ending | $ |
$ 529,425
|
Stock Options Vested and Exercisable | shares |
40,200,144
|
Stock Options Vested and Exercisable, Weighted Average Exercise Price | $ / shares |
$ 0.13
|
Stock Options Vested and Exercisable, Weighted Average Remaining Contractual Life |
4 years 9 months 18 days
|
Stock Options Vested and Exercisable, Aggregate Intrinsic Value | $ |
$ 523,425
|
X |
- DefinitionWeighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
crvw_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term begining.
+ References
+ Details
Name: |
crvw_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term ending.
+ References
+ Details
Name: |
crvw_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Other current assets consist of the following: (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
Prepaid insurance |
$ 309,386
|
$ 36,639
|
Other prepaid expenses |
20,451
|
34,381
|
TOTAL OTHER CURRENT ASSETS |
$ 329,837
|
$ 71,020
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_PrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5
+ Details
Name: |
us-gaap_PrepaidInsurance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.3
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2
+ Details
Name: |
us-gaap_InventoryFinishedGoodsNetOfReserves |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.3
Property and equipment consist of the following: (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
$ 13,431,398
|
$ 13,424,954
|
Less: accumulated depreciation |
(13,055,872)
|
(12,782,395)
|
Total property and equipment , net |
375,526
|
642,559
|
Network Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
12,620,258
|
12,620,258
|
Office Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
240,874
|
234,430
|
Vehicles [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
232,411
|
232,411
|
Test Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
230,365
|
230,365
|
Furniture and Fixtures [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
92,846
|
92,846
|
Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
9,523
|
9,523
|
Leasehold Improvements [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Total property and equipment |
$ 5,121
|
$ 5,121
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvw_NetworkEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvw_TestEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Intangible assets consist of the following: (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] |
|
|
Cost |
$ 1,234,087
|
$ 1,299,746
|
Accumulated amortization |
495,224
|
479,640
|
Intangible assets, net |
738,863
|
820,106
|
Patents and Trademarks [Member] |
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
Cost |
1,213,850
|
1,213,850
|
Accumulated amortization |
481,058
|
395,715
|
Intangible assets, net |
732,792
|
818,135
|
Other Intangible Assets [Member] |
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
Cost |
20,237
|
85,896
|
Accumulated amortization |
14,166
|
83,925
|
Intangible assets, net |
$ 6,071
|
$ 1,971
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=crvw_PatentsTrademarksMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Other assets consist of the following: (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Other assets noncurrent gross |
$ 2,016,968
|
$ 1,812,137
|
Accumulated amortization |
1,746,121
|
1,602,488
|
Other assets, net |
270,847
|
209,649
|
Deferred Installation Costs [Member] |
|
|
Other assets noncurrent gross |
1,352,041
|
1,352,041
|
Accumulated amortization |
1,340,363
|
1,318,580
|
Other assets, net |
11,678
|
33,461
|
Deferred Sales Commissions [Member] |
|
|
Other assets noncurrent gross |
368,804
|
163,973
|
Accumulated amortization |
207,672
|
98,116
|
Other assets, net |
161,132
|
65,857
|
Prepaid License Fee [Member] |
|
|
Other assets noncurrent gross |
249,999
|
249,999
|
Accumulated amortization |
198,086
|
185,792
|
Other assets, net |
51,913
|
64,207
|
Security Deposit [Member] |
|
|
Other assets noncurrent gross |
46,124
|
46,124
|
Accumulated amortization |
|
|
Other assets, net |
$ 46,124
|
$ 46,124
|
X |
- DefinitionAccumulated Amortization related to other assets.
+ References
+ Details
Name: |
crvw_OtherAssetsAccumulatedAmortization |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate gross amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
+ Details
Name: |
crvw_OtherAssetsNoncurrentGross |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_OtherAssetsMiscellaneousNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_BalanceSheetLocationAxis=crvw_DeferredInstallationCostsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BalanceSheetLocationAxis=crvw_DeferredSalesCommissionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BalanceSheetLocationAxis=crvw_PrepaidLicenseFeeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BalanceSheetLocationAxis=crvw_SecurityDepositMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Other current liabilities consist of the following: (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Payables and Accruals [Abstract] |
|
|
|
Accrued interest |
|
$ 15,258,611
|
$ 12,933,611
|
Accrued interest, related parties |
|
418,403
|
337,027
|
Allowance for system removal |
|
54,802
|
54,802
|
Accrued paid time off |
|
152,291
|
154,776
|
Deferred officer compensation |
[1] |
139,041
|
139,041
|
Deferred revenue |
|
1,207,338
|
890,631
|
Other accrued liabilities |
|
302,299
|
43,389
|
TOTAL OTHER CURRENT LIABILITIES |
|
$ 17,532,785
|
$ 14,553,277
|
|
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for allowance for system removal. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
+ Details
Name: |
crvw_AllowanceSystemRemovalCurrent |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 25 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3
+ Details
Name: |
us-gaap_AccruedVacationCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2
+ Details
Name: |
us-gaap_ContractWithCustomerLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483070/710-10-25-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483043/710-10-30-2
+ Details
Name: |
us-gaap_DeferredCompensationLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
X |
- DefinitionPercentage of limitation of taxable income for net operating loss carryforwards.
+ References
+ Details
Name: |
crvw_PercentageOfOperatingLossCarryforwardsLimitation |
Namespace Prefix: |
crvw_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.23.3
AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative) - USD ($)
|
|
3 Months Ended |
9 Months Ended |
|
May 31, 2023 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Jun. 26, 2015 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
Interest expense |
|
$ 830,994
|
|
$ 1,146,820
|
|
$ 2,527,955
|
$ 5,137,272
|
|
PDL Modification Agreement [Member] |
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
Interest expense |
|
|
$ 802,125
|
|
$ 775,000
|
|
|
|
Seventh Amendment to Credit Agreement [Member] |
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
Excess Cash Flow threshold for mandatory quarterly loan prepayment |
$ 600,000
|
|
|
|
|
|
|
|
Cash threshold for mandatory monthly transfers to Inventory Reserve Account |
1,200,000
|
|
|
|
|
|
|
|
Inventory Reserve Account threshold for mandatory loan prepayment |
$ 600,000
|
|
|
|
|
|
|
|
Prepayment percentage of gross debt proceeds |
100.00%
|
|
|
|
|
|
|
|
Debt maturity date |
Dec. 31, 2024
|
|
|
|
|
|
|
|
PDL BioPharma, Inc. [Member] |
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
Line of Credit Facility, Maximum Borrowing Capacity |
|
|
|
|
|
|
|
$ 40,000,000
|
PDL BioPharma, Inc. [Member] | Tranche 1 [Member] |
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
Line of Credit Facility, Maximum Borrowing Capacity |
|
|
|
|
|
|
|
$ 20,000,000
|
X |
- DefinitionRequired prepayment percentage of the gross proceeds of any indebtedness incurred by the Company (other than permitted indebtedness) under Credit Agreement.
+ References
+ Details
Name: |
crvw_PrepaymentPercentageOfGrossDebtProceeds |
Namespace Prefix: |
crvw_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=crvw_PDLModificationAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_SeventhAmendmentToCreditAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LineOfCreditFacilityAxis=crvw_PDLBioPharmaIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_Tranche1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
AGREEMENT WITH HEALTHCOR (Details Narrative) - USD ($)
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
|
May 24, 2023 |
Mar. 30, 2023 |
Dec. 30, 2022 |
Mar. 08, 2022 |
Mar. 06, 2022 |
Apr. 21, 2011 |
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Jul. 02, 2022 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt to equity conversion (in dollars per share) |
|
|
|
|
|
|
$ 0.10
|
$ 0.10
|
$ 0.10
|
|
$ 0.10
|
|
|
Noteholders owning replacement notes |
|
|
|
|
|
|
|
$ 18,000,000
|
$ 26,200,000
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
$ 830,994
|
|
|
$ 1,146,820
|
$ 2,527,955
|
$ 5,137,272
|
|
Interest incurred and paid in kind |
|
|
|
|
|
|
|
|
|
|
|
|
|
HealthCor Ninth Amendment Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount |
|
|
|
|
|
|
378,000
|
|
|
|
378,000
|
|
|
HealthCor Allonge No.3 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount |
|
|
|
|
|
|
420,000
|
|
|
|
420,000
|
|
|
HealthCor Allonge No.4 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount |
|
|
|
|
|
|
$ 240,000
|
|
|
|
240,000
|
|
|
2011 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
2014 HealthCor Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of principal suspended interest accrual |
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
2015 Supplemental Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of principal suspended interest accrual |
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
Eighth Amendment Supplemental Closing Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of principal suspended interest accrual |
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
Tenth Amendment Supplemental Closing Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of principal suspended interest accrual |
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
Twelfth Amendment Supplemental Closing Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of principal suspended interest accrual |
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
Thirteenth Amendment Supplemental Closing Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of principal suspended interest accrual |
|
|
|
|
|
|
|
|
|
|
|
|
100.00%
|
Replacement Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument additional value |
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
Debt to equity conversion (in dollars per share) |
$ 0.10
|
$ 0.10
|
$ 0.10
|
|
|
|
|
|
|
|
|
|
|
Gain on troubled debt restructuring |
|
|
$ 1,489,357
|
|
|
|
|
|
|
|
|
|
|
Noteholders owning replacement notes |
$ 18,000,000
|
$ 26,200,000
|
|
|
|
|
|
|
|
|
|
|
|
Noteholders owning replacement notes (in shares) |
180,000,000
|
262,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Tranche One [Member] | Replacement Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt to equity conversion (in dollars per share) |
|
$ 0.10
|
|
|
|
|
|
|
|
|
|
|
|
Noteholders owning replacement notes |
|
$ 36,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Conversion percentage |
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
Noteholders owning replacement notes (in shares) |
|
180,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Tranche Two [Member] | Replacement Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt to equity conversion (in dollars per share) |
|
$ 0.10
|
|
|
|
|
|
|
|
|
|
|
|
Noteholders owning replacement notes |
|
$ 8,200,000
|
|
|
|
|
|
|
|
|
|
|
|
Noteholders owning replacement notes (in shares) |
|
262,000,000
|
|
|
|
|
|
|
|
|
|
|
|
HealthCor Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest incurred and paid in kind |
|
|
|
|
|
|
|
|
|
|
$ 0
|
$ 0
|
|
HealthCor Purchase Agreement [Member] | Convertible Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loan amount |
|
|
|
|
|
$ 9,316,000
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
Apr. 20, 2021
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
|
|
|
5,488,456
|
|
|
|
|
|
|
|
Exercise price of warrants |
|
|
|
|
|
$ 1.40
|
|
|
|
|
|
|
|
HealthCor Purchase Agreement [Member] | 2011 Senior Secured Convertible Note#2 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loan amount |
|
|
|
|
|
$ 10,684,000
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
|
|
|
6,294,403
|
|
|
|
|
|
|
|
HealthCor Purchase Agreement [Member] | Convertible Debt 2 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in interest rate (per annum) should default occur |
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
HealthCor Purchase Agreement [Member] | Convertible Debt 2 [Member] | First Five Year Note Period [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate during period |
|
|
|
|
|
12.50%
|
|
|
|
|
|
|
|
HealthCor Purchase Agreement [Member] | Convertible Debt 2 [Member] | Second Five Year Note Period [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate during period |
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
HealthCor Note Extensions [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
|
3,000,000
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants |
|
|
|
$ 0.09
|
|
|
|
|
|
|
|
|
|
Warrants expiration date |
|
|
|
Mar. 08, 2032
|
|
|
|
|
|
|
|
|
|
Value of warrants |
|
|
|
$ 240,000
|
|
|
|
|
|
|
|
|
|
HealthCor Note Extensions [Member] | 2011 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
Apr. 20, 2023
|
Apr. 20, 2022
|
|
|
|
|
|
|
|
|
HealthCor Note Extensions [Member] | 2012 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
Apr. 20, 2023
|
Apr. 20, 2022
|
|
|
|
|
|
|
|
|
X |
- DefinitionAdditional value of debt instrument.
+ References
+ Details
Name: |
crvw_DebtInstrumentAdditionalValue |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPercentage of debt instrument converted.
+ References
+ Details
Name: |
crvw_DebtInstrumentPercentageConverted |
Namespace Prefix: |
crvw_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe issuance of warrants (shares).
+ References
+ Details
Name: |
crvw_IssuanceOfWarrants |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage of principal for which interest accrual is suspended.
+ References
+ Details
Name: |
crvw_PercentageOfPrincipalSuspendedInterestAccrual |
Namespace Prefix: |
crvw_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe average effective interest rate during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateDuringPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIncremental percentage increase (decrease) in the stated rate on a debt instrument.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFor a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 60 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481408/470-60-50-1
+ Details
Name: |
us-gaap_GainsLossesOnRestructuringOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_PaidInKindInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=crvw_HealthCorNinthAmendmentWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=crvw_HealthCorAllongeNo3WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=crvw_HealthCorAllongeNo4WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_Notes2011Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_HealthCorNotes2014Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_SupplementalNotes2015Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_EighthAmendmentSupplementalClosingNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_TenthAmendmentSupplementalClosingNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_TwelfthAmendmentSupplementalClosingNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_ThirteenthAmendmentSupplementalClosingNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_ReplacementNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=crvw_TrancheOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=crvw_TrancheTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_CounterpartyNameAxis=crvw_HealthCor3Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=crvw_ConvertibleDebt1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=crvw_ConvertibleDebt2Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VariableRateAxis=crvw_FirstFiveYearNotePeriodMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VariableRateAxis=crvw_SecondFiveYearNotePeriodMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_CounterpartyNameAxis=crvw_HealthCorNoteExtensionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_Notes2012Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionThe due date of a debt payment prior to revision.
+ References
+ Details
Name: |
crvw_DebtPreviousPaymentDueDate |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe due date of a debt payment after revision.
+ References
+ Details
Name: |
crvw_DebtRevisedPaymentDueDate |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_CounterpartyNameAxis=crvw_RockwellMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=crvw_SecondRockwellNoteAmendmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=crvw_RockwellNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- References
+ Details
Name: |
crvw_DisclosureLeaseAbstract |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
LEASE (Details Narrative)
|
|
|
9 Months Ended |
Mar. 04, 2020 |
Sep. 08, 2009
ft²
|
Sep. 30, 2023
USD ($)
|
Sep. 30, 2022
USD ($)
|
Lease |
|
|
|
|
Remaining lease term |
|
|
23 months
|
|
Expiration of lease |
Aug. 31, 2025
|
Jun. 30, 2015
|
Aug. 31, 2025
|
|
Area of lease | ft² |
|
10,578
|
|
|
Rent expense | $ |
|
|
$ 221,535
|
$ 226,108
|
X |
- References
+ Details
Name: |
crvw_DisclosureLeaseAbstract |
Namespace Prefix: |
crvw_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format.
+ References
+ Details
Name: |
us-gaap_LeaseExpirationDate1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeOperatingLeaseRemainingLeaseTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
Careview Communications (QB) (USOTC:CRVW)
過去 株価チャート
から 7 2024 まで 8 2024
Careview Communications (QB) (USOTC:CRVW)
過去 株価チャート
から 8 2023 まで 8 2024